WO1991016024A1 - Cationic lipids for intracellular delivery of biologically active molecules - Google Patents
Cationic lipids for intracellular delivery of biologically active molecules Download PDFInfo
- Publication number
- WO1991016024A1 WO1991016024A1 PCT/US1991/002691 US9102691W WO9116024A1 WO 1991016024 A1 WO1991016024 A1 WO 1991016024A1 US 9102691 W US9102691 W US 9102691W WO 9116024 A1 WO9116024 A1 WO 9116024A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipid
- transfection
- cationic
- formulation
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK91908905T DK0523189T3 (en) | 1990-04-19 | 1991-04-18 | Cationic lipids for intracellular delivery of biologically active molecules |
CA002079814A CA2079814C (en) | 1990-04-19 | 1991-04-18 | Cationic lipids for intracellular delivery of biologically active molecules |
EP91908905A EP0523189B1 (en) | 1990-04-19 | 1991-04-18 | Cationic lipids for intracellular delivery of biologically active molecules |
DE69131347T DE69131347T2 (en) | 1990-04-19 | 1991-04-18 | CATIONIC LIPIDS FOR THE INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES |
GR990402051T GR3030974T3 (en) | 1990-04-19 | 1999-08-13 | Selective system scan for multizone radiotelephone subscriber units. |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51121990A | 1990-04-19 | 1990-04-19 | |
US511,219 | 1990-04-19 | ||
US56344490A | 1990-08-07 | 1990-08-07 | |
US563,444 | 1990-08-07 | ||
US686,746 | 1991-04-16 | ||
US07/686,746 US5264618A (en) | 1990-04-19 | 1991-04-16 | Cationic lipids for intracellular delivery of biologically active molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991016024A1 true WO1991016024A1 (en) | 1991-10-31 |
Family
ID=27414476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/002691 WO1991016024A1 (en) | 1990-04-19 | 1991-04-18 | Cationic lipids for intracellular delivery of biologically active molecules |
Country Status (11)
Country | Link |
---|---|
US (2) | US5264618A (en) |
EP (1) | EP0523189B1 (en) |
JP (1) | JP2538474B2 (en) |
AT (1) | ATE181319T1 (en) |
AU (1) | AU7854791A (en) |
CA (1) | CA2079814C (en) |
DE (1) | DE69131347T2 (en) |
DK (1) | DK0523189T3 (en) |
ES (1) | ES2134775T3 (en) |
GR (1) | GR3030974T3 (en) |
WO (1) | WO1991016024A1 (en) |
Cited By (526)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994001138A1 (en) * | 1992-07-09 | 1994-01-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Covalent polar lipid-peptide conjugates for biological targeting |
WO1994009827A1 (en) * | 1992-11-05 | 1994-05-11 | Genzyme Corporation | Process for making lipid conjugates |
EP0607408A1 (en) * | 1992-07-13 | 1994-07-27 | Eukarion, Inc. | Transvascular and intracellular delivery of lipidized proteins |
EP0625049A1 (en) * | 1992-01-23 | 1994-11-23 | Vical, Inc. | Ex vivo gene transfer |
WO1995002698A1 (en) * | 1993-07-12 | 1995-01-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
EP0636028A1 (en) * | 1992-04-03 | 1995-02-01 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system |
EP0638236A1 (en) * | 1993-08-03 | 1995-02-15 | Kao Corporation | Agricultural chemical composition |
EP0656883A1 (en) * | 1992-08-28 | 1995-06-14 | Life Technologies, Inc. | Cationic lipids |
WO1995017373A1 (en) * | 1993-12-20 | 1995-06-29 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
WO1995026356A1 (en) * | 1994-03-29 | 1995-10-05 | Northwestern University | Novel cationic phospholipids for transfection |
FR2722506A1 (en) * | 1994-07-13 | 1996-01-19 | Rhone Poulenc Rorer Sa | COMPOSITION CONTAINING NUCLEIC ACIDS, PREPARATION AND USES |
WO1996003517A1 (en) * | 1994-07-26 | 1996-02-08 | Boehringer Ingelheim International Gmbh | Process for preparing viruses and viral vectors |
EP0702516A1 (en) * | 1993-06-01 | 1996-03-27 | Life Technologies Inc. | Genetic immunization with cationic lipids |
US5552155A (en) * | 1992-12-04 | 1996-09-03 | The Liposome Company, Inc. | Fusogenic lipsomes and methods for making and using same |
EP0737750A2 (en) * | 1989-03-21 | 1996-10-16 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
WO1996034109A1 (en) * | 1995-04-25 | 1996-10-31 | Vical Incorporated | Single-vial formulations of dna/lipid complexes |
EP0747351A2 (en) * | 1995-06-07 | 1996-12-11 | Gen-Probe Incorporated | Thiocationic lipids, pharmaceutical compositions and methods of use thereof |
WO1997011935A1 (en) * | 1995-09-27 | 1997-04-03 | The Regents Of The University Of California | Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes |
WO1997013743A1 (en) * | 1995-09-27 | 1997-04-17 | Univ California | Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin: polynucleotide transfection complexes |
WO1997025339A1 (en) * | 1996-01-05 | 1997-07-17 | Commonwealth Scientific And Industrial Research Organisation | Composition and method for delivery of nucleic acids |
US5667764A (en) * | 1988-05-02 | 1997-09-16 | Zynaxis, Inc. | Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles |
WO1997041834A1 (en) * | 1996-05-08 | 1997-11-13 | Nika Health Products Limited | Cationic virosomes as transfer system for genetic material |
EP0807116A1 (en) * | 1994-06-22 | 1997-11-19 | Megabios Corporation | Cationic amphiphiles |
US5693769A (en) * | 1991-12-13 | 1997-12-02 | Transcell Technologies, Inc. | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
US5705693A (en) * | 1994-07-08 | 1998-01-06 | Gilead Sciences, Inc. | Cationic lipids |
WO1998002190A2 (en) * | 1996-07-12 | 1998-01-22 | Genzyme Corporation | Cationic amphiphile/dna complexes |
US5711964A (en) * | 1995-06-07 | 1998-01-27 | United States Of America | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D |
WO1998003204A1 (en) * | 1996-07-23 | 1998-01-29 | Oregon Health Sciences University | Covalent polar lipid conjugates with biologically-active compounds for use in salves |
US5736392A (en) * | 1995-06-07 | 1998-04-07 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
US5739271A (en) * | 1995-06-07 | 1998-04-14 | Gen-Probe Incorporated | Thiocationic lipids |
FR2754828A1 (en) * | 1996-10-23 | 1998-04-24 | Univ Toulouse | ARTIFICIAL MEMBRANAR STRUCTURE, PROCESS AND POLYMER FOR ITS PREPARATION, PROCEDURE FOR PREPARING THIS POLYMER, PARTICLE AND FILM INCLUDING THIS STRUCTURE |
US5753613A (en) * | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US5756352A (en) * | 1995-06-07 | 1998-05-26 | Gen-Probe Incorporated | Thiocationic lipid-nucleic acid conjugates |
US5759519A (en) * | 1995-06-07 | 1998-06-02 | Gen-Probe Incorporated | Method for the intracellular delivery of biomolecules using thiocationic lipids |
US5770580A (en) * | 1992-04-13 | 1998-06-23 | Baylor College Of Medicine | Somatic gene therapy to cells associated with fluid spaces |
US5785992A (en) * | 1994-09-30 | 1998-07-28 | Inex Pharmaceuticals Corp. | Compositions for the introduction of polyanionic materials into cells |
US5795870A (en) * | 1991-12-13 | 1998-08-18 | Trustees Of Princeton University | Compositions and methods for cell transformation |
WO1998037916A1 (en) * | 1997-02-28 | 1998-09-03 | Transgene S.A. | Novel lipid compounds and compositions containing same used for the transfer of at least an active substance, in particular a polynucleotide, in a target cell and therapeutic use |
US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5851548A (en) * | 1995-06-07 | 1998-12-22 | Gen-Probe Incorporated | Liposomes containing cationic lipids and vitamin D |
WO1999008997A1 (en) * | 1997-08-13 | 1999-02-25 | Biontex Laboratories Gmbh | Novel lipopolyamines, and the preparation and use thereof |
US5939401A (en) * | 1994-12-09 | 1999-08-17 | Genzyme Corporation | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules |
US5965519A (en) * | 1990-11-01 | 1999-10-12 | Oregon Health Sciences University | Covalent polar lipid conjugates with biologically-active compounds for use in salves |
US5965441A (en) * | 1996-11-13 | 1999-10-12 | The General Hospital Coporation | HSV/AAV hybrid amplicon vectors |
US5976567A (en) * | 1995-06-07 | 1999-11-02 | Inex Pharmaceuticals Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US6051429A (en) * | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
US6057299A (en) * | 1994-01-13 | 2000-05-02 | Calydon, Inc. | Tissue-specific enhancer active in prostate |
US6063759A (en) * | 1990-11-01 | 2000-05-16 | Oregon Health Sciences University | Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting |
US6075012A (en) * | 1994-02-11 | 2000-06-13 | Life Technologies, Inc. | Reagents for intracellular delivery of macromolecules |
US6093816A (en) * | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
US6136792A (en) * | 1994-01-13 | 2000-10-24 | Calydon, Inc. | Prostate specific enhancer polynucleotides and methods of use thereof |
US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
US6331524B1 (en) | 1994-12-09 | 2001-12-18 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy |
US6383814B1 (en) | 1994-12-09 | 2002-05-07 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
WO2002051800A2 (en) * | 2000-12-27 | 2002-07-04 | G.O.T. Therapeutics Gmbh | Sulphur-containing amphiphilic agents for the transfer of biologically active molecules into cells |
WO2003052095A2 (en) * | 2001-12-14 | 2003-06-26 | Transgene S.A. | Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell |
US6586410B1 (en) | 1995-06-07 | 2003-07-01 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
EP1333094A2 (en) | 1996-10-01 | 2003-08-06 | Geron Corporation | Human telomerase catalytic subunit |
US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US6710035B2 (en) | 1989-03-21 | 2004-03-23 | Vical Incorporated | Generation of an immune response to a pathogen |
US6750198B1 (en) | 1999-02-25 | 2004-06-15 | Fumedica Gmbh | Preparation for the treatment of pigmentation disorders |
WO2005014791A2 (en) | 2003-08-08 | 2005-02-17 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
US6916918B2 (en) | 1997-08-04 | 2005-07-12 | Cell Genesys, Inc. | Human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof |
US6989434B1 (en) | 1994-02-11 | 2006-01-24 | Invitrogen Corporation | Reagents for intracellular delivery of macromolecules |
US6995008B1 (en) | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
US7094756B2 (en) | 2001-06-22 | 2006-08-22 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Abin-mediated hepatitis protection |
US7105331B2 (en) | 1996-07-03 | 2006-09-12 | Genetics Institute, Llc | ICE/CED-3 like protease designated FMH-1 |
US7122656B2 (en) | 2002-01-10 | 2006-10-17 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Splice variant of MyD88 and uses thereof |
US7135192B2 (en) | 1997-03-12 | 2006-11-14 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
US7135324B2 (en) | 2002-09-04 | 2006-11-14 | The University Of Connecticut | Viral recombinases, related articles, and methods of use thereof |
WO2006130974A1 (en) | 2005-06-08 | 2006-12-14 | Cangene Corporation | Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria |
US7238369B2 (en) | 1997-03-12 | 2007-07-03 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
US7358085B2 (en) | 2005-02-28 | 2008-04-15 | Sangamo Biosciences, Inc. | Anti-angiogenic methods and compositions |
EP1938843A1 (en) * | 2006-12-19 | 2008-07-02 | Novosom AG | Lipids and lipid assemblies comrising transfection enhancer elements |
US7407776B2 (en) | 2003-09-19 | 2008-08-05 | Sangamo Biosciences, Inc. | Engineered zinc finger proteins for regulation of gene expression |
US7414026B2 (en) | 1998-05-06 | 2008-08-19 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Inhibitors of NF-kappaB activation |
US7534775B2 (en) | 2004-04-08 | 2009-05-19 | Sangamo Biosciences, Inc. | Methods and compositions for modulating cardiac contractility |
EP2081028A1 (en) | 1999-07-15 | 2009-07-22 | bioMérieux S.A. | Use of a polypeptide to detect, prevent or treat a pathological state associated with a degenerative, neurological, autoimmune illness |
EP2128248A1 (en) | 2002-02-01 | 2009-12-02 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
WO2009151591A2 (en) | 2008-06-10 | 2009-12-17 | Sangamo Biosciences, Inc. | Methods and compositions for generation of bax- and bak-deficient cell lines |
WO2010021692A1 (en) | 2008-08-22 | 2010-02-25 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
WO2010065123A1 (en) | 2008-12-04 | 2010-06-10 | Sangamo Biosciences, Inc. | Genome editing in rats using zinc-finger nucleases |
US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
EP2207032A1 (en) | 2000-02-08 | 2010-07-14 | Sangamo BioSciences, Inc. | Cells expressing zinc finger protein for drug discovery |
EP2213731A1 (en) | 2006-05-25 | 2010-08-04 | Sangamo BioSciences, Inc. | Variant foki cleavage half-domains |
EP2216407A2 (en) | 2003-03-07 | 2010-08-11 | Alnylam Pharmaceuticals, Inc. | Therapeutic Compositions |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
US7803397B2 (en) | 2003-09-15 | 2010-09-28 | Protiva Biotherapeutics, Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
US7807815B2 (en) | 2004-07-02 | 2010-10-05 | Protiva Biotherapeutics, Inc. | Compositions comprising immunostimulatory siRNA molecules and DLinDMA or DLenDMA |
WO2010117464A1 (en) | 2009-04-09 | 2010-10-14 | Sangamo Biosciences, Inc. | Targeted integration into stem cells |
WO2010148010A1 (en) | 2009-06-15 | 2010-12-23 | 4S3 Bioscience Inc. | Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides |
EP2266396A2 (en) | 2001-09-24 | 2010-12-29 | Sangamo BioSciences, Inc. | Modulation of stem cells using zinc finger proteins |
US7868162B2 (en) | 1998-12-30 | 2011-01-11 | Lakewood-Amedex, Inc. | Antimicrobial and antiviral compounds and methods for their use |
WO2011003834A1 (en) | 2009-07-09 | 2011-01-13 | Marina Biotech, Inc. | Amphoteric liposomes comprising imino lipids |
US7901709B2 (en) | 1998-06-18 | 2011-03-08 | Duke University | Temperature-sensitive liposomal formulation |
EP2292274A1 (en) | 2004-09-16 | 2011-03-09 | Sangamo BioSciences, Inc. | Compositions and methods for protein production |
US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
EP2311466A2 (en) | 2001-05-03 | 2011-04-20 | Lakewood-Amedex, Inc | Antimicrobial compounds and methods for their use |
US7982027B2 (en) | 2003-07-16 | 2011-07-19 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
EP2345417A1 (en) | 2005-12-22 | 2011-07-20 | Vib Vzw | Means and methods for mediating protein interference |
WO2011090804A1 (en) | 2010-01-22 | 2011-07-28 | Dow Agrosciences Llc | Targeted genomic alteration |
EP2351765A2 (en) | 2001-07-10 | 2011-08-03 | Lakewood-Amedex, Inc | Oligonucleotide-containing pharmacological compositions and their use |
WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
WO2011109427A2 (en) | 2010-03-01 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Improving the biological activity of sirna through modulation of its thermodynamic profile |
WO2011117352A1 (en) | 2010-03-24 | 2011-09-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Primate model from the family cercopithecidae infected by a hbv strain of human genotype |
WO2011119871A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Phrmaceuticals Corporation | Rna interference in ocular indications |
WO2011119887A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Rna interference in dermal and fibrotic indications |
WO2011130729A2 (en) | 2010-04-16 | 2011-10-20 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using fgf |
WO2011136369A1 (en) | 2010-04-28 | 2011-11-03 | 協和発酵キリン株式会社 | Cationic lipid |
WO2011136368A1 (en) | 2010-04-28 | 2011-11-03 | 協和発酵キリン株式会社 | Cationic lipid |
US8058069B2 (en) | 2008-04-15 | 2011-11-15 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
EP2397549A2 (en) | 1999-02-04 | 2011-12-21 | BP Corporation North America Inc. | Non-stochastic generation of genetic vaccines and enzymes |
US8101741B2 (en) | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
WO2012047598A1 (en) | 2010-09-27 | 2012-04-12 | Sangamo Biosciences, Inc. | Methods and compositions for inhibiting viral entry into cells |
US8158595B2 (en) | 2006-11-09 | 2012-04-17 | California Institute Of Technology | Modular aptamer-regulated ribozymes |
US8283333B2 (en) | 2009-07-01 | 2012-10-09 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
US8313925B2 (en) | 2005-07-26 | 2012-11-20 | Sangamo Biosciences, Inc. | Zinc finger proteins and method for inactivating a dhfr gene in a chinese hamster ovary cell |
CN102796016A (en) * | 2004-11-26 | 2012-11-28 | 默克专利股份有限公司 | Stable crystal modifications of dotap chloride |
EP2527435A2 (en) | 2007-07-12 | 2012-11-28 | Sangamo BioSciences, Inc. | Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression |
EP2527439A2 (en) | 2007-12-11 | 2012-11-28 | The Scripps Research Institute | Compositions and methods related to mRNA translational enhancer elements |
US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
WO2012177784A2 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals | Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof |
WO2013012674A1 (en) | 2011-07-15 | 2013-01-24 | The General Hospital Corporation | Methods of transcription activator like effector assembly |
US8367815B2 (en) | 2007-08-28 | 2013-02-05 | California Institute Of Technology | Modular polynucleotides for ligand-controlled regulatory systems |
US8435960B2 (en) | 1998-12-30 | 2013-05-07 | Lakewood-Amedex, Inc. | Devices for improved wound management |
WO2013065825A1 (en) | 2011-11-02 | 2013-05-10 | 協和発酵キリン株式会社 | Cationic lipid |
WO2013075035A1 (en) | 2011-11-18 | 2013-05-23 | Alnylam Pharmaceuticals | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
WO2013074974A2 (en) | 2011-11-18 | 2013-05-23 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
WO2013089152A1 (en) | 2011-12-12 | 2013-06-20 | 協和発酵キリン株式会社 | Lipid nanoparticles containing combinations of cationic lipids |
US20130156849A1 (en) * | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
WO2013089151A1 (en) | 2011-12-12 | 2013-06-20 | 協和発酵キリン株式会社 | Lipid nanoparticles for drug delivery system containing cationic lipids |
EP2615106A1 (en) | 2010-02-08 | 2013-07-17 | Sangamo BioSciences, Inc. | Engineered cleavage half-domains |
WO2013130824A1 (en) | 2012-02-29 | 2013-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
US8541628B2 (en) | 1995-11-30 | 2013-09-24 | Vical Incorporated | Complex cationic lipids having quaternary nitrogens therein |
US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
WO2013163430A2 (en) | 2012-04-26 | 2013-10-31 | Alnylam Pharmaceuticals | Serpinc1 irna compositions and methods of use thereof |
EP2660322A2 (en) | 2003-04-17 | 2013-11-06 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
WO2014007398A1 (en) | 2012-07-06 | 2014-01-09 | 協和発酵キリン株式会社 | Cationic lipid |
WO2014011901A2 (en) | 2012-07-11 | 2014-01-16 | Sangamo Biosciences, Inc. | Methods and compositions for delivery of biologics |
WO2014011237A1 (en) | 2012-07-11 | 2014-01-16 | Sangamo Biosciences, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
WO2014013995A1 (en) | 2012-07-16 | 2014-01-23 | 協和発酵キリン株式会社 | Rnai pharmaceutical composition capable of suppressing expression of kras gene |
WO2014022739A2 (en) | 2012-08-03 | 2014-02-06 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
US8664189B2 (en) | 2008-09-22 | 2014-03-04 | Rxi Pharmaceuticals Corporation | RNA interference in skin indications |
WO2014036219A2 (en) | 2012-08-29 | 2014-03-06 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
US8669418B2 (en) | 2005-12-22 | 2014-03-11 | Vib Vzw | Means and methods for mediating protein interference |
WO2014059173A2 (en) | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
WO2014059255A1 (en) | 2012-10-12 | 2014-04-17 | The General Hospital Corporation | Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins |
EP2727600A1 (en) | 2009-07-28 | 2014-05-07 | Sangamo BioSciences, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
WO2014089541A2 (en) | 2012-12-07 | 2014-06-12 | Haplomics, Inc. | Factor viii mutation repair and tolerance induction |
WO2014089313A1 (en) | 2012-12-05 | 2014-06-12 | Alnylam Pharmaceuticals | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2014093661A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products |
WO2014093622A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
WO2014093712A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
WO2014093635A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
WO2014093595A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
WO2014130723A1 (en) | 2013-02-20 | 2014-08-28 | Valerion Therapeutics, Llc | Methods and compositions for treatment of pompe disease |
EP2784162A1 (en) | 2012-12-12 | 2014-10-01 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
US8865667B2 (en) | 2007-09-12 | 2014-10-21 | California Institute Of Technology | Higher-order cellular information processing devices |
WO2014190157A1 (en) | 2013-05-22 | 2014-11-27 | Alnylam Pharmaceuticals, Inc. | Tmprss6 compositions and methods of use thereof |
WO2014190137A1 (en) | 2013-05-22 | 2014-11-27 | Alnylam Pharmaceuticals, Inc. | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2014190181A1 (en) | 2013-05-22 | 2014-11-27 | Northwestern University | Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis |
WO2014204729A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
WO2014204728A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
WO2015031619A1 (en) | 2013-08-28 | 2015-03-05 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
WO2015042564A1 (en) | 2013-09-23 | 2015-03-26 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing transthyretin (ttr) associated diseases |
US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
WO2015057980A1 (en) | 2013-10-17 | 2015-04-23 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
US9029524B2 (en) | 2007-12-10 | 2015-05-12 | California Institute Of Technology | Signal activated RNA interference |
WO2015070212A1 (en) | 2013-11-11 | 2015-05-14 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
US9040495B2 (en) | 2007-08-28 | 2015-05-26 | California Institute Of Technology | General composition framework for ligand-controlled RNA regulatory systems |
WO2015085113A1 (en) | 2013-12-04 | 2015-06-11 | Rxi Pharmaceuticals Corporation | Methods for treatment of wound healing utilizing chemically modified oligonucleotides |
US9057057B2 (en) | 2010-07-27 | 2015-06-16 | The Johns Hopkins University | Obligate heterodimer variants of foki cleavage domain |
WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
WO2015089465A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
US9074211B2 (en) | 2008-11-19 | 2015-07-07 | Rxi Pharmaceuticals Corporation | Inhibition of MAP4K4 through RNAI |
US9074224B2 (en) | 2009-08-03 | 2015-07-07 | Recombinetics, Inc. | Methods and compositions for targeted gene modification |
WO2015106128A2 (en) | 2014-01-09 | 2015-07-16 | Alnylam Pharmaceuticals, Inc. | MODIFIED RNAi AGENTS |
WO2015117081A2 (en) | 2014-02-03 | 2015-08-06 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a beta thalessemia |
WO2015123264A1 (en) | 2014-02-11 | 2015-08-20 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
US9139554B2 (en) | 2008-10-09 | 2015-09-22 | Tekmira Pharmaceuticals Corporation | Amino lipids and methods for the delivery of nucleic acids |
WO2015143046A2 (en) | 2014-03-18 | 2015-09-24 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of zinc finger protein expression |
US9145555B2 (en) | 2009-04-02 | 2015-09-29 | California Institute Of Technology | Integrated—ligand-responsive microRNAs |
WO2015168605A1 (en) | 2014-05-01 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules |
WO2015168108A2 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic targeting mdm2 or mycn |
WO2015171932A1 (en) | 2014-05-08 | 2015-11-12 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
EP2947146A1 (en) | 2004-02-05 | 2015-11-25 | Sangamo BioSciences, Inc. | Methods and compositions for targeted cleavage and recombination |
WO2015179724A1 (en) | 2014-05-22 | 2015-11-26 | Alnylam Pharmaceuticals, Inc. | Angiotensinogen (agt) irna compositions and methods of use thereof |
WO2015184268A1 (en) | 2014-05-30 | 2015-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods of delivering treatments for latent viral infections |
EP2980220A1 (en) | 2005-09-20 | 2016-02-03 | BASF Plant Science GmbH | Improved methods controlling gene expression |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
WO2016028649A1 (en) | 2014-08-20 | 2016-02-25 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
WO2016037071A2 (en) | 2014-09-05 | 2016-03-10 | Rxi Pharmaceuticals Corporation | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
WO2016044416A1 (en) | 2014-09-16 | 2016-03-24 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
WO2016049251A1 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes |
US9301993B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding apoptosis inducing factor 1 |
US9309568B2 (en) | 2004-10-05 | 2016-04-12 | California Institute Of Technology | Aptamer regulated nucleic acids and uses thereof |
WO2016057693A1 (en) | 2014-10-10 | 2016-04-14 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
WO2016057893A1 (en) | 2014-10-10 | 2016-04-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
EP3009511A2 (en) | 2015-06-18 | 2016-04-20 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
WO2016061487A1 (en) | 2014-10-17 | 2016-04-21 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
WO2016077321A1 (en) | 2014-11-10 | 2016-05-19 | Alnylam Pharmaceuticals, Inc. | Hepatitis b virus (hbv) irna compositions and methods of use thereof |
WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
US9358300B2 (en) | 1998-11-12 | 2016-06-07 | Life Technologies Corporation | Transfection reagents |
WO2016094867A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Protected guide rnas (pgrnas) |
WO2016094872A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
WO2016106244A1 (en) | 2014-12-24 | 2016-06-30 | The Broad Institute Inc. | Crispr having or associated with destabilization domains |
WO2016108926A1 (en) | 2014-12-30 | 2016-07-07 | The Broad Institute Inc. | Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis |
WO2016123230A1 (en) | 2015-01-28 | 2016-08-04 | Pioneer Hi-Bred International, Inc. | Crispr hybrid dna/rna polynucleotides and methods of use |
WO2016130806A2 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
EP3061834A1 (en) | 2005-10-21 | 2016-08-31 | The Regents of the University of California | Shp-2 gene mutations in melanoma |
WO2016161446A1 (en) | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
WO2016164746A1 (en) | 2015-04-08 | 2016-10-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
WO2016179342A2 (en) | 2015-05-06 | 2016-11-10 | Alnylam Pharmaceuticals, Inc. | Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof |
US9492386B2 (en) | 2002-06-28 | 2016-11-15 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
WO2016186772A2 (en) | 2015-05-16 | 2016-11-24 | Genzyme Corporation | Gene editing of deep intronic mutations |
WO2016196388A1 (en) | 2015-05-29 | 2016-12-08 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
WO2016201301A1 (en) | 2015-06-12 | 2016-12-15 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
WO2016205728A1 (en) | 2015-06-17 | 2016-12-22 | Massachusetts Institute Of Technology | Crispr mediated recording of cellular events |
WO2016205749A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2016205764A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
US9533047B2 (en) | 2011-03-31 | 2017-01-03 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
WO2017011286A1 (en) | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof |
WO2017011519A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
WO2017040078A1 (en) | 2015-09-02 | 2017-03-09 | Alnylam Pharmaceuticals, Inc. | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
US9592250B2 (en) | 2002-02-01 | 2017-03-14 | Life Technologies Corporation | Double-stranded oligonucleotides |
EP3141265A1 (en) | 2007-12-04 | 2017-03-15 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
WO2017048620A1 (en) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
EP3156062A1 (en) | 2010-05-17 | 2017-04-19 | Sangamo BioSciences, Inc. | Novel dna-binding proteins and uses thereof |
WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
WO2017070605A1 (en) | 2015-10-22 | 2017-04-27 | The Broad Institute Inc. | Type vi-b crispr enzymes and systems |
WO2017100542A1 (en) | 2015-12-10 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof |
WO2017106537A2 (en) | 2015-12-18 | 2017-06-22 | Sangamo Biosciences, Inc. | Targeted disruption of the mhc cell receptor |
WO2017106528A2 (en) | 2015-12-18 | 2017-06-22 | Sangamo Biosciences, Inc. | Targeted disruption of the t cell receptor |
WO2017106657A1 (en) | 2015-12-18 | 2017-06-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2017111172A1 (en) | 2015-12-25 | 2017-06-29 | 協和発酵キリン株式会社 | Compounds as cationic lipids |
WO2017123757A1 (en) | 2016-01-15 | 2017-07-20 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of neurologic disease |
WO2017165788A1 (en) | 2016-03-24 | 2017-09-28 | Marquette University | Quantitative flagellar fluorescent markers and standards |
WO2017184768A1 (en) | 2016-04-19 | 2017-10-26 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2017184786A1 (en) | 2016-04-19 | 2017-10-26 | The Broad Institute Inc. | Cpf1 complexes with reduced indel activity |
WO2017189308A1 (en) | 2016-04-19 | 2017-11-02 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2017214518A1 (en) | 2016-06-10 | 2017-12-14 | Alnylam Pharmaceuticals, Inc. | COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
WO2017219027A1 (en) | 2016-06-17 | 2017-12-21 | The Broad Institute Inc. | Type vi crispr orthologs and systems |
WO2018005873A1 (en) | 2016-06-29 | 2018-01-04 | The Broad Institute Inc. | Crispr-cas systems having destabilization domain |
WO2018013840A1 (en) | 2016-07-13 | 2018-01-18 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
WO2018013932A1 (en) | 2016-07-15 | 2018-01-18 | Salk Institute For Biological Studies | Methods and compositions for genome editing in non-dividing cells |
US9890364B2 (en) | 2012-05-29 | 2018-02-13 | The General Hospital Corporation | TAL-Tet1 fusion proteins and methods of use thereof |
WO2018029586A1 (en) | 2016-08-07 | 2018-02-15 | Novartis Ag | Mrna-mediated immunization methods |
WO2018035388A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
WO2018035387A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
WO2018039448A1 (en) | 2016-08-24 | 2018-03-01 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
WO2018039440A1 (en) | 2016-08-24 | 2018-03-01 | Sangamo Therapeutics, Inc. | Regulation of gene expression using engineered nucleases |
WO2018067826A1 (en) | 2016-10-05 | 2018-04-12 | Cellular Dynamics International, Inc. | Generating mature lineages from induced pluripotent stem cells with mecp2 disruption |
WO2018071873A2 (en) | 2016-10-13 | 2018-04-19 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
EP3311822A1 (en) | 2010-11-17 | 2018-04-25 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating pd1 |
EP3312281A2 (en) | 2013-03-14 | 2018-04-25 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
WO2018081775A1 (en) | 2016-10-31 | 2018-05-03 | Sangamo Therapeutics, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
WO2018098117A1 (en) | 2016-11-23 | 2018-05-31 | Alnylam Pharmaceuticals, Inc. | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2018102612A1 (en) | 2016-12-02 | 2018-06-07 | Juno Therapeutics, Inc. | Engineered b cells and related compositions and methods |
WO2018106782A1 (en) | 2016-12-08 | 2018-06-14 | Case Western Reserve University | Methods and compositions for enhancing functional myelin production |
WO2018112320A1 (en) | 2016-12-16 | 2018-06-21 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions |
WO2018119060A1 (en) | 2016-12-20 | 2018-06-28 | Bristol-Myers Squibb Company | Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome |
EP3354275A1 (en) | 2009-02-04 | 2018-08-01 | Sangamo Therapeutics, Inc. | Methods and compositions for treating neuropathies |
WO2018170333A1 (en) | 2017-03-15 | 2018-09-20 | The Broad Institute, Inc. | Novel cas13b orthologues crispr enzymes and systems |
WO2018191388A1 (en) | 2017-04-12 | 2018-10-18 | The Broad Institute, Inc. | Novel type vi crispr orthologs and systems |
WO2018195165A1 (en) | 2017-04-18 | 2018-10-25 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
WO2018208910A1 (en) | 2017-05-09 | 2018-11-15 | The Broad Institute Inc. | Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases |
US10131904B2 (en) | 2008-02-11 | 2018-11-20 | Rxi Pharmaceuticals Corporation | Modified RNAi polynucleotides and uses thereof |
WO2018229521A1 (en) | 2016-06-16 | 2018-12-20 | Oslo Universitetssykehus Hf | Improved gene editing |
WO2018234370A1 (en) | 2017-06-20 | 2018-12-27 | Institut Curie | Immune cells defective for suv39h1 |
WO2019005884A1 (en) | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing |
WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
US10195280B2 (en) | 2014-07-15 | 2019-02-05 | Life Technologies Corporation | Compositions and methods for efficient delivery of molecules to cells |
WO2019060746A1 (en) | 2017-09-21 | 2019-03-28 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
WO2019089922A1 (en) | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
US10287565B2 (en) | 2014-07-28 | 2019-05-14 | Sk Innovation Co., Ltd. | Isoprene synthase and method of preparing isoprene using thereof |
WO2019100023A1 (en) | 2017-11-17 | 2019-05-23 | Iovance Biotherapeutics, Inc. | Til expansion from fine needle aspirates and small biopsies |
WO2019100039A1 (en) | 2017-11-20 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
WO2019103857A1 (en) | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
EP3492593A1 (en) | 2013-11-13 | 2019-06-05 | Children's Medical Center Corporation | Nuclease-mediated regulation of gene expression |
EP3498833A1 (en) | 2011-09-21 | 2019-06-19 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of transgene expression |
WO2019126651A1 (en) | 2017-12-21 | 2019-06-27 | Alnylam Pharmaceuticals, Inc. | Chirally-enriched double-stranded rna agents |
WO2019136456A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
WO2019143678A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
WO2019143675A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
WO2019143677A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency |
WO2019160383A1 (en) | 2018-02-19 | 2019-08-22 | 고려대학교 산학협력단 | Vaccine comprising epitope of heat shock protein, and use thereof |
WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
WO2019236566A1 (en) | 2018-06-05 | 2019-12-12 | Lifeedit, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
US10544405B2 (en) | 2013-01-16 | 2020-01-28 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
EP3604533A1 (en) | 2008-04-11 | 2020-02-05 | Arbutus Biopharma Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
WO2020033601A1 (en) | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Novel cas12b enzymes and systems |
WO2020041380A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
GB202000934D0 (en) | 2020-01-22 | 2020-03-04 | Ucl Business Ltd | Engineered immune cells |
WO2020060986A1 (en) | 2018-09-18 | 2020-03-26 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
WO2020069373A1 (en) | 2018-09-28 | 2020-04-02 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
WO2020069029A1 (en) | 2018-09-26 | 2020-04-02 | Emendobio Inc. | Novel crispr nucleases |
WO2020065062A1 (en) | 2018-09-28 | 2020-04-02 | Wageningen Universiteit | Off-target activity inhibitors for guided endonucleases |
WO2020079033A1 (en) | 2018-10-15 | 2020-04-23 | Fondazione Telethon | Genome editing methods and constructs |
WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
WO2020096927A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
WO2020096988A2 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
WO2020096986A2 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
WO2020096989A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
EP3653229A1 (en) | 2013-12-12 | 2020-05-20 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing |
WO2020102659A1 (en) | 2018-11-15 | 2020-05-22 | The Broad Institute, Inc. | G-to-t base editors and uses thereof |
US10676749B2 (en) | 2013-02-07 | 2020-06-09 | The General Hospital Corporation | Tale transcriptional activators |
WO2020117840A2 (en) | 2018-12-05 | 2020-06-11 | Empirico Inc. | Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions |
WO2020131862A1 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Crispr-associated transposase systems and methods of use thereof |
WO2020132521A1 (en) | 2018-12-20 | 2020-06-25 | Praxis Precision Medicines, Inc. | Compositions and methods for the treatment of kcnt1 related disorders |
WO2020131547A1 (en) | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
EP3674411A1 (en) | 2013-06-17 | 2020-07-01 | The Broad Institute, Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
EP3674408A1 (en) | 2014-06-16 | 2020-07-01 | The Johns Hopkins University | Compositions and methods for the expression of crispr guide rnas |
WO2020139783A2 (en) | 2018-12-27 | 2020-07-02 | Lifeedit, Inc. | Polypeptides useful for gene editing and methods of use |
US10724020B2 (en) | 2016-02-02 | 2020-07-28 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
EP3686279A1 (en) | 2014-08-17 | 2020-07-29 | The Broad Institute, Inc. | Genome editing using cas9 nickases |
US10730942B2 (en) | 2016-07-25 | 2020-08-04 | Ucl Business Ltd | Protein-based T-cell receptor knockdown |
US10738278B2 (en) | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
WO2020163307A1 (en) | 2019-02-06 | 2020-08-13 | Emendobio Inc. | New engineered high fidelity cas9 |
WO2020163379A1 (en) | 2019-02-05 | 2020-08-13 | Emendobio Inc. | Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene |
WO2020172343A2 (en) | 2019-02-19 | 2020-08-27 | Massachusetts Institute Of Technology | Methods for treating injuries |
WO2020181195A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through adenine excision |
WO2020181180A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | A:t to c:g base editors and uses thereof |
WO2020180733A1 (en) | 2019-03-01 | 2020-09-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2020181193A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through adenosine methylation |
WO2020181178A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through thymine alkylation |
WO2020181202A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | A:t to t:a base editing through adenine deamination and oxidation |
WO2020183197A1 (en) | 2019-03-14 | 2020-09-17 | Ucl Business Ltd | Minimal promoter |
WO2020191171A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
WO2020191102A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
US10786533B2 (en) | 2015-07-15 | 2020-09-29 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
WO2020205838A1 (en) | 2019-04-02 | 2020-10-08 | Sangamo Therapeutics, Inc. | Methods for the treatment of beta-thalassemia |
WO2020210751A1 (en) | 2019-04-12 | 2020-10-15 | The Broad Institute, Inc. | System for genome editing |
US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
EP3725885A1 (en) | 2013-06-17 | 2020-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
EP3730615A2 (en) | 2013-05-15 | 2020-10-28 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
WO2020223539A1 (en) | 2019-04-30 | 2020-11-05 | The Broad Institute, Inc. | Methods and compositions for barcoding nucleic acid libraries and cell populations |
WO2020232271A1 (en) | 2019-05-14 | 2020-11-19 | The Broad Institute, Inc. | Compositions and methods for targeting multinucleated cells |
WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
WO2020236600A1 (en) | 2019-05-17 | 2020-11-26 | Alnylam Pharmaceuticals, Inc. | Oral delivery of oligonucleotides |
WO2020236982A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Aav delivery of nucleobase editors |
WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
WO2020243276A1 (en) | 2019-05-29 | 2020-12-03 | Altria Client Services Llc | Compositions and methods for producing tobacco plants and products having reduced or eliminated suckers |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
WO2020243485A1 (en) | 2019-05-29 | 2020-12-03 | Massachusetts Institute Of Technology | Hiv-1 specific immunogen compositions and methods of use |
EP3757116A1 (en) | 2013-12-09 | 2020-12-30 | Sangamo Therapeutics, Inc. | Methods and compositions for genome engineering |
WO2021001534A1 (en) | 2019-07-03 | 2021-01-07 | Wageningen Universiteit | Crispr type v-u1 system from mycobacterium mucogenicum and uses thereof |
WO2021013950A1 (en) | 2019-07-23 | 2021-01-28 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
WO2021025750A1 (en) | 2019-08-08 | 2021-02-11 | The Broad Institute, Inc. | Base editors with diversified targeting scope |
WO2021030666A1 (en) | 2019-08-15 | 2021-02-18 | The Broad Institute, Inc. | Base editing by transglycosylation |
WO2021030522A1 (en) | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021030344A1 (en) | 2019-08-12 | 2021-02-18 | Lifeedit, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2021034717A1 (en) | 2019-08-16 | 2021-02-25 | Massachusetts Institute Of Technology | Targeted trans-splicing using crispr/cas13 |
WO2021045292A1 (en) | 2019-09-03 | 2021-03-11 | 주식회사 제노포커스 | Crm197 protein expression method |
EP3798306A1 (en) | 2013-12-12 | 2021-03-31 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
WO2021072248A2 (en) | 2019-10-10 | 2021-04-15 | Altria Client Services Llc | Pale yellow locus and its applications in tobacco |
WO2021072328A1 (en) | 2019-10-10 | 2021-04-15 | The Broad Institute, Inc. | Methods and compositions for prime editing rna |
WO2021087036A1 (en) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021087361A1 (en) | 2019-11-01 | 2021-05-06 | Sangamo Therapeutics, Inc. | Zinc finger nuclease variants for treating or preventing lysosomal storage diseases |
US11001845B2 (en) | 2015-07-06 | 2021-05-11 | Phio Pharmaceuticals Corp. | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) |
WO2021092464A2 (en) | 2019-11-08 | 2021-05-14 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy |
EP3825406A1 (en) | 2013-06-17 | 2021-05-26 | The Broad Institute Inc. | Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy |
WO2021102373A1 (en) | 2019-11-22 | 2021-05-27 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
WO2021108717A2 (en) | 2019-11-26 | 2021-06-03 | The Broad Institute, Inc | Systems and methods for evaluating cas9-independent off-target editing of nucleic acids |
WO2021118990A1 (en) | 2019-12-11 | 2021-06-17 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
WO2021119226A1 (en) | 2019-12-13 | 2021-06-17 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
WO2021126435A1 (en) | 2019-12-20 | 2021-06-24 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
WO2021138247A1 (en) | 2019-12-30 | 2021-07-08 | LifeEDIT Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2021138537A1 (en) | 2019-12-31 | 2021-07-08 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides with improved systemic delivery |
WO2021155065A1 (en) | 2020-01-28 | 2021-08-05 | The Broad Institute, Inc. | Base editors, compositions, and methods for modifying the mitochondrial genome |
WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
WO2021158921A2 (en) | 2020-02-05 | 2021-08-12 | The Broad Institute, Inc. | Adenine base editors and uses thereof |
WO2021158999A1 (en) | 2020-02-05 | 2021-08-12 | The Broad Institute, Inc. | Gene editing methods for treating spinal muscular atrophy |
WO2021163191A1 (en) | 2020-02-10 | 2021-08-19 | Board Of Regents, The University Of Texas System | Methods for rapid cloning and expression of hla class i cells |
WO2021178607A1 (en) | 2020-03-05 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
US11116778B2 (en) | 2019-01-15 | 2021-09-14 | Empirico Inc. | Prodrugs of ALOX-15 inhibitors and methods of using the same |
US11124796B2 (en) | 2014-09-24 | 2021-09-21 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
WO2021195307A1 (en) | 2020-03-26 | 2021-09-30 | Alnylam Pharmaceuticals, Inc. | Coronavirus irna compositions and methods of use thereof |
WO2021206922A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
WO2021206917A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021217002A1 (en) | 2020-04-24 | 2021-10-28 | Lifeedit Therapeutics, Inc . | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2021222065A1 (en) | 2020-04-27 | 2021-11-04 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein e (apoe) irna agent compositions and methods of use thereof |
WO2021222318A1 (en) | 2020-04-28 | 2021-11-04 | The Broad Institute, Inc. | Targeted base editing of the ush2a gene |
WO2021226061A1 (en) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
WO2021224395A1 (en) | 2020-05-06 | 2021-11-11 | Cellectis S.A. | Methods for targeted insertion of exogenous sequences in cellular genomes |
WO2021224416A1 (en) | 2020-05-06 | 2021-11-11 | Cellectis S.A. | Methods to genetically modify cells for delivery of therapeutic proteins |
WO2021231692A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
WO2021231675A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
WO2021231679A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
WO2021231673A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
WO2021231685A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
WO2021231437A1 (en) | 2020-05-11 | 2021-11-18 | LifeEDIT Therapeutics, Inc. | Rna-guided nucleic acid binding proteins and active fragments and variants thereof and methods of use |
WO2021231691A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi) |
WO2021231698A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
WO2021231680A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
EP3916086A1 (en) | 2017-06-23 | 2021-12-01 | Inscripta, Inc. | Nucleic acid-guided nucleases |
WO2021252557A1 (en) | 2020-06-09 | 2021-12-16 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US11219695B2 (en) | 2016-10-20 | 2022-01-11 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of Fabry disease |
WO2022011262A1 (en) | 2020-07-10 | 2022-01-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating epilepsy |
WO2022015969A1 (en) | 2020-07-15 | 2022-01-20 | LifeEDIT Therapeutics, Inc. | Uracil stabilizing proteins and active fragments and variants thereof and methods of use |
WO2022023576A1 (en) | 2020-07-30 | 2022-02-03 | Institut Curie | Immune cells defective for socs1 |
US11246933B1 (en) | 2011-12-07 | 2022-02-15 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
WO2022034374A2 (en) | 2020-08-11 | 2022-02-17 | University Of Oslo | Improved gene editing |
WO2022046760A2 (en) | 2020-08-25 | 2022-03-03 | Kite Pharma, Inc. | T cells with improved functionality |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
WO2022051591A2 (en) | 2020-09-04 | 2022-03-10 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
WO2022056254A2 (en) | 2020-09-11 | 2022-03-17 | LifeEDIT Therapeutics, Inc. | Dna modifying enzymes and active fragments and variants thereof and methods of use |
WO2022060927A1 (en) | 2020-09-17 | 2022-03-24 | Northwestern University | Engineered mammalian genetic circuits and methods of using the same |
WO2022066847A1 (en) | 2020-09-24 | 2022-03-31 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
WO2022076291A1 (en) | 2020-10-05 | 2022-04-14 | Alnylam Pharmaceuticals, Inc. | G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
WO2022081015A1 (en) | 2020-10-16 | 2022-04-21 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Anti-tumor immunity induces the presentation of aberrant peptides |
WO2022087329A1 (en) | 2020-10-23 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
WO2022087041A1 (en) | 2020-10-21 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
WO2022119873A1 (en) | 2020-12-01 | 2022-06-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
WO2022150790A2 (en) | 2021-01-11 | 2022-07-14 | The Broad Institute, Inc. | Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision |
WO2022164319A1 (en) | 2021-01-29 | 2022-08-04 | Wageningen Universiteit | Crispr-associated base-editing of the complementary strand |
US11408000B2 (en) | 2020-06-03 | 2022-08-09 | Triplet Therapeutics, Inc. | Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity |
WO2022169836A1 (en) | 2021-02-03 | 2022-08-11 | Altria Client Services Llc | Terpene production in plants |
WO2022174000A2 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
WO2022182864A1 (en) | 2021-02-25 | 2022-09-01 | Alnylam Pharmaceuticals, Inc. | Prion protein (prnp) irna compositions and methods and methods of use thereof |
WO2022192789A1 (en) | 2021-03-12 | 2022-09-15 | Synthego Corporation | Genetically modified cells expressing antigen-containing fusion proteins and uses thereof |
WO2022192519A1 (en) | 2021-03-12 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
WO2022204093A1 (en) | 2021-03-22 | 2022-09-29 | LifeEDIT Therapeutics, Inc. | Dna modifyng enzymes and active fragments and variants thereof and methods of use |
WO2022212231A2 (en) | 2021-03-29 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
WO2022232343A1 (en) | 2021-04-29 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
WO2022245583A1 (en) | 2021-05-18 | 2022-11-24 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
WO2022243565A1 (en) | 2021-05-21 | 2022-11-24 | Cellectis S.A. | Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors |
WO2022246023A1 (en) | 2021-05-20 | 2022-11-24 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
WO2022256290A2 (en) | 2021-06-04 | 2022-12-08 | Alnylam Pharmaceuticals, Inc. | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2022261509A1 (en) | 2021-06-11 | 2022-12-15 | The Broad Institute, Inc. | Improved cytosine to guanine base editors |
WO2022261394A1 (en) | 2021-06-11 | 2022-12-15 | LifeEDIT Therapeutics, Inc. | Rna polymerase iii promoters and methods of use |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
WO2023278410A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2023278407A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
WO2023003995A1 (en) | 2021-07-23 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Beta-catenin (ctnnb1) irna compositions and methods of use thereof |
WO2023015265A2 (en) | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides |
WO2023015309A2 (en) | 2021-08-06 | 2023-02-09 | The Broad Institute, Inc. | Improved prime editors and methods of use |
WO2023015264A1 (en) | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides |
US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US11591544B2 (en) | 2020-11-25 | 2023-02-28 | Akagera Medicines, Inc. | Ionizable cationic lipids |
WO2023055239A1 (en) | 2021-10-01 | 2023-04-06 | Koninklijke Nederlandse Akademie Van Wetenschappen | Mammalian cardiac regeneration |
DE112021002672T5 (en) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE |
WO2023069603A1 (en) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
WO2023076450A2 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2023076898A1 (en) | 2021-10-25 | 2023-05-04 | The Broad Institute, Inc. | Methods and compositions for editing a genome with prime editing and a recombinase |
WO2023077148A1 (en) | 2021-11-01 | 2023-05-04 | Tome Biosciences, Inc. | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
WO2023080788A1 (en) | 2021-11-05 | 2023-05-11 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Tryptophan depletion induces production and presentation of tryptophan to phenylalanine substitutions |
US11649444B1 (en) | 2021-11-02 | 2023-05-16 | Huidagene Therapeutics Co., Ltd. | CRISPR-CAS12i systems |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
WO2023096494A1 (en) | 2021-11-26 | 2023-06-01 | Synvolux Ip B.V. | Conserved coronavirus t cell epitopes |
WO2023122762A1 (en) | 2021-12-22 | 2023-06-29 | Camp4 Therapeutics Corporation | Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas |
WO2023122764A1 (en) | 2021-12-22 | 2023-06-29 | Tome Biosciences, Inc. | Co-delivery of a gene editor construct and a donor template |
US11692182B2 (en) | 2015-10-09 | 2023-07-04 | Monsanto Technology Llc | RNA-guided DNA nucleases and uses thereof |
WO2023126458A1 (en) | 2021-12-28 | 2023-07-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
WO2023139557A1 (en) | 2022-01-24 | 2023-07-27 | LifeEDIT Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
WO2023150637A1 (en) | 2022-02-02 | 2023-08-10 | Inscripta, Inc. | Nucleic acid-guided nickase fusion proteins |
EP4234570A2 (en) | 2018-09-18 | 2023-08-30 | Sangamo Therapeutics, Inc. | Programmed cell death 1 (pd1) specific nucleases |
EP4245853A2 (en) | 2013-06-17 | 2023-09-20 | The Broad Institute, Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
US11766488B2 (en) | 2016-07-05 | 2023-09-26 | The Johns Hopkins University | Compositions and methods comprising improvements of CRISPR guide RNAS using the H1 promoter |
WO2023196851A1 (en) | 2022-04-06 | 2023-10-12 | President And Fellows Of Harvard College | Reversing aging of the central nervous system |
WO2023196802A1 (en) | 2022-04-04 | 2023-10-12 | The Broad Institute, Inc. | Cas9 variants having non-canonical pam specificities and uses thereof |
WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
WO2023212715A1 (en) | 2022-04-28 | 2023-11-02 | The Broad Institute, Inc. | Aav vectors encoding base editors and uses thereof |
WO2023215831A1 (en) | 2022-05-04 | 2023-11-09 | Tome Biosciences, Inc. | Guide rna compositions for programmable gene insertion |
WO2023220459A1 (en) | 2022-05-13 | 2023-11-16 | Northwestern University | Active loading of cargo entity into lipid bilayer particles using dimerization domains |
WO2023220457A1 (en) | 2022-05-13 | 2023-11-16 | Northwestern University | Receptor engagement-mediated enhancement of biologics delivery |
WO2023220392A1 (en) | 2022-05-13 | 2023-11-16 | Northwestern University | Synthetic modular extracellular sensors that employ natural receptor ligand-binding domains |
US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
WO2023222928A2 (en) | 2022-05-20 | 2023-11-23 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
WO2023230613A1 (en) | 2022-05-27 | 2023-11-30 | The Broad Institute, Inc. | Improved mitochondrial base editors and methods for editing mitochondrial dna |
WO2023230433A1 (en) | 2022-05-23 | 2023-11-30 | Altria Client Services Llc | Methods and compositions for regulating alkaloids in tobacco field |
WO2023240137A1 (en) | 2022-06-08 | 2023-12-14 | The Board Institute, Inc. | Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing |
WO2023240277A2 (en) | 2022-06-10 | 2023-12-14 | Camp4 Therapeutics Corporation | Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas |
WO2024003334A1 (en) | 2022-06-30 | 2024-01-04 | Cellectis S.A. | Enhancing safety of t-cell-mediated immunotherapy |
US11866469B2 (en) | 2019-02-06 | 2024-01-09 | Klogenix Llc | DNA binding proteins and uses thereof |
US11872262B2 (en) | 2017-05-09 | 2024-01-16 | Vib Vzw | Means and methods for treating bacterial infections |
WO2024015383A1 (en) | 2022-07-12 | 2024-01-18 | Northwestern University | Engineered hypoxia biosensors and methods of using the same |
WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
WO2024031038A1 (en) | 2022-08-05 | 2024-02-08 | Altria Client Services Llc | Methods and compositions for regulating alkaloids in tobacco |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
WO2024033901A1 (en) | 2022-08-12 | 2024-02-15 | LifeEDIT Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2024040083A1 (en) | 2022-08-16 | 2024-02-22 | The Broad Institute, Inc. | Evolved cytosine deaminases and methods of editing dna using same |
WO2024042489A1 (en) | 2022-08-25 | 2024-02-29 | LifeEDIT Therapeutics, Inc. | Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing |
US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
WO2024047587A1 (en) | 2022-08-31 | 2024-03-07 | Regel Therapeutics, Inc. | Cas-phi compositions and methods of use |
EP4335925A2 (en) | 2019-04-09 | 2024-03-13 | The Regents of the University of California | Long-lasting analgesia via targeted in vivo epigenetic repression |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
Families Citing this family (935)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6156304A (en) * | 1990-12-20 | 2000-12-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Gene transfer for studying and treating a connective tissue of a mammalian host |
US6605712B1 (en) * | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
US7202225B1 (en) * | 1993-10-15 | 2007-04-10 | Emanuele R Martin | Therapeutic delivery compositions and methods of use thereof |
US20020123476A1 (en) * | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
US5756353A (en) * | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
US6627615B1 (en) | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
CA2126101A1 (en) | 1991-12-17 | 1993-06-24 | Robert J. Debs | Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr) |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5885970A (en) * | 1992-03-16 | 1999-03-23 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against human protein kinase C |
US6113946A (en) * | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
US20020108136A1 (en) * | 1997-03-21 | 2002-08-08 | Sri | Transgenic animals produced by homologous sequence targeting |
US6806084B1 (en) * | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
IL105914A0 (en) * | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
US7105574B1 (en) | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US5523389A (en) * | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
US5705655A (en) * | 1992-12-17 | 1998-01-06 | Megabios Corporation | Amphiphilic nitrogen containing imidazolinium derivative compounds and uses |
US5631237A (en) * | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
ATE258685T1 (en) * | 1993-03-09 | 2004-02-15 | Baxter Int | MACROMOLECULAR MICROPARTICLES AND METHOD FOR THE PRODUCTION THEREOF |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US6348449B1 (en) | 1993-09-21 | 2002-02-19 | The Trustees Of The University Of Pennsylvania | Methods of inducing mucosal immunity |
US5665879A (en) * | 1993-11-24 | 1997-09-09 | Megabios Corporation | Amphiphilic derivatives of piperazine |
KR960705771A (en) * | 1993-11-24 | 1996-11-08 | 벤자민 에프 맥그로우 | Amphiphilic derivatives of guanidine (AMPHIPHILIC DERIVATIVES OF GUANIDINE) |
JPH09505593A (en) * | 1993-11-24 | 1997-06-03 | メガバイオス・コーポレイション | Amphiphilic derivatives of piperazine |
US6613351B1 (en) * | 1993-12-20 | 2003-09-02 | Biotech Tools S.A. | Compound capable of introducing at least one molecule into a cell |
US5928944A (en) * | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
US6074840A (en) | 1994-02-18 | 2000-06-13 | The Regents Of The University Of Michigan | Recombinant production of latent TGF-beta binding protein-3 (LTBP-3) |
US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US5962427A (en) | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
US5763416A (en) | 1994-02-18 | 1998-06-09 | The Regent Of The University Of Michigan | Gene transfer into bone cells and tissues |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
CA2187322A1 (en) * | 1994-04-07 | 1995-10-19 | Israel Rubinstein | Vasoactive intestinal polypeptide |
WO1995031183A1 (en) * | 1994-05-16 | 1995-11-23 | Washington University | Cell membrane fusion composition and method |
US7592317B1 (en) * | 1994-08-11 | 2009-09-22 | The University Of Chicago | Constitutive gene expression in conjuction with ionizing radiation |
AUPM747694A0 (en) * | 1994-08-16 | 1994-09-08 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids and peptides |
US5892071A (en) * | 1994-09-30 | 1999-04-06 | The Reagents Of The University Of California | Cationic transport reagents |
US5527928A (en) * | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
US6911216B1 (en) | 1994-10-12 | 2005-06-28 | Genzyme Corporation | Targeted delivery via biodegradable polymers |
US5641665A (en) * | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
US5767099A (en) * | 1994-12-09 | 1998-06-16 | Genzyme Corporation | Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules |
US5719131A (en) * | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
US6071890A (en) * | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US5910487A (en) * | 1994-12-09 | 1999-06-08 | Genzyme Corporation | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
US5747471A (en) * | 1994-12-09 | 1998-05-05 | Genzyme Corporation | Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules |
US5840710A (en) * | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
US5650096A (en) * | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US6630455B1 (en) | 1995-01-13 | 2003-10-07 | Vanderbilt University | Methods for inducing mucosal immune responses |
US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5929043A (en) * | 1995-01-31 | 1999-07-27 | Pangene Corporation | Recombinase mediated DNA therapies |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US6752987B1 (en) | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
WO1996026742A1 (en) | 1995-02-28 | 1996-09-06 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
US20030148968A1 (en) * | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
US5962428A (en) * | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US20020183288A1 (en) * | 1995-04-03 | 2002-12-05 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
US6242434B1 (en) * | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
US20040043971A1 (en) * | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
US6420549B1 (en) | 1995-06-06 | 2002-07-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide analogs having modified dimers |
US5994315A (en) * | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
EP0840744A4 (en) * | 1995-06-07 | 1999-03-10 | Genta Inc | Phosphonic acid-based cationic lipids |
US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5869040A (en) * | 1995-06-07 | 1999-02-09 | Biogen, Inc | Gene therapy methods and compositions |
US20030069173A1 (en) * | 1998-03-16 | 2003-04-10 | Life Technologies, Inc. | Peptide-enhanced transfections |
JPH11507352A (en) | 1995-06-07 | 1999-06-29 | ジンタ・インコーポレイテッド | New carbamate-based cationic lipids |
DE19521412A1 (en) * | 1995-06-14 | 1996-12-19 | Boehringer Mannheim Gmbh | New cationic and polycationic amphiphiles, reagents containing them and their use |
US5931809A (en) * | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
US6339173B1 (en) | 1996-07-22 | 2002-01-15 | Promega Biosciences, Inc. | Amide-based cationic lipids |
CA2227373A1 (en) * | 1995-07-21 | 1997-02-06 | Promega Biosciences, Inc. | Novel amide-based cationic lipids |
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
NO953680D0 (en) * | 1995-09-18 | 1995-09-18 | Hans Prydz | Cell cycle Enzymes |
US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
US6086913A (en) * | 1995-11-01 | 2000-07-11 | University Of British Columbia | Liposomal delivery of AAV vectors |
US6126964A (en) * | 1996-01-04 | 2000-10-03 | Mirus Corporation | Process of making a compound by forming a polymer from a template drug |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
US20040014709A1 (en) * | 1996-01-08 | 2004-01-22 | Canji, Inc. | Methods and compositions for interferon therapy |
US7002027B1 (en) | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
US6392069B2 (en) * | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
AU2112697A (en) * | 1996-02-09 | 1997-08-28 | Pi-Wan Cheng | Receptor ligand-facilitated delivery of biologically active molecules |
WO1997034483A1 (en) * | 1996-03-18 | 1997-09-25 | California Institute Of Technology | Methods for increasing or decreasing transfection efficiency |
US5783566A (en) * | 1996-05-10 | 1998-07-21 | California Institute Of Technology | Method for increasing or decreasing transfection efficiency |
US5994317A (en) * | 1996-04-09 | 1999-11-30 | Vical Incorporated | Quaternary cytofectins |
US5798250A (en) * | 1996-04-15 | 1998-08-25 | Icn Pharmaceuticals, Inc. | Facilitating hepatitus virus infection in cell culture using a membrane stressor |
ATE345682T1 (en) * | 1996-05-01 | 2006-12-15 | Imarx Pharmaceutical Corp | IN VITRO METHOD FOR INTRODUCING NUCLEIC ACIDS INTO A CELL |
WO1997042819A1 (en) * | 1996-05-13 | 1997-11-20 | Alberto Haces | Cationic lipids for transfection of negatively charged or neutral molecules into living cells |
US5980935A (en) * | 1996-05-15 | 1999-11-09 | Kirpotin; Dmitri | Cationic lipids and methods of use therefor |
US6274136B1 (en) * | 1996-05-29 | 2001-08-14 | University Of Southern California | Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease |
US8323963B2 (en) * | 1996-05-29 | 2012-12-04 | University Of Southern California | Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease |
US5935936A (en) * | 1996-06-03 | 1999-08-10 | Genzyme Corporation | Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
ES2305157T3 (en) * | 1996-09-13 | 2008-11-01 | Lipoxen Technologies Limited | LIPOSOMES |
US7384923B2 (en) * | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
US5861397A (en) * | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
JP2001510457A (en) * | 1996-11-12 | 2001-07-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Preparation of stable lipid-nucleic acid complex formulations effective for in vivo delivery |
US6210707B1 (en) * | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
CZ299055B6 (en) | 1996-12-06 | 2008-04-09 | Aventis Pharmaceuticals Inc. | Isolated polypeptide encoded by a lipase like gene, composition having phospholipase activity, pharmaceutical composition, isolated immunizing peptide and nucleic acid, biologically compatible solution, vector, recombinant cell, formulation useable f |
US7008776B1 (en) * | 1996-12-06 | 2006-03-07 | Aventis Pharmaceuticals Inc. | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
WO1998024936A1 (en) * | 1996-12-06 | 1998-06-11 | The Regents Of The University Of California | Macromolecule-lipid complexes and methods for making and using |
US20020128240A1 (en) * | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
US6527716B1 (en) | 1997-12-30 | 2003-03-04 | Altea Technologies, Inc. | Microporation of tissue for delivery of bioactive agents |
US20030129194A1 (en) * | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
PL336231A1 (en) * | 1997-02-13 | 2000-06-19 | Bone Care International | System for aimed therapeutic delivery of vitamin d compounds |
US5965542A (en) * | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
US5948653A (en) | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
US5925628A (en) * | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5958894A (en) * | 1997-04-04 | 1999-09-28 | Megabios Corporation | Amphiphilic biguanide derivatives |
US6235310B1 (en) | 1997-04-04 | 2001-05-22 | Valentis, Inc. | Methods of delivery using cationic lipids and helper lipids |
US5912239A (en) * | 1997-04-04 | 1999-06-15 | Genzyme Corporation | Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules |
FR2761912B1 (en) * | 1997-04-14 | 1999-07-02 | Capsulis | PROCESS FOR ADHERING A PRODUCT TO A SURFACE |
CN1177934C (en) | 1997-04-28 | 2004-12-01 | 阿文蒂斯药物股份有限公司 | Adneovirus-mediated intratumoral delivery of angiogenesis antagonist for treatment of tumors |
KR20010020375A (en) * | 1997-04-30 | 2001-03-15 | 무레 미카엘 에프. | In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes |
US5948925A (en) * | 1997-05-06 | 1999-09-07 | Genzyme Corporation | Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids |
US5952516A (en) * | 1997-05-08 | 1999-09-14 | Genzyme Corporation | Cationic amphiphiles containing multiplesteroid lipophilic groups |
US5942634A (en) * | 1997-05-09 | 1999-08-24 | Genzyme Corporation | Cationic amphiphiles for cell transfections |
US6835395B1 (en) | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
DE69841002D1 (en) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Highly effective encapsulation of nucleic acids in lipid vesicles |
US20030104044A1 (en) * | 1997-05-14 | 2003-06-05 | Semple Sean C. | Compositions for stimulating cytokine secretion and inducing an immune response |
WO1999002192A1 (en) * | 1997-07-11 | 1999-01-21 | Brandeis University | Method of inducing apoptosis by reducing the level of thiamin |
US20090239940A1 (en) * | 1997-07-22 | 2009-09-24 | Del Monte Federica | Treating heart failure and ventricular arrhythmias |
EP1007673B1 (en) | 1997-07-30 | 2008-12-17 | Emory University | Novel bone mineralization proteins, dna, vectors, expression systems |
US7923250B2 (en) | 1997-07-30 | 2011-04-12 | Warsaw Orthopedic, Inc. | Methods of expressing LIM mineralization protein in non-osseous cells |
AU9016998A (en) * | 1997-08-08 | 1999-03-01 | Newbiotics, Inc. | Methods and compositions for overcoming resistance to biologic and chemotherapy |
US6818627B1 (en) | 1997-08-14 | 2004-11-16 | The Trustees Of The University Of Pennsylvania | Functional fragments of HIV-1 Vpr protein and methods of using the same |
US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US6884842B2 (en) | 1997-10-14 | 2005-04-26 | Alnis Biosciences, Inc. | Molecular compounds having complementary surfaces to targets |
US6875606B1 (en) | 1997-10-23 | 2005-04-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Human α-7 nicotinic receptor promoter |
US5998482A (en) * | 1997-11-10 | 1999-12-07 | David; Sunil A. | Use of synthetic polycationic amphiphilic substances with fatty acid or hydrocarbon substituents as anti-sepsis agents |
EP1987845B1 (en) | 1997-11-20 | 2012-03-21 | Vical Incorporated | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor. |
DK1039931T3 (en) * | 1997-12-01 | 2005-08-08 | Fang Fang | Multivalent recombinant antibodies to treat HRV infections |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
FR2772047B1 (en) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | GENOMIC SEQUENCE AND POLYPEPTIDES OF CIRCOVIRUS ASSOCIATED WITH PIGLET LOSS DISEASE (MAP), APPLICATIONS TO DIAGNOSIS AND TO PREVENTION AND / OR TREATMENT OF INFECTION |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
EP1047774A1 (en) * | 1998-01-16 | 2000-11-02 | California Pacific Medical Center Research Institute | Methods and compositions for gene delivery |
CN1192102C (en) | 1998-01-23 | 2005-03-09 | 新生物生物公司 | Enzyme catalyzed therapeutic agents |
US7462605B2 (en) * | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
US6410328B1 (en) * | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
EP1982990A1 (en) | 1998-03-19 | 2008-10-22 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
US6271209B1 (en) * | 1998-04-03 | 2001-08-07 | Valentis, Inc. | Cationic lipid formulation delivering nucleic acid to peritoneal tumors |
US6043390A (en) * | 1998-04-03 | 2000-03-28 | The Regents Of The University Of California | Pentaerythritol lipid derivatives and nucleic-acid complexes |
US6225456B1 (en) | 1998-05-07 | 2001-05-01 | University Technololy Corporation | Ras suppressor SUR-5 |
US6506889B1 (en) | 1998-05-19 | 2003-01-14 | University Technology Corporation | Ras suppressor SUR-8 and related compositions and methods |
ATE506073T1 (en) * | 1998-05-29 | 2011-05-15 | Scripps Research Inst | METHOD FOR MODULATING ANGIOGENesis USING TYROSINE KINASE SRC |
US6200598B1 (en) * | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
US20040077603A1 (en) * | 1998-08-28 | 2004-04-22 | Wilhelm Stoffel | Synthetic tear fluid |
EP1832657B1 (en) | 1998-09-09 | 2012-10-24 | Genzyme Corporation | Methylation of plasmid vectors |
US6135976A (en) | 1998-09-25 | 2000-10-24 | Ekos Corporation | Method, device and kit for performing gene therapy |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
WO2000030444A1 (en) * | 1998-11-25 | 2000-06-02 | Vanderbilt University | Cationic liposomes for gene transfer |
ATE271032T1 (en) * | 1998-11-25 | 2004-07-15 | Gene Therapy Systems Inc | AMPHIPHILIC POLYAMINE COMPOUNDS |
US20030035798A1 (en) * | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
US6441156B1 (en) * | 1998-12-30 | 2002-08-27 | The United States Of America As Represented By The Department Of Health And Human Services | Calcium channel compositions and methods of use thereof |
US20020103359A1 (en) * | 1999-12-07 | 2002-08-01 | Gregory Donoho | Novel human membrane proteins and polynucleotides encoding the same |
US6570003B1 (en) * | 2001-01-09 | 2003-05-27 | Lexion Genetics Incorporated | Human 7TM proteins and polynucleotides encoding the same |
AU776150B2 (en) * | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
IL144845A0 (en) | 1999-03-03 | 2002-06-30 | Univ Pennsylvania | Vaccines and gene therapy compositions and methods of making and using the same |
US7393548B2 (en) * | 1999-03-22 | 2008-07-01 | J.P. M.E.D. Ltd. | Nano oil in glycerin emulsion |
AU4032300A (en) | 1999-03-24 | 2000-10-09 | Gene Therapy Systems, Inc. | Method for generating transcriptionally active dna fragments |
WO2000057917A2 (en) * | 1999-03-26 | 2000-10-05 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
US6379698B1 (en) * | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
US6696424B1 (en) | 1999-05-28 | 2004-02-24 | Vical Incorporated | Cytofectin dimers and methods of use thereof |
WO2000073263A1 (en) * | 1999-05-28 | 2000-12-07 | Vical Incorporated | Cytofectin dimers and methods of use thereof |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US6943152B1 (en) | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
US20010048940A1 (en) * | 1999-06-18 | 2001-12-06 | Jennifer D. Tousignant | Cationic amphiphile micellar complexes |
US6683061B1 (en) | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
JP2003525866A (en) | 1999-07-22 | 2003-09-02 | ニューバイオティックス インコーポレイテッド | Methods for treating refractory tumors |
US20030078499A1 (en) * | 1999-08-12 | 2003-04-24 | Eppstein Jonathan A. | Microporation of tissue for delivery of bioactive agents |
US20050249794A1 (en) * | 1999-08-27 | 2005-11-10 | Semple Sean C | Compositions for stimulating cytokine secretion and inducing an immune response |
AUPQ259399A0 (en) * | 1999-09-01 | 1999-09-23 | Lustre Investments Pte Ltd | Therapeutic agents |
US20020049312A1 (en) * | 2000-05-23 | 2002-04-25 | Turner C. Alexander | Noel human thrombospondin-like proteins and polynucleotides encoding the same |
US6716614B1 (en) | 1999-09-02 | 2004-04-06 | Lexicon Genetics Incorporated | Human calcium dependent proteases, polynucleotides encoding the same, and uses thereof |
US20080003673A1 (en) * | 1999-09-02 | 2008-01-03 | Alejandro Abuin | Novel human proteases and polynucleotides encoding the same |
US6448388B1 (en) | 2000-08-16 | 2002-09-10 | Lexicon Genetics Incorporated | Human proteases and polynucleotides encoding the same |
US20030050464A1 (en) * | 2000-07-28 | 2003-03-13 | Yi Hu | Novel human proteases and polynucleotides encoding the same |
US20050153323A1 (en) * | 2000-07-28 | 2005-07-14 | Yi Hu | Novel human proteases and polynucleotides encoding the same |
WO2001017508A1 (en) * | 1999-09-09 | 2001-03-15 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
US6790660B1 (en) * | 2001-09-18 | 2004-09-14 | Lexicon Genetics Incorporated | Human kielin-like proteins and polynucleotides encoding the same |
US20020107382A1 (en) * | 2000-09-27 | 2002-08-08 | Friddle Carl Johan | Novel human protease inhibitor proteins and polynucleotides encoding the same |
US6867291B1 (en) * | 2000-09-15 | 2005-03-15 | Lexicon Genetics Incorporated | Human hemicentin proteins and polynucleotides encoding the same |
US6602698B2 (en) | 1999-12-07 | 2003-08-05 | Lexicon Genetics Incorporated | Human kinase proteins and polynucleotides encoding the same |
US6586230B1 (en) * | 2000-10-27 | 2003-07-01 | Lexicon Genetics Incorporated | Human kinase and polynucleotides encoding the same |
US20080050809A1 (en) * | 1999-09-28 | 2008-02-28 | Alejandro Abuin | Novel human kinases and polynucleotides encoding the same |
US6841377B1 (en) * | 2001-06-13 | 2005-01-11 | Lexicon Genetics Incorporated | Human kinase and polynucleotides encoding the same |
US6759527B2 (en) | 2001-03-20 | 2004-07-06 | Lexicon Genetics Incorporated | Human kinase and polynucleotides encoding the same |
US6797510B1 (en) * | 2001-05-24 | 2004-09-28 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
US6720173B1 (en) | 1999-11-08 | 2004-04-13 | Lexicon Genetics Incorporated | Human kinase protein and polynucleotides encoding the same |
US6777545B2 (en) | 2001-04-06 | 2004-08-17 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
US6511840B1 (en) | 2000-06-15 | 2003-01-28 | Lexicon Genetics Incorporated | Human kinase proteins and polynucleotides encoding the same |
US6541252B1 (en) | 2000-05-19 | 2003-04-01 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
US7892541B1 (en) | 1999-09-30 | 2011-02-22 | Tumor Biology Investment Group, Inc. | Soluble epidermal growth factor receptor isoforms |
US20080213878A1 (en) * | 1999-10-19 | 2008-09-04 | Gregory Donoho | Novel human membrane proteins and polynucleotides encoding the same |
EP1242588A2 (en) * | 1999-11-12 | 2002-09-25 | Lexicon Genetics Incorporated | Human proteins with homology to carboxypeptidases and polynucleotides encoding the same |
AU1920601A (en) * | 1999-11-19 | 2001-05-30 | Lexicon Genetics Incorporated | Novel human secreted proteins and polynucleotides encoding the same |
ES2170622B1 (en) * | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | CLONES AND INFECTIVE VECTORS DERIVED FROM CORONAVIRUS AND ITS APPLICATIONS. |
WO2001042477A1 (en) * | 1999-12-13 | 2001-06-14 | Lexicon Genetics Incorporated | Novel human transferase proteins and polynucleotides encoding the same |
US20030008813A1 (en) * | 1999-12-17 | 2003-01-09 | Felgner Philip L. | Intracellular protein delivery compositions and methods of use |
AU2092901A (en) * | 1999-12-22 | 2001-07-03 | Lexicon Genetics Incorporated | Polynucleotides encoding human protease homologs |
WO2001046417A2 (en) * | 1999-12-22 | 2001-06-28 | Lexicon Genetics Incorporated | Human membrane proteins and polynucleotides encoding the same having homology to cd20 proteins and ige receptors |
FR2802925B1 (en) * | 1999-12-23 | 2002-03-22 | Commissariat Energie Atomique | CATIONIC AMPHIPHILES, THEIR APPLICATIONS AND THEIR SYNTHESIS METHOD |
AU2460001A (en) * | 1999-12-27 | 2001-07-09 | Regents Of The University Of California, The | Gene therapy for congestive heart failure |
CN1433478A (en) * | 1999-12-30 | 2003-07-30 | 诺瓦提斯公司 | Novel colloid synthetic vectors for gene therapy |
JP2004502402A (en) * | 2000-01-06 | 2004-01-29 | レキシコン・ジェネティクス・インコーポレーテッド | Novel human protease and polynucleotide encoding it |
US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
EP1248846A2 (en) * | 2000-01-18 | 2002-10-16 | Lexicon Genetics Incorporated | Human kinase protein and polynucleotides encoding the same |
US7078388B2 (en) * | 2000-01-21 | 2006-07-18 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
US20040002472A1 (en) * | 2000-01-21 | 2004-01-01 | Audonnet Jean-Christophe Francis | Vaccination or immunization using a prime-boost regimen |
US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
AU2001253117B8 (en) * | 2000-01-26 | 2006-08-03 | Lexicon Pharmaceuticals, Inc. | Human neurexin-like proteins and polynucleotides encoding the same |
AU9256001A (en) * | 2000-01-28 | 2001-12-17 | Lexicon Genetics Incorporated | Novel human enzymes and polynucleotides encoding the same |
JP2003520607A (en) * | 2000-01-28 | 2003-07-08 | レキシコン・ジェネティクス・インコーポレーテッド | Human membrane proteins and polynucleotides encoding them |
CA2399663A1 (en) * | 2000-02-04 | 2001-08-09 | Lexicon Genetics Incorporated | Novel human enzymes and polynucleotides encoding the same |
ATE438660T1 (en) * | 2000-02-04 | 2009-08-15 | Lexicon Pharmaceuticals Inc | NEW HUMAN G-PROTEIN COUPLED RECEPTORS AND POLYNUCLEOTIDES CODING THEREFOR |
CA2399876A1 (en) * | 2000-02-11 | 2001-08-16 | Lexicon Genetics Incorporated | Human proteases and polynucleotides encoding the same |
CN1184076C (en) | 2000-02-16 | 2005-01-12 | 精工爱普生株式会社 | Ink box and connecting assembly for ink-jet printer and ink-jet printer |
AU2001238503A1 (en) | 2000-02-17 | 2001-08-27 | Lexicon Genetics Incorporated | Novel human thrombospondin repeat proteins and polynucleotides encoding the same |
EP1259610A2 (en) * | 2000-02-29 | 2002-11-27 | Lexicon Genetics Incorporated | Human transporter proteins and polynucleotides encoding the same |
WO2001064903A2 (en) * | 2000-02-29 | 2001-09-07 | Lexicon Genetics Incorporated | Novel human transferase proteins and polynucleotides encoding the same |
WO2001066744A2 (en) * | 2000-03-06 | 2001-09-13 | Lexicon Genetics Incorporated | Human transporter proteins and polynucleotides encoding the same |
CA2402227A1 (en) | 2000-03-10 | 2001-09-20 | Lexicon Genetics Incorporated | Human g-coupled protein receptor kinases and polynucleotides encoding the same |
EP1276500B1 (en) | 2000-03-13 | 2011-06-08 | Cornell Research Foundation, Inc. | Blocking leukocyte emigration and inflammation by interfering with cd99/hec2 |
CA2403205A1 (en) | 2000-03-13 | 2001-09-20 | Engene, Inc. | Compositions and methods of regulated protein expression in gut endocrine k cells |
CA2402936A1 (en) * | 2000-03-13 | 2001-09-20 | Lexicon Genetics Incorporated | Human phospholipases and polynucleotides encoding the same |
AU2001245871B2 (en) * | 2000-03-20 | 2006-06-01 | Lexicon Pharmaceuticals, Inc. | Novel human secreted proteins and polynucleotides encoding the same |
US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
AU2001249389A1 (en) * | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
GB0018307D0 (en) | 2000-07-26 | 2000-09-13 | Aventis Pharm Prod Inc | Polypeptides |
JP2004505610A (en) * | 2000-04-03 | 2004-02-26 | レキシコン・ジェネティクス・インコーポレーテッド | Novel human ion channel protein and polynucleotide encoding the same |
CA2405729A1 (en) * | 2000-04-12 | 2001-10-25 | Lexicon Genetics Incorporated | Human metalloprotease and polynucleotides encoding the same |
EP1276849A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | Albumin fusion proteins |
AU5345901A (en) * | 2000-04-13 | 2001-10-30 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
EP1278551A2 (en) * | 2000-04-21 | 2003-01-29 | Vical Incorporated | Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
JP2004511205A (en) | 2000-04-25 | 2004-04-15 | レキシコン・ジェネティクス・インコーポレーテッド | Novel human kinase protein and polynucleotide encoding it |
WO2001088134A2 (en) * | 2000-05-12 | 2001-11-22 | Lexicon Genetics Incorporated | Novel human lipocalin homologs and polynucleotides encoding the same |
US6680172B1 (en) | 2000-05-16 | 2004-01-20 | Regents Of The University Of Michigan | Treatments and markers for cancers of the central nervous system |
WO2001088133A2 (en) * | 2000-05-18 | 2001-11-22 | Lexicon Genetics Incorporated | Human semaphorin homologs and polynucleotides encoding the same |
US6790667B1 (en) | 2000-05-30 | 2004-09-14 | Lexicon Genetics Incorporated | Human mitochondrial proteins and polynucleotides encoding the same |
DK1290028T3 (en) | 2000-06-05 | 2010-04-26 | Brigham & Womens Hospital | Gene encoding a multidrug resistance human P-glycoprotein homolog on chromosome 7p15-21, and uses thereof |
US6703495B2 (en) * | 2000-06-07 | 2004-03-09 | Lexicon Genetics Incorporated | Polynucleotides encoding human transporter protein |
US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
DK1295611T3 (en) * | 2000-06-20 | 2010-10-04 | Dainippon Sumitomo Pharma Co | Oligonucleotide Transforming Compounds |
JP2004510412A (en) * | 2000-06-27 | 2004-04-08 | レキシコン・ジェネティクス・インコーポレーテッド | Novel human GABA receptor and polynucleotide encoding the receptor |
WO2002006218A2 (en) * | 2000-07-18 | 2002-01-24 | Bone Care International, Inc. | STABILIZED 1α-HYDROXY VITAMIN D |
EP1315800A2 (en) * | 2000-07-21 | 2003-06-04 | Incyte Genomics, Inc. | Human proteases |
US6887685B1 (en) | 2000-07-25 | 2005-05-03 | Lexicon Genetics Incorporated | Human thymosin protein and polynucleotides encoding the same |
WO2002010410A1 (en) * | 2000-07-27 | 2002-02-07 | The Trustees Of The University Of Pennsylvania | Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses |
US20020076780A1 (en) * | 2000-08-16 | 2002-06-20 | Turner C. Alexander | Novel human ion channel proteins and polynucleotides encoding the same |
WO2002016564A2 (en) * | 2000-08-22 | 2002-02-28 | Lexicon Genetics Incorporated | Novel human proteases and polynucleotides encoding the same |
WO2002016435A2 (en) * | 2000-08-22 | 2002-02-28 | Lexicon Genetics Incorporated | Human 7tm proteins and polynucleotides encoding the same |
AU8847801A (en) | 2000-08-25 | 2002-03-04 | Basf Plant Science Gmbh | Plant polynucleotides encoding novel prenyl proteases |
AU2001285326A1 (en) * | 2000-08-31 | 2002-03-13 | Lexicon Genetics Incorporated | Human kinase proteins and polynucleotides encoding the same |
US7229790B2 (en) * | 2000-09-01 | 2007-06-12 | Lexicon Pharmaceuticals, Inc. | Human GABA transporter protein and polynucleotides encoding the same |
CA2423942A1 (en) | 2000-09-27 | 2002-04-04 | Lexicon Genetics Incorporated | Human ion-exchanger proteins and polynucleotides encoding the same |
US6777232B1 (en) * | 2000-10-02 | 2004-08-17 | Lexicon Genetics Incorporated | Human membrane proteins and polynucleotides encoding the same |
US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
US20050059031A1 (en) | 2000-10-06 | 2005-03-17 | Quantum Dot Corporation | Method for enhancing transport of semiconductor nanocrystals across biological membranes |
AU2002213183A1 (en) | 2000-10-12 | 2002-04-22 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
US7001763B1 (en) | 2000-10-17 | 2006-02-21 | Lexicon Genetics Incorporated | Human semaphorin proteins and polynucleotides encoding the same |
US6831059B2 (en) | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
AU2002232387A1 (en) * | 2000-10-27 | 2002-05-06 | Invitrogen Corporation | Method for introducing antisense oligonucleotides into eucaryotic cells |
EP1624062A3 (en) * | 2000-10-27 | 2006-02-22 | Lexicon Genetics Incorporated | Human 7tm proteins and polynucleotides encoding them |
US7060442B2 (en) * | 2000-10-30 | 2006-06-13 | Regents Of The University Of Michigan | Modulators on Nod2 signaling |
CA2427701A1 (en) * | 2000-10-30 | 2002-05-10 | Lexicon Genetics Incorporated | Human 7tm proteins and polynucleotides encoding the same |
CA2427828A1 (en) * | 2000-11-01 | 2002-05-10 | Lexicon Genetics Incorporated | Novel human proteases and polynucleotides encoding the same |
CA2429519A1 (en) * | 2000-11-15 | 2002-06-27 | Lexicon Genetics Incorporated | Novel human secreted proteins and polynucleotides encoding the same |
AU2002228633A1 (en) | 2000-11-20 | 2002-06-03 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
US7223600B2 (en) * | 2000-11-29 | 2007-05-29 | The Norwegian Radium Hospital Research Foundation | Photochemical internalization for delivery of molecules into the cytosol |
PE20020574A1 (en) | 2000-12-06 | 2002-07-02 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA |
WO2002055685A2 (en) | 2000-12-11 | 2002-07-18 | Lexicon Genetics Incorporated | Novel human kinase and polynucleotides encoding the same |
AU2002232642B2 (en) * | 2000-12-12 | 2007-02-01 | Lexicon Pharmaceuticals, Inc. | Novel human kinases and uses thereof |
US6583269B1 (en) * | 2000-12-18 | 2003-06-24 | Lexicon Genetics Incorporated | Human protease inhibitor and polynucleotides encoding the same |
EP1370656A2 (en) * | 2000-12-20 | 2003-12-17 | Lexicon Genetics Incorporated | Novel human ion channel protein and polynucleotides encoding the same |
US6852844B1 (en) * | 2000-12-20 | 2005-02-08 | Lexicon Genetics Incorporated | Human protocadherin proteins and polynucleotides encoding the same |
WO2002059325A2 (en) * | 2000-12-27 | 2002-08-01 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
DE60144198D1 (en) | 2000-12-28 | 2011-04-21 | Wyeth Llc | RECOMBINANT PROTECTION PROTEIN FROM STREPTOCOCCUS PNEUMONIAE |
WO2002053753A2 (en) * | 2001-01-05 | 2002-07-11 | Lexicon Genetics Incorporated | Novel human lipase and polynucleotides encoding the same |
WO2002053754A2 (en) * | 2001-01-08 | 2002-07-11 | Lexicon Genetics Incorporated | Human protease and polynucleotides encoding the same |
US7138388B2 (en) * | 2001-01-19 | 2006-11-21 | Celmed Oncology (Usa), Inc. | Methods to treat autoimmune and inflammatory conditions |
JP2004524835A (en) * | 2001-01-23 | 2004-08-19 | レキシコン・ジェネティクス・インコーポレーテッド | Novel human kinase and polynucleotide encoding it |
WO2002059328A1 (en) * | 2001-01-24 | 2002-08-01 | Lexicon Genetics Incorporated | Human lipase and polynucleotides encoding the same |
EP1229134A3 (en) * | 2001-01-31 | 2004-01-28 | Nucleonics, Inc | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
WO2002063002A2 (en) * | 2001-02-02 | 2002-08-15 | Lexicon Genetics Incorporated | Novel human transporter protein and polynucleotides encoding the same |
WO2002066612A2 (en) | 2001-02-20 | 2002-08-29 | Rheogene, Inc. | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
CA2441444C (en) | 2001-02-20 | 2013-09-03 | Rheogene Holdings, Inc. | Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system |
CA2473197A1 (en) * | 2001-02-20 | 2002-08-29 | Lexicon Genetics Incorporated | Novel human protease and polynucleotides encoding the same |
DK1534738T3 (en) | 2001-02-20 | 2012-10-01 | Intrexon Corp | Novel substitution mutant receptors and their use in an inducible gene expression system based on a nuclear receptor |
CA2438119C (en) * | 2001-02-20 | 2014-12-16 | Rheogene Holdings, Inc. | Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system |
ATE448793T1 (en) | 2001-03-02 | 2009-12-15 | Univ Rockefeller | RECOMBINANT HYBRID ALLERGEN CONSTRUCTS WITH REDUCED ALLERGENITY WHILE MAINTAINING THE IMMUNOGENICITY OF THE NATURAL ALLERGEN |
JP3929250B2 (en) * | 2001-03-08 | 2007-06-13 | 株式会社ルネサステクノロジ | Semiconductor device |
WO2002072774A2 (en) * | 2001-03-12 | 2002-09-19 | Lexicon Genetics Incorporated | Novel human transporter proteins and polynucleotides encoding the same |
AU2002245593A1 (en) * | 2001-03-12 | 2002-09-24 | Lexicon Genetics Incorporated | Novel human dectin proteins and polynucleotides encoding the same |
CA2440563A1 (en) * | 2001-03-12 | 2002-09-19 | Lexicon Genetics Incorporated | Novel human egf-family proteins and polynucleotides encoding the same |
AU2002254174A1 (en) * | 2001-03-13 | 2002-09-24 | Vical Incorporated | Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases |
US6994995B1 (en) * | 2001-03-16 | 2006-02-07 | Lexicon Genetics Incorporated | Human synaptotagmin and polynucleotides encoding the same |
US6613534B2 (en) | 2001-03-20 | 2003-09-02 | Wake Forest University Health Sciences | MAP-2 as a determinant of metastatic potential |
US7294511B2 (en) | 2001-03-22 | 2007-11-13 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
US20030186390A1 (en) * | 2001-03-22 | 2003-10-02 | De Jong Gary | Methods for delivering nucleic acid molecules into cells and assessment thereof |
US6936469B2 (en) * | 2001-03-22 | 2005-08-30 | Chromos Molecular Systems Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
US20030096414A1 (en) * | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
US20040028651A1 (en) * | 2001-03-29 | 2004-02-12 | Karrupiah Muthumani | Composition and methods of using hiv vpr |
US20040242523A1 (en) * | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
US8034791B2 (en) | 2001-04-06 | 2011-10-11 | The University Of Chicago | Activation of Egr-1 promoter by DNA damaging chemotherapeutics |
EP1390075B1 (en) * | 2001-04-06 | 2012-01-18 | The University of Chicago | Chemotherapeutic induction of egr-1 promoter activity in gene therapy |
CA2443319A1 (en) * | 2001-04-06 | 2002-10-17 | Lexicon Genetics Incorporated | Novel human kinase and polynucleotides encoding the same |
US6644173B2 (en) * | 2001-04-11 | 2003-11-11 | Keuring, Incorporated | Beverage filter cartridge holder |
IL158328A0 (en) * | 2001-04-13 | 2004-05-12 | Wyeth Corp | Surface proteins of streptococcus pyogenes |
DE60236646D1 (en) | 2001-04-13 | 2010-07-22 | Human Genome Sciences Inc | Anti-VEGF-2 antibodies |
US20070128229A1 (en) * | 2002-04-12 | 2007-06-07 | Wyeth | Surface proteins of Streptococcus pyogenes |
US6607895B2 (en) | 2001-04-16 | 2003-08-19 | Lexicon Genetics Incorporated | Human adenylsuccinate synthetase and polynucleotides encoding the same |
US20020165175A1 (en) * | 2001-04-17 | 2002-11-07 | Xiaowu Liang | Fast and enzymeless cloning of nucleic acid fragments |
US20030203865A1 (en) * | 2001-04-30 | 2003-10-30 | Pierrot Harvie | Lipid-comprising drug delivery complexes and methods for their production |
US20030077829A1 (en) * | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
US20030166893A1 (en) * | 2001-04-30 | 2003-09-04 | Yi Hu | Novel human nuclear transporters and polynucleotides encoding the same |
WO2002090517A2 (en) * | 2001-05-09 | 2002-11-14 | Lexicon Genetics Incorporated | Novel human kinases and polynucleotides encoding the same |
US20020193585A1 (en) * | 2001-05-25 | 2002-12-19 | Walke D. Wade | Novel human transporter proteins and polynucleotides encoding the same |
EP1461425B1 (en) | 2001-05-29 | 2008-02-13 | Lexicon Pharmaceuticals, Inc. | Novel human hydroxylases and polynucleotides encoding the same |
US7744882B2 (en) | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 methods of detection and antibodies |
US7745398B2 (en) * | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 and treatment of cancer |
US20030027301A1 (en) * | 2001-06-14 | 2003-02-06 | Yi Hu | Novel human transporter proteins and polynucleotides encoding the same |
EP1992643A3 (en) | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
ES2324525T3 (en) * | 2001-06-20 | 2009-08-10 | Dainippon Sumitomo Pharma Co., Ltd. | METHOD TO PROMOTE TRANSFER OF NUCLEIC ACIDS. |
CA2790034A1 (en) | 2001-06-21 | 2003-01-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
JP2004536089A (en) * | 2001-06-26 | 2004-12-02 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム | Formulations and methods for introducing substances into cells |
WO2003004609A2 (en) * | 2001-07-03 | 2003-01-16 | Lexicon Genetics Incorporated | Novel human kielin-like proteins and polynucleotides encoding the same |
JP2005522192A (en) | 2001-07-19 | 2005-07-28 | パーラン セラピューティクス, インコーポレイテッド | Multimeric proteins and methods of making and using multimeric proteins |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
WO2003014318A2 (en) * | 2001-08-08 | 2003-02-20 | Genzyme Corporation | Methods for treating diabetes and other blood sugar disorders |
US20040143104A1 (en) * | 2001-08-08 | 2004-07-22 | Wadsworth Samuel C. | Methods of treating diabetes and other blood sugar disorders |
WO2003016481A2 (en) * | 2001-08-14 | 2003-02-27 | Lexicon Genetics Incorporated | Novel human collagen proteins and polynucleotides encoding the same |
WO2003024392A2 (en) | 2001-09-18 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
DE10244149A1 (en) * | 2001-09-25 | 2003-04-30 | Werner Keber | Preventing prohibited approaches by aircraft to ground objects to be protected involves virtual prohibited zones providing adequate horizontal separation, minimum vertical separation |
JP2005507247A (en) * | 2001-09-26 | 2005-03-17 | レオジーン・ホールディングス,インコーポレーテッド | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
MXPA04002810A (en) | 2001-09-26 | 2005-06-06 | Rheogene Holdings Inc | Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof. |
US20040023910A1 (en) * | 2001-09-28 | 2004-02-05 | Zhiming Zhang | Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
US7906102B2 (en) | 2001-10-03 | 2011-03-15 | Vanderbilt University | Ligands to radiation-induced molecules |
AU2002362753B9 (en) * | 2001-10-05 | 2008-05-15 | The Trustees Of The University Of Pennsylvania | Compositions for and methods of treating and preventing sirs/sepsis |
NZ566396A (en) | 2001-10-09 | 2009-07-31 | Isis Pharmaceuticals Inc | Antisense modulation of insulin-like growth factor binding protein 5 expressions |
US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
MX339524B (en) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Novel immunogenic compositions for the prevention and treatment of meningococcal disease. |
WO2003088808A2 (en) | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
IL161733A0 (en) | 2001-11-02 | 2005-11-20 | Insert Therapeutics Inc | Methods and compositions for therapeutic use of rna interference |
AU2002348163A1 (en) * | 2001-11-02 | 2003-05-19 | Intradigm Corporation | Therapeutic methods for nucleic acid delivery vehicles |
US7488313B2 (en) * | 2001-11-29 | 2009-02-10 | Boston Scientific Scimed, Inc. | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
WO2003053365A2 (en) * | 2001-12-20 | 2003-07-03 | Schering-Plough Corporation | Syn3 compositions and methods |
US7255874B1 (en) | 2001-12-21 | 2007-08-14 | Closure Medical Corporation | Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto |
EP2277889B1 (en) | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
EP1575571A4 (en) | 2002-01-02 | 2008-06-25 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
JP2005530695A (en) * | 2002-02-15 | 2005-10-13 | ザイコス インク. | Electroporation method for introducing physiologically active substances into cells |
DE10207177A1 (en) * | 2002-02-19 | 2003-09-04 | Novosom Ag | Optionally cationic lipids |
JP2005530704A (en) * | 2002-03-05 | 2005-10-13 | トランセイブ, インク. | Inhalation system for preventing and treating intracellular infections |
AU2003265226A1 (en) | 2002-03-11 | 2003-12-19 | Altea Therapeutics Corporation | Transdermal drug delivery device, method and use |
US9918665B2 (en) | 2002-03-11 | 2018-03-20 | Nitto Denko Corporation | Transdermal porator and patch system and method for using same |
US8116860B2 (en) * | 2002-03-11 | 2012-02-14 | Altea Therapeutics Corporation | Transdermal porator and patch system and method for using same |
US20030180712A1 (en) | 2002-03-20 | 2003-09-25 | Biostratum Ab | Inhibition of the beta3 subunit of L-type Ca2+ channels |
US20040180438A1 (en) | 2002-04-26 | 2004-09-16 | Pachuk Catherine J. | Methods and compositions for silencing genes without inducing toxicity |
US20040267355A1 (en) * | 2002-04-30 | 2004-12-30 | Neal Scott | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
AU2003221584A1 (en) * | 2002-05-01 | 2003-11-17 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
JP4868739B2 (en) * | 2002-05-06 | 2012-02-01 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Nucleic acid delivery methods |
US7598421B2 (en) * | 2002-05-08 | 2009-10-06 | Ucl Biomedica Plc | Materials for the delivery of biologically-active material to cells |
US20040013649A1 (en) * | 2002-05-10 | 2004-01-22 | Inex Pharmaceuticals Corporation | Cancer vaccines and methods of using the same |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
WO2003100008A2 (en) | 2002-05-24 | 2003-12-04 | Schering Corporation | Neutralizing human anti-igfr antibody |
EA200401565A1 (en) * | 2002-05-24 | 2005-04-28 | Неофарм, Инк. | METHOD FOR OBTAINING CARDIOLYPINE OR ANALOGUE OF CARDIOLIPINE (OPTIONS), METHOD FOR OBTAINING LIPOSOME AND COMPOSITION OF CARDIOLIPINE FOR TREATING DISEASES (OPTIONS) |
JP2006518701A (en) * | 2002-05-24 | 2006-08-17 | ネオファーム、インコーポレイティッド | Cardiolipin composition, process for its production and use |
AU2003261103A1 (en) * | 2002-07-02 | 2004-01-23 | Uab Research Foundation | Compounds promoting delivery of genes |
US7375093B2 (en) | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
EP1519745B1 (en) | 2002-07-05 | 2006-12-20 | Lipoxen Technologies Limited | Method to enhance an immune response of nucleic acid vaccination |
AU2003274906A1 (en) * | 2002-07-31 | 2004-02-16 | Nucleonics, Inc. | Double stranded rna structures and constructs, and methods for generating and using the same |
US20040034336A1 (en) * | 2002-08-08 | 2004-02-19 | Neal Scott | Charged liposomes/micelles with encapsulted medical compounds |
US7785608B2 (en) * | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
AU2003273271A1 (en) * | 2002-09-09 | 2004-03-29 | The Brigham And Women's Hospital, Inc. | Genes and proteins altering tau-related neurodegeneration |
AU2003278776A1 (en) * | 2002-09-10 | 2004-04-30 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection |
EP1537208A1 (en) | 2002-09-13 | 2005-06-08 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
US20040053895A1 (en) * | 2002-09-18 | 2004-03-18 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
US20060189554A1 (en) * | 2002-09-24 | 2006-08-24 | Russell Mumper | Nanoparticle-Based vaccine delivery system containing adjuvant |
WO2004031350A2 (en) | 2002-09-26 | 2004-04-15 | Amgen, Inc. | Modulation of forkhead box o1a expression |
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
US20050277611A1 (en) * | 2002-10-16 | 2005-12-15 | Neopharm, Inc. | Cationic cardiolipin analoges and its use thereof |
US6863731B2 (en) * | 2002-10-18 | 2005-03-08 | Controls Corporation Of America | System for deposition of inert barrier coating to increase corrosion resistance |
ES2686361T3 (en) * | 2002-10-29 | 2018-10-17 | Insmed Incorporated | Liposomes comprising an aminoglycoside for the treatment of lung infections |
US7718189B2 (en) * | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
JP3447009B1 (en) * | 2002-10-29 | 2003-09-16 | 實 平垣 | Construct structure and method for producing the same |
US7879351B2 (en) * | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
WO2008103472A2 (en) | 2007-02-23 | 2008-08-28 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
CA2504720C (en) | 2002-11-05 | 2013-12-24 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
WO2004044139A2 (en) | 2002-11-05 | 2004-05-27 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
CA2505801A1 (en) | 2002-11-13 | 2004-05-27 | Rosanne Crooke | Antisense modulation of apolipoprotein b expression |
DK1569695T3 (en) | 2002-11-13 | 2013-08-05 | Genzyme Corp | ANTISENSE MODULATION OF APOLIPOPROTEIN-B EXPRESSION |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
EP1903056A3 (en) | 2002-12-10 | 2008-05-07 | Idm Pharma, Inc. | HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof |
EP1581201A4 (en) * | 2002-12-23 | 2011-03-30 | Vical Inc | Method for producing sterile polynucleotide based medicaments |
AU2003293195A1 (en) * | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
AU2003301148A1 (en) | 2002-12-23 | 2004-07-22 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US20070269891A9 (en) * | 2003-01-13 | 2007-11-22 | Yasunobu Tanaka | Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells |
US20040138154A1 (en) | 2003-01-13 | 2004-07-15 | Lei Yu | Solid surface for biomolecule delivery and high-throughput assay |
EP1585815A4 (en) * | 2003-01-21 | 2006-02-22 | Bristol Myers Squibb Co | Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof |
US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
NZ541637A (en) | 2003-02-11 | 2008-07-31 | Antisense Therapeutics Pty Ltd | Modulation of insulin like growth factor I receptor |
CA2516188C (en) * | 2003-02-14 | 2012-04-17 | University Of South Florida | Chitosan-derivatives for gene delivery and expression |
US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
CA2522213A1 (en) * | 2003-04-08 | 2004-10-28 | Dante J. Marciani | Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines |
KR20060019515A (en) * | 2003-04-16 | 2006-03-03 | 와이어쓰 홀딩스 코포레이션 | Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
AU2004231740A1 (en) * | 2003-04-17 | 2004-11-04 | The Trustees Of Columbia University In The City Ofnew York | Desmoglein 4 is a novel gene involved in hair growth |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
EP1628647A4 (en) * | 2003-05-22 | 2007-10-24 | Molecular Transfer Inc | Novel lipids for transfection of nucleic acids |
CN1984921B (en) | 2003-06-03 | 2010-06-16 | Isis药物公司 | Modulation of survivin expression |
NZ543970A (en) * | 2003-06-04 | 2008-09-26 | Canji Inc | Methods and compositions for interferon therapy |
SI2270162T1 (en) | 2003-06-12 | 2019-03-29 | Alnylam Pharmaceuticals Inc. | Conserved hbv and hcv sequences useful for gene silencing |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
US20060078560A1 (en) * | 2003-06-23 | 2006-04-13 | Neopharm, Inc. | Method of inducing apoptosis and inhibiting cardiolipin synthesis |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US7330851B2 (en) * | 2003-08-18 | 2008-02-12 | Eaglehawk, Limited | Data security through dissembly of data elements or connections between elements |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
EP1656453A2 (en) * | 2003-08-22 | 2006-05-17 | Nucleonics, Inc. | Eukaryotic expression systems for expression of inhibitory rna in multiple intracellular compartments |
WO2005023292A1 (en) | 2003-09-03 | 2005-03-17 | The General Hospital Corporation | Methods of treating restenosis |
EP1668130A2 (en) | 2003-09-18 | 2006-06-14 | Isis Pharmaceuticals, Inc. | Modulation of eif4e expression |
ES2437491T3 (en) | 2003-10-10 | 2014-01-10 | Alchemia Oncology Pty Limited | Modulation of the synthesis and degradation of hyaluronan in the treatment of disease |
DE10347710B4 (en) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Recombinant vaccines and their use |
WO2005048988A1 (en) * | 2003-10-22 | 2005-06-02 | Neal Scott | Charged liposomes/micelles with encapsulated medical compounds |
US8016811B2 (en) | 2003-10-24 | 2011-09-13 | Altea Therapeutics Corporation | Method for transdermal delivery of permeant substances |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
ITMI20032185A1 (en) * | 2003-11-12 | 2005-05-13 | Chemi Spa | PROCESS FOR THE SYNTHESIS OF CATIONIC LIPIDS. |
EP1689432B1 (en) | 2003-11-17 | 2009-12-30 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US20050107318A1 (en) * | 2003-11-17 | 2005-05-19 | Samuel Wadsworth | Methods of treating diabetes and other blood sugar disorders |
EP1696034A4 (en) * | 2003-12-19 | 2006-12-27 | Dainippon Sumitomo Pharma Co | Novel method of nucleic acid transfer |
SE0303588D0 (en) | 2003-12-30 | 2003-12-30 | Bioactive Polymers Ab C O Lund | Surface protection of exposed biological tissues |
EP2363480A3 (en) | 2004-01-20 | 2015-10-07 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
US7468431B2 (en) | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
US7432057B2 (en) * | 2004-01-30 | 2008-10-07 | Michigan State University | Genetic test for PSE-susceptible turkeys |
JP4884367B2 (en) * | 2004-02-24 | 2012-02-29 | アボット・ヘルスケア・プロダクツ・ベスローテン・フェンノートシャップ | Method for determining the risk of developing a neurological disease |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
WO2005089268A2 (en) | 2004-03-15 | 2005-09-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of rna by rnase h |
DE602005023426D1 (en) | 2004-03-25 | 2010-10-21 | California Inst Of Techn | Hybridization CHAIN REACTION |
JP5184077B2 (en) * | 2004-03-26 | 2013-04-17 | キュリス,インコーポレイテッド | RNA interference modulator of hedgehog signaling and use thereof |
US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
US20050260652A1 (en) * | 2004-04-15 | 2005-11-24 | The General Hospital Corporation | Compositions and methods that modulate RNA interference |
EP2267458A3 (en) | 2004-04-20 | 2011-04-06 | Galapagos N.V. | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
MXPA06012162A (en) | 2004-04-27 | 2007-03-30 | Galapagos Nv | Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts. |
US7935510B2 (en) * | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
KR101462825B1 (en) | 2004-05-03 | 2014-11-21 | 헤르메스 바이오사이언스, 인코포레이티드 | Liposomes useful for drug delivery |
EP1766094A4 (en) * | 2004-05-18 | 2009-11-25 | Vical Inc | Influenza virus vaccine composition and method of use |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
WO2005121778A2 (en) | 2004-06-14 | 2005-12-22 | Galapagos N.V. | Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases |
EP2386856B1 (en) | 2004-06-21 | 2013-07-24 | Galapagos N.V. | Methods and means for treatment of osteoarthritis |
US7094775B2 (en) | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
CA2573176A1 (en) * | 2004-07-09 | 2006-01-19 | Bc Cancer Agency | Nup98-hox fusions for expansion of hemopoietic stem cells |
US7604798B2 (en) * | 2004-07-15 | 2009-10-20 | Northwestern University | Methods and compositions for importing nucleic acids into cell nuclei |
CA2573702C (en) | 2004-07-16 | 2013-10-15 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv |
US20060051405A1 (en) * | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
MX2007001679A (en) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevention and treatment of synucleinopathic and amyloidogenic disease. |
DE602005024015D1 (en) | 2004-08-23 | 2010-11-18 | Alnylam Pharmaceuticals Inc | EXPRESSION CONSTRUCTS WITH SEVERAL RNA POLYMERASE III PROMOTERS |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
JP2008514202A (en) | 2004-09-24 | 2008-05-08 | ニュークレオニクス・インコーポレイテッド | Targeting reverse-strand intermediates of single-stranded viruses by RNAI |
US7485468B2 (en) | 2004-10-15 | 2009-02-03 | Galapagos Bv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
US20090281025A1 (en) * | 2004-10-18 | 2009-11-12 | Mount Sinai School Of Medicine Of New York University | Inhibition of tumor growth and metastasis by atf2-derived peptides |
US8293253B2 (en) * | 2004-10-28 | 2012-10-23 | Idexx Laboratories, Inc. | Compositions for controlled delivery of pharmaceutically active compounds |
US20060147449A1 (en) * | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
WO2006053430A1 (en) * | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
US20060134221A1 (en) * | 2004-12-03 | 2006-06-22 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
CA2592099A1 (en) | 2004-12-22 | 2006-06-29 | Nucleonics, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
US9034650B2 (en) | 2005-02-02 | 2015-05-19 | Intrexon Corporation | Site-specific serine recombinases and methods of their use |
CA2596506C (en) | 2005-02-09 | 2021-04-06 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
US7727721B2 (en) * | 2005-03-08 | 2010-06-01 | California Institute Of Technology | Hybridization chain reaction amplification for in situ imaging |
CN101175769A (en) | 2005-03-10 | 2008-05-07 | 健泰科生物技术公司 | Methods and compositions for modulating vascular integrity |
US20090062184A1 (en) * | 2005-03-24 | 2009-03-05 | Dainippon Sumitomo Pharma Co., Ltd. | Fine particulate preparation comprising complex of nucleic acid molecule and collagen |
ES2381201T3 (en) | 2005-03-31 | 2012-05-24 | Calando Pharmaceuticals, Inc. | Inhibitors of the subunit 2 of the ribonucleotide reductase and uses thereof |
US20070026061A1 (en) * | 2005-05-25 | 2007-02-01 | Nahid Ali | Liposomal formulation and use thereof |
ES2696824T3 (en) | 2005-05-31 | 2019-01-18 | Univ Colorado Regents | Methods to supply genes |
US8088382B2 (en) * | 2005-07-05 | 2012-01-03 | Cornell Research Foundation, Inc. | Methods of inhibiting transendothelial migration of neutrophils and monocytes with anti-CD99L2 antibodies |
US20070054873A1 (en) * | 2005-08-26 | 2007-03-08 | Protiva Biotherapeutics, Inc. | Glucocorticoid modulation of nucleic acid-mediated immune stimulation |
US7666584B2 (en) * | 2005-09-01 | 2010-02-23 | Philadelphia Health & Education Coporation | Identification of a pin specific gene and protein (PIN-1) useful as a diagnostic treatment for prostate cancer |
DE102005046490A1 (en) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency |
US7312079B1 (en) | 2005-10-06 | 2007-12-25 | Lexicon Pharmaceuticals, Inc. | Variants of FAM3C |
US7960357B2 (en) | 2005-10-07 | 2011-06-14 | California Institute Of Technology | PKR activation via hybridization chain reaction |
US8114440B2 (en) | 2005-11-16 | 2012-02-14 | Idexx Laboratories Inc. | Pharmaceutical compositions for the administration of aptamers |
US7754679B2 (en) * | 2005-11-16 | 2010-07-13 | Idexx Laboratories, Inc. | Pharmaceutical compositions for the administration of aptamers |
WO2007062380A2 (en) | 2005-11-21 | 2007-05-31 | Isis Pharmaceuticals, Inc. | Modulation of eif4e-bp2 expression |
TWI461436B (en) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
PL1962805T3 (en) | 2005-12-08 | 2017-01-31 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections |
US10647960B2 (en) * | 2005-12-13 | 2020-05-12 | The Trustees Of The University Of Pennsylvania | Transcriptome transfer produces cellular phenotype conversion |
WO2007070705A2 (en) | 2005-12-15 | 2007-06-21 | The Trustees Of The University Of Pennsylvania | Cationic lipid-mediated vectors |
US20090221684A1 (en) * | 2005-12-22 | 2009-09-03 | Trustees Of Boston University | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof |
EP3210633B1 (en) | 2006-01-26 | 2019-06-19 | Ionis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
EP1981838B1 (en) * | 2006-02-07 | 2015-12-02 | Council of Scientific and Industrial Research | Process for synthesis of glycomimicking cationic amphiphiles |
EP1994043A4 (en) | 2006-02-10 | 2009-05-20 | Univ Cincinnati | Phosphatase inhibitor protein-1 as a regulator of cardiac function |
EP2614839A3 (en) | 2006-04-05 | 2015-01-28 | Genentech, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
CA2651800A1 (en) * | 2006-04-24 | 2007-11-08 | Shantha West, Inc. | Agrm2 antigen |
WO2007125173A2 (en) | 2006-05-03 | 2007-11-08 | Baltic Technology Development, Ltd. | Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease |
EP2604255B1 (en) | 2006-05-05 | 2017-10-25 | Molecular Transfer, Inc. | Novel reagents for transfection of eukaryotic cells |
GB0610636D0 (en) | 2006-05-30 | 2006-07-05 | Univ London | Materials and complexes for the delivery of biologically-active material to cells |
WO2008042024A2 (en) | 2006-06-01 | 2008-04-10 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
US20080004410A1 (en) * | 2006-06-30 | 2008-01-03 | Yu-Chin Lai | Hydrophilic macromonomers having alpha,beta-conjugated carboxylic terminal group and medical devices incorporating same |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
JP5072275B2 (en) | 2006-07-03 | 2012-11-14 | テルモ株式会社 | Method for separating closed vesicles, method for producing preparation and evaluation method |
WO2008011473A2 (en) | 2006-07-19 | 2008-01-24 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hbxip |
RU2500815C2 (en) * | 2006-07-28 | 2013-12-10 | Санофи-Авентис | Composition and method of tumour curing |
ES2388567T3 (en) | 2006-10-19 | 2012-10-16 | Csl Limited | Anti-il-13r alpha 1 antibodies and uses thereof |
WO2008060813A2 (en) | 2006-10-19 | 2008-05-22 | Merck & Co., Inc. | High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
US8466154B2 (en) * | 2006-10-27 | 2013-06-18 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to wrapping of dehydrons |
EP2431053A1 (en) | 2006-11-27 | 2012-03-21 | Patrys Limited | Novel glycosylated peptide target in neoplastic cells |
AR064642A1 (en) * | 2006-12-22 | 2009-04-15 | Wyeth Corp | POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD |
EP2118118B1 (en) * | 2007-01-19 | 2017-09-27 | Exiqon A/S | Mediated cellular delivery of lna oligonucleotides |
WO2008094945A2 (en) | 2007-01-29 | 2008-08-07 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating protein expression |
WO2009045469A2 (en) | 2007-10-02 | 2009-04-09 | Amgen Inc. | Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof |
JP5357782B2 (en) | 2007-02-21 | 2013-12-04 | バクシネックス インコーポレーティッド | Regulation of NKT cell activity by antigen-loaded CD1d molecules |
US7875431B2 (en) | 2007-02-22 | 2011-01-25 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
DK2118300T3 (en) | 2007-02-23 | 2015-07-13 | Prothena Biosciences Ltd | PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE |
WO2008106646A2 (en) * | 2007-03-01 | 2008-09-04 | Introgen Therapeutics, Inc | Methods and formulations for topical gene therapy |
WO2008106658A2 (en) | 2007-03-01 | 2008-09-04 | California Institute Of Technology | TRIGGERED RNAi |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
DE102007015598A1 (en) * | 2007-03-29 | 2008-10-02 | Heinrich-Heine-Universität Düsseldorf | Use of fluorochemical compounds for diagnostic purposes using imaging techniques |
WO2008124768A1 (en) | 2007-04-09 | 2008-10-16 | The General Hospital Corporation | Hemojuvelin fusion proteins and uses thereof |
HUE040417T2 (en) | 2007-05-04 | 2019-03-28 | Marina Biotech Inc | Amino acid lipids and uses thereof |
WO2008137717A1 (en) | 2007-05-04 | 2008-11-13 | Transave, Inc. | Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof |
US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
EP2155770B1 (en) | 2007-05-16 | 2013-10-16 | California Institute of Technology | A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways |
KR20100028038A (en) | 2007-05-16 | 2010-03-11 | 매트 몰타 어드밴스드 테크놀로지스 리미티드 | Treatment and prevention of influenza |
WO2008148057A2 (en) | 2007-05-23 | 2008-12-04 | Vical Incorporated | Cationic lipids compositions and methods for enhancing immune responses to vaccines |
CN104761466A (en) | 2007-05-29 | 2015-07-08 | 英特拉克森公司 | Chiral diacylhydrazine ligands for modulating expression of exogenous genes via ecdysone receptor complex |
US20080312174A1 (en) * | 2007-06-05 | 2008-12-18 | Nitto Denko Corporation | Water soluble crosslinked polymers |
EP2162747B1 (en) | 2007-06-20 | 2014-04-30 | Galapagos N.V. | Molecular targets and methods to identify compounds for treating bone and joint degenerative diseases |
US20090069266A1 (en) * | 2007-06-27 | 2009-03-12 | Northwestern University | Methods and compositions for nucleic acid transfer into cells |
WO2009011855A2 (en) * | 2007-07-16 | 2009-01-22 | California Institute Of Technology | Selection of nucleic acid-based sensor domains within nucleic acid switch platform |
US8828960B2 (en) * | 2007-07-17 | 2014-09-09 | Idexx Laboratories, Inc. | Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds |
MX2010001993A (en) | 2007-08-23 | 2010-03-11 | Intrexon Corp | Methods and compositions for diagnosing disease. |
AU2008302504B2 (en) * | 2007-09-17 | 2014-08-14 | Agrofresh Inc. | Compositions and methods for the modification of physiological responses in plants |
EP2205249B1 (en) | 2007-09-28 | 2018-11-07 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
WO2009046407A2 (en) | 2007-10-04 | 2009-04-09 | Zymogenetics, Inc. | B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS |
JP2010539993A (en) * | 2007-10-08 | 2010-12-24 | イントレキソン コーポレーション | Use for the treatment of genetically engineered dendritic cells and cancer |
GB0720486D0 (en) * | 2007-10-19 | 2007-11-28 | Univ Edinburgh | Cationic lipids |
CA2739011A1 (en) * | 2007-10-29 | 2009-05-07 | The Regents Of The University Of California | Osteoarthritis gene therapy |
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
DE102008023913A1 (en) | 2008-05-16 | 2009-11-19 | Biontex Laboratories Gmbh | Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense |
DE102007056488A1 (en) | 2007-11-22 | 2009-07-23 | Biontex Laboratories Gmbh | Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense |
DE102008016275A1 (en) | 2008-03-28 | 2009-11-19 | Biontex Laboratories Gmbh | Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense |
EP2363494A1 (en) | 2007-11-22 | 2011-09-07 | Biontex Laboratories Gmbh | Improvement of transfection results of non-viral gene delivery systems by influencing the congenital immune system |
US8779088B2 (en) | 2007-12-17 | 2014-07-15 | Marfl Ab | Vaccine for the treatment of Mycobacterium related disorders |
WO2009082817A1 (en) | 2007-12-27 | 2009-07-09 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering rna |
ES2544679T3 (en) | 2007-12-28 | 2015-09-02 | Prothena Biosciences Limited | Treatment and prophylaxis of amyloidosis |
US8497364B2 (en) * | 2008-02-27 | 2013-07-30 | California Institute Of Technology | Triggered RNAi |
US20110045001A1 (en) * | 2008-03-28 | 2011-02-24 | Biontex Laboratories Gmbh | Transfection results of non-viral gene delivery systems by influencing of the innate immune system |
US8114983B2 (en) | 2008-04-04 | 2012-02-14 | Calando Pharmaceuticals, Inc. | Compositions and use of EPAS1 inhibitors |
EP2770057A1 (en) | 2008-04-15 | 2014-08-27 | Protiva Biotherapeutics Inc. | Silencing of CSN5 gene expression using interfering RNA |
WO2009129227A1 (en) | 2008-04-17 | 2009-10-22 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
US20100021904A1 (en) * | 2008-05-21 | 2010-01-28 | Pierce Niles A | Shielded cross-linking probes |
US20100021901A1 (en) * | 2008-05-22 | 2010-01-28 | Peng Yin | Compositions and methods for detecting analytes |
US8241854B2 (en) * | 2008-05-22 | 2012-08-14 | California Institute Of Technology | Triggered RNAi |
ATE550024T1 (en) | 2008-05-30 | 2012-04-15 | Univ Yale | TARGETED OLIGONUCLEOTIDE COMPOSITIONS FOR MODIFYING GENE EXPRESSION |
MX2010014358A (en) | 2008-06-20 | 2011-07-04 | Wyeth Llc | Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains. |
EP3081648A1 (en) | 2008-08-25 | 2016-10-19 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
EP2816113A3 (en) | 2008-09-11 | 2015-03-25 | Galapagos N.V. | Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator |
CN104382853A (en) | 2008-10-16 | 2015-03-04 | 玛瑞纳生物技术有限公司 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics |
NO2356135T3 (en) * | 2008-11-05 | 2018-03-24 | ||
ES2629630T3 (en) | 2008-12-04 | 2017-08-11 | Curna, Inc. | Treatment of diseases related to erythropoietin (EPO) by inhibiting the natural antisense transcript to EPO |
CN102307997B (en) | 2008-12-04 | 2018-03-30 | 库尔纳公司 | By suppressing to treat the related disease of Sirtuin 1 (SIRT1) for the natural antisense transcript of Sirtuin 1 |
US20110294870A1 (en) | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
FR2941152B1 (en) * | 2009-01-20 | 2013-10-18 | Centre Nat Rech Scient | VECTORS COMPRISING ANIONIC MACROMOLECULE AND CATIONIC LIPID FOR THE ADMINISTRATION OF SMALL NUCLEIC ACIDS |
CN102439149B (en) | 2009-02-12 | 2018-01-02 | 库尔纳公司 | By suppressing to treat the related diseases of GDNF for the natural antisense transcript of the glial derived neurotrophic factor (GDNF) |
ES2762610T3 (en) | 2009-02-12 | 2020-05-25 | Curna Inc | Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of natural antisense transcript for BDNF |
WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
EP2398481A2 (en) | 2009-02-19 | 2011-12-28 | Galapagos N.V. | Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation |
EP2398479A2 (en) | 2009-02-19 | 2011-12-28 | Galapagos N.V. | Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation |
US20120035245A1 (en) | 2009-02-19 | 2012-02-09 | Richard Antonius Jozef Janssen | Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation |
ES2845644T3 (en) | 2009-03-04 | 2021-07-27 | Curna Inc | Treatment of sirtuin1-related diseases (SIRT1) by inhibition of the natural antisense transcript to sirtuin 1 |
MX2011009751A (en) | 2009-03-16 | 2011-09-29 | Opko Curna Llc | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2. |
WO2010107740A2 (en) | 2009-03-17 | 2010-09-23 | Curna, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
WO2010115825A2 (en) | 2009-03-31 | 2010-10-14 | Robert Zimmermann | Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor |
WO2010112569A1 (en) | 2009-03-31 | 2010-10-07 | Robert Zimmermann | Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor |
EP3043179B1 (en) | 2009-04-01 | 2020-05-06 | Galapagos N.V. | Methods and means for treatment of osteoarthritis |
EP2417984B1 (en) | 2009-04-10 | 2016-03-30 | Kyowa Hakko Kirin Co., Ltd. | Method for treatment of blood tumor using anti-tim-3 antibody |
EP2419121B1 (en) | 2009-04-17 | 2018-07-18 | New York University | Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof |
EP3524275A1 (en) | 2009-04-22 | 2019-08-14 | Massachusetts Institute Of Technology | Innate immune supression enables repeated delivery of long rna molecules |
US20100273203A1 (en) * | 2009-04-23 | 2010-10-28 | Board Of Trustees Of The University Of Arkansas | Methods and compositions for detecting metabolites |
WO2010126066A1 (en) | 2009-04-27 | 2010-11-04 | 協和発酵キリン株式会社 | Anti-il-3rα antibody for use in treatment of blood tumor |
US8044215B2 (en) * | 2009-04-29 | 2011-10-25 | Juvaris Biotherapeutics, Inc. | Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds |
EP2424987B1 (en) | 2009-05-01 | 2017-11-15 | CuRNA, Inc. | Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg |
JP6250930B2 (en) | 2009-05-06 | 2017-12-20 | クルナ・インコーポレーテッド | Treatment of TTP-related diseases by suppression of natural antisense transcripts against tristetraproline (TTP) |
CN102459596B (en) | 2009-05-06 | 2016-09-07 | 库尔纳公司 | By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene |
CN102985548B (en) | 2009-05-16 | 2016-10-26 | 崔坤元 | For deliver treatment molecule comprise cationic amphiphilic thing and the compositions of auxiliary lipid |
CN102575251B (en) | 2009-05-18 | 2018-12-04 | 库尔纳公司 | The relevant disease of the reprogramming factor is treated by inhibiting the natural antisense transcript for the reprogramming factor |
KR101703695B1 (en) | 2009-05-22 | 2017-02-08 | 큐알엔에이, 인크. | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
CN103221541B (en) | 2009-05-28 | 2017-03-01 | 库尔纳公司 | Antiviral gene relevant disease is treated by the natural antisense transcript suppressing antiviral gene |
KR101702689B1 (en) | 2009-06-16 | 2017-02-06 | 큐알엔에이, 인크. | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
CA2765889A1 (en) | 2009-06-24 | 2010-12-29 | Opko Curna, Llc | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
CA2765815A1 (en) | 2009-06-26 | 2010-12-29 | Opko Curna, Llc | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
US8716464B2 (en) | 2009-07-20 | 2014-05-06 | Thomas W. Geisbert | Compositions and methods for silencing Ebola virus gene expression |
WO2011015573A1 (en) | 2009-08-03 | 2011-02-10 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
WO2011015572A1 (en) | 2009-08-03 | 2011-02-10 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
US9234199B2 (en) | 2009-08-05 | 2016-01-12 | Curna, Inc. | Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS) |
US8410064B2 (en) * | 2009-08-24 | 2013-04-02 | The Board Of Trustees Of The University Of Arkansas | Classical cannabinoid metabolites and methods of use thereof |
CN102482671B (en) | 2009-08-25 | 2017-12-01 | 库尔纳公司 | IQGAP relevant diseases are treated by suppressing the natural antisense transcript of ' gtpase activating protein containing IQ die bodys ' (IQGAP) |
US9321823B2 (en) | 2009-09-02 | 2016-04-26 | Genentech, Inc. | Mutant smoothened and methods of using the same |
WO2011038160A2 (en) | 2009-09-23 | 2011-03-31 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes expressed in cancer |
CA2780741C (en) | 2009-10-12 | 2023-04-04 | Smith Holdings, Llc | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
BR112012009409A2 (en) | 2009-10-22 | 2017-02-21 | Genentech Inc | method of identifying an inhibitory substance, antagonist molecule, isolated nucleic acid, vector, host cell, method of making the molecule, composition, article of manufacture, method of inhibiting a biological activity, method of treating a pathological condition, method for detect msp in a sample and method to detect hepsin in a sample |
WO2011056682A1 (en) | 2009-10-27 | 2011-05-12 | The University Of British Columbia | Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids |
US20120244169A1 (en) | 2009-11-06 | 2012-09-27 | Fibrogen, Inc. | Treatment for Radiation-Induced Disorders |
WO2011060233A1 (en) | 2009-11-11 | 2011-05-19 | The Trustees Of The University Of Pennsylvania | Anti-tem1 antibodies and uses thereof |
AR079217A1 (en) | 2009-11-30 | 2012-01-04 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT |
PL3338765T3 (en) | 2009-12-01 | 2019-06-28 | Translate Bio, Inc. | Steroid derivative for the delivery of mrna in human genetic diseases |
MX2012006580A (en) | 2009-12-11 | 2012-09-28 | Genecode As | Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators. |
ES2661813T3 (en) | 2009-12-16 | 2018-04-04 | Curna, Inc. | Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene |
CA2782373C (en) | 2009-12-23 | 2019-03-26 | Opko Curna, Llc | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
WO2011090740A2 (en) | 2009-12-29 | 2011-07-28 | Opko Curna, Llc | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
ES2585829T3 (en) | 2009-12-29 | 2016-10-10 | Curna, Inc. | Treatment of diseases related to tumor protein 63 (p63) by inhibition of natural antisense transcription to p63 |
KR101878501B1 (en) | 2010-01-04 | 2018-08-07 | 큐알엔에이, 인크. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
DK2524039T3 (en) | 2010-01-11 | 2018-03-12 | Curna Inc | TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG |
US8883739B2 (en) | 2010-01-19 | 2014-11-11 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for male reproductive disorders |
CN102782135A (en) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1 |
CN102844435B (en) | 2010-02-22 | 2017-05-10 | 库尔纳公司 | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
MX2012009215A (en) | 2010-02-23 | 2012-11-23 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor. |
US9121022B2 (en) | 2010-03-08 | 2015-09-01 | Monsanto Technology Llc | Method for controlling herbicide-resistant plants |
US9186370B2 (en) | 2010-03-19 | 2015-11-17 | University Of South Alabama | Methods and compositions for the treatment of cancer |
TWI688395B (en) | 2010-03-23 | 2020-03-21 | 英翠克頌公司 | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
RU2615143C2 (en) | 2010-03-24 | 2017-04-04 | Адвирна | Self-delivered rnai compounds of reduced size |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
US8883218B2 (en) | 2010-03-26 | 2014-11-11 | The Board Of Trustees Of The University Of Arkansas | Anti-cancer nanoparticle compositions and methods of use |
WO2011120023A1 (en) | 2010-03-26 | 2011-09-29 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting survivin gene expression uses thereof |
RU2610661C2 (en) | 2010-04-09 | 2017-02-14 | Курна, Инк. | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
WO2011130114A1 (en) | 2010-04-12 | 2011-10-20 | Iowa State University Research Foundation, Inc. | Nanoparticles and nanoparticle compositions |
WO2011133584A2 (en) | 2010-04-19 | 2011-10-27 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting hras gene expression and uses thereof |
WO2011139842A2 (en) | 2010-04-28 | 2011-11-10 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof |
WO2011139917A1 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
MA34291B1 (en) | 2010-05-03 | 2013-06-01 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR |
CN107988228B (en) | 2010-05-03 | 2022-01-25 | 库尔纳公司 | Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to Sirtuin (SIRT) |
WO2011141704A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc | Novel cyclic cationic lipids and methods of use |
JP5866106B2 (en) | 2010-05-12 | 2016-02-17 | コロンビア ユニヴァーシティ | Method for producing enteroendocrine cells that produce and secrete insulin |
JP2013527856A (en) | 2010-05-12 | 2013-07-04 | プロチバ バイオセラピューティクス インコーポレイティッド | Cationic lipids and methods of use |
TWI531370B (en) | 2010-05-14 | 2016-05-01 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
US8658780B2 (en) | 2010-05-18 | 2014-02-25 | California Institute Of Technology | Triggered covalent probes for imaging and silencing genetic expression |
US8895528B2 (en) | 2010-05-26 | 2014-11-25 | Curna, Inc. | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 |
EP2580238A1 (en) | 2010-06-09 | 2013-04-17 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
JP2013530187A (en) | 2010-06-17 | 2013-07-25 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Compositions and methods for treating inflammatory diseases. |
DK2591114T3 (en) | 2010-07-06 | 2016-08-29 | Glaxosmithkline Biologicals Sa | Immunization of large mammals with low doses of RNA |
NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
US20130171241A1 (en) | 2010-07-06 | 2013-07-04 | Novartis Ag | Liposomes with lipids having an advantageous pka-value for rna delivery |
LT3243526T (en) | 2010-07-06 | 2020-02-10 | Glaxosmithkline Biologicals S.A. | Delivery of rna to trigger multiple immune pathways |
CN103068982B (en) | 2010-07-14 | 2017-06-09 | 库尔纳公司 | DLG relevant diseases are treated by suppressing the natural antisense transcript of the big homologue of plate-like (DLG) |
US9834439B2 (en) | 2010-07-20 | 2017-12-05 | California Institute Of Technology | Biomolecular self-assembly |
US8962241B2 (en) | 2010-07-20 | 2015-02-24 | California Institute Of Technology | Triggered molecular geometry based bioimaging probes |
US8877438B2 (en) | 2010-07-20 | 2014-11-04 | California Institute Of Technology | Self-assembled polynucleotide structure |
WO2012025873A2 (en) | 2010-08-23 | 2012-03-01 | Wyeth Llc | STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS |
ES2918649T3 (en) | 2010-08-31 | 2022-07-19 | Glaxosmithkline Biologicals Sa | Pegylated liposomes for delivery of RNA encoding an immunogen |
PE20140173A1 (en) | 2010-09-10 | 2014-02-20 | Wyeth Llc | NON-LIPIDED VARIANTS OF NEISSERIA MENINGITIDIS ANTIGENS ORF2086 |
US8703824B2 (en) | 2010-09-14 | 2014-04-22 | Council Of Scientific & Industrial Research | Cationic amphiphiles with mannose-mimicking head-groups and a process for the preparation thereof |
WO2012047968A2 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
EP2625274B1 (en) | 2010-10-06 | 2017-07-19 | CuRNA, Inc. | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
BR112013008700B8 (en) | 2010-10-11 | 2022-10-04 | Novartis Ag | SELF-REPLICATING RNA MOLECULE, ALPHAVIRUS REPLICON PARTICLE, COMPOSITION, RECOMBINANT DNA MOLECULE, USE OF SELF-REPLICATING RNA MOLECULE |
CA2815212A1 (en) | 2010-10-22 | 2012-04-26 | Curna, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
JP6073795B2 (en) | 2010-10-27 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | Treatment of IFRD1-related diseases by inhibition of natural antisense transcripts to interferon-related developmental regulator 1 (IFRD1) |
WO2012061811A2 (en) | 2010-11-05 | 2012-05-10 | Fibrogen, Inc. | Treatment method for lung remodeling diseases |
CN103459599B (en) | 2010-11-23 | 2017-06-16 | 库尔纳公司 | NANOG relevant diseases are treated by suppressing the natural antisense transcript of NANOG |
US20120310140A1 (en) | 2010-12-01 | 2012-12-06 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
NZ611427A (en) | 2010-12-06 | 2015-08-28 | Penn State Res Found | Compositions and methods relating to proliferative diseases |
BR112013014457A8 (en) | 2010-12-09 | 2017-12-19 | Pasteur Institut | uses of the enzyme 6-methylguanine-dna-methyltrasferase (mgmt, ec 2.1.1.63) to increase heterologous protein production, as well as expression vector, recombinant cells and fusion polypeptide comprising peptide secretion signal and snap protein |
US9095598B2 (en) | 2010-12-28 | 2015-08-04 | The Board Of Trustees Of The University Of Arkansas | Stilbenoid derivatives and their uses |
EP2670426B1 (en) | 2011-01-31 | 2017-05-10 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
WO2012106508A1 (en) | 2011-02-02 | 2012-08-09 | Pfizer Inc. | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf) |
WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
EP2492279A1 (en) | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Rapid immunogen selection method using lentiviral display |
WO2012122025A2 (en) | 2011-03-04 | 2012-09-13 | Intrexon Corporation | Vectors conditionally expressing protein |
WO2012135696A2 (en) | 2011-04-01 | 2012-10-04 | University Of South Alabama | Methods and compositions for the diagnosis, classification, and treatment of cancer |
AU2012242642A1 (en) | 2011-04-13 | 2013-05-02 | Ionis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US20130101628A1 (en) * | 2011-04-29 | 2013-04-25 | Northwestern University | Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use |
CA2836499C (en) * | 2011-05-20 | 2019-01-15 | Michael Wilhelm PLATSCHER | Stable crystal modifications of dotap chloride |
HRP20211595T1 (en) | 2011-05-24 | 2022-01-21 | BioNTech SE | Individualized vaccines for cancer |
EP4043025A1 (en) | 2011-06-08 | 2022-08-17 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
JP6188686B2 (en) | 2011-06-09 | 2017-08-30 | カッパーアールエヌエー,インコーポレイテッド | Treatment of FXN-related diseases by inhibition of natural antisense transcripts to frataxin (FXN) |
SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
CN103597074A (en) | 2011-06-16 | 2014-02-19 | Isis制药公司 | Antisense modulation of fibroblast growth factor receptor 4 expression |
MX350198B (en) | 2011-07-06 | 2017-08-30 | Novartis Ag | Oil-in-water emulsions that contain nucleic acids. |
MX350258B (en) | 2011-07-06 | 2017-08-31 | Novartis Ag | Cationic oil-in-water emulsions. |
WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
EP2546358A1 (en) | 2011-07-15 | 2013-01-16 | Laboratorios Del. Dr. Esteve, S.A. | Methods and reagents for efficient control of HIV progression |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
AU2012308694B2 (en) | 2011-09-13 | 2018-06-14 | Monsanto Technology Llc | Methods and compositions for weed control |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
SG10201912964PA (en) | 2011-09-19 | 2020-02-27 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
CN103814132B (en) | 2011-09-20 | 2018-06-05 | 苏州瑞博生物技术有限公司 | The antisense of GCGR expression is adjusted |
US20130071403A1 (en) | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
WO2013043720A1 (en) | 2011-09-20 | 2013-03-28 | The University Of North Carolina At Chapel Hill | Regulation of sodium channels by plunc proteins |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
WO2013053765A1 (en) | 2011-10-11 | 2013-04-18 | Proyecto De Biomedicina Cima, S.L. | A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma |
CN103906838A (en) | 2011-10-25 | 2014-07-02 | Isis制药公司 | Antisense modulation of GCCR expression |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
EP2788316B1 (en) * | 2011-12-07 | 2019-04-24 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
MX349562B (en) | 2011-12-09 | 2017-08-02 | Pasteur Institut | Multiplex immuno screening assay. |
US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
UY34536A (en) | 2011-12-22 | 2013-07-31 | Alios Biopharma Inc | NUCLEOSIDS REPLACED, NUCLEOTID AND ANALOG OF THE SAME |
US9464291B2 (en) | 2012-01-06 | 2016-10-11 | University Of South Alabama | Methods and compositions for the treatment of cancer |
EP3381461B1 (en) | 2012-01-09 | 2021-03-10 | Serpin Pharma, LLC | Peptides and methods of using same |
US9352042B2 (en) | 2012-02-24 | 2016-05-31 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
SG10201602558UA (en) | 2012-03-09 | 2016-05-30 | Pfizer | Neisseria meningitidis compositions and methods thereof |
SA115360586B1 (en) | 2012-03-09 | 2017-04-12 | فايزر انك | Neisseria meningitidis compositions and methods thereof |
US20150031750A1 (en) | 2012-03-15 | 2015-01-29 | The Scripps Research Institute | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
US9783610B2 (en) | 2012-04-27 | 2017-10-10 | The Trustees Of The University Of Pennsylvania | Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof |
JP6402097B2 (en) | 2012-05-21 | 2018-10-10 | インスメッド インコーポレイテッド | System for treating pulmonary infections |
AR091143A1 (en) | 2012-05-24 | 2015-01-14 | Seeds Ltd Ab | COMPOSITIONS AND METHODS TO SILENCE GENETIC EXPRESSION |
WO2013185116A1 (en) * | 2012-06-08 | 2013-12-12 | Payne Joseph E | Lipids for therapeutic agent delivery formulations |
EP2859102A4 (en) | 2012-06-08 | 2016-05-11 | Shire Human Genetic Therapies | Nuclease resistant polynucleotides and uses thereof |
ES2631608T3 (en) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Env-glycoprotein variant of HIV-1 |
EP2698377A1 (en) | 2012-08-17 | 2014-02-19 | Laboratorios Del. Dr. Esteve, S.A. | Enhanced rapid immunogen selection method for HIV gp120 variants |
US9605074B2 (en) | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
US9365856B2 (en) | 2012-09-14 | 2016-06-14 | The Board Of Trustees Of The University Of Arkansas | Methods of using a serum response factor isoform |
WO2014041179A1 (en) | 2012-09-17 | 2014-03-20 | Chemedest Ltd. | Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists |
JP2015530413A (en) | 2012-09-21 | 2015-10-15 | ベデュ−アッド,フランク | Improved vaccine compositions and methods of use |
CA2892391C (en) | 2012-11-28 | 2023-10-17 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
ES2743039T3 (en) | 2012-11-29 | 2020-02-18 | Insmed Inc | Vancomycin stabilized formulations |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
BR112015015975A2 (en) | 2013-01-01 | 2018-11-06 | A. B. Seeds Ltd. | isolated dsrna molecules and methods of using them for silencing target molecules of interest. |
WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
WO2014124334A2 (en) | 2013-02-08 | 2014-08-14 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
EP2964665B1 (en) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogenic fusion polypeptides |
EP2968613B1 (en) | 2013-03-11 | 2019-09-11 | University of Florida Research Foundation, Inc. | Delivery of card protein as therapy for occular inflammation |
EP2968470B1 (en) | 2013-03-12 | 2020-10-28 | The General Hospital Corporation | Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases |
AU2014249015B2 (en) | 2013-03-13 | 2020-04-16 | Monsanto Technology Llc | Methods and compositions for weed control |
UY35385A (en) | 2013-03-13 | 2014-09-30 | Monsanto Technology Llc | ? METHODS AND COMPOSITIONS FOR WEED CONTROL ?. |
AU2014248515B2 (en) | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
US9952202B2 (en) | 2013-03-14 | 2018-04-24 | Galapagos Nv | Methods of identifying compounds for the treatment of fibrosis by using S1PR5 |
JP6437467B2 (en) | 2013-03-14 | 2018-12-19 | ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. | Molecular targets and compounds useful in the treatment of fibrotic diseases and methods for identifying them |
PT2968586T (en) | 2013-03-14 | 2018-11-13 | Ethris Gmbh | Cftr mrna compositions and related methods and uses |
EP2972381A2 (en) | 2013-03-14 | 2016-01-20 | Galapagos NV | Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition |
EP2970955B1 (en) | 2013-03-14 | 2018-11-14 | Translate Bio, Inc. | Methods for purification of messenger rna |
AU2013381922A1 (en) | 2013-03-15 | 2015-09-24 | The Penn State Research Foundation | Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer |
CN105283439B (en) | 2013-03-15 | 2018-02-02 | 英特瑞克斯顿股份有限公司 | The dibenzoylhydrazine of boracic |
WO2014152497A2 (en) | 2013-03-15 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for cognitive disorders |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
CN110237270A (en) | 2013-03-15 | 2019-09-17 | 洛马林达大学 | The treatment of autoimmune disease |
CA2905649A1 (en) | 2013-03-15 | 2014-09-18 | The Penn State Research Foundation | Compositions and methods including celecoxib and plumbagin relating to treatment of cancer |
WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
US20160130585A1 (en) | 2013-05-28 | 2016-05-12 | The Johns Hopkins University | Aptamers for the treatment of sickle cell disease |
CA2918787A1 (en) | 2013-06-13 | 2014-12-18 | George Tachas | Combination therapy |
US20160152952A1 (en) | 2013-06-25 | 2016-06-02 | Temple University-Of The Commonwealth System Of Higher Education | Cortical Bone-Derived Stem Cells |
US9856472B2 (en) | 2013-07-01 | 2018-01-02 | California Institute Of Technology | Small conditional RNAs |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
RU2703498C2 (en) | 2013-07-19 | 2019-10-17 | Монсанто Текнолоджи Ллс | Compositions and methods for controlling leptinotarsa |
JP6620093B2 (en) | 2013-07-23 | 2019-12-11 | アービュートゥス バイオファーマ コーポレイションArbutus Biopharma Corporation | Compositions and methods for delivering messenger RNA |
US10894963B2 (en) | 2013-07-25 | 2021-01-19 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
US10568898B2 (en) * | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
WO2015031645A1 (en) | 2013-08-28 | 2015-03-05 | Washington University | Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
US20150197534A1 (en) | 2013-09-05 | 2015-07-16 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
CA2923129C (en) | 2013-09-08 | 2020-06-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
WO2015042466A2 (en) | 2013-09-19 | 2015-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for inhibiting jc virus (jcv) |
KR20160046879A (en) | 2013-09-25 | 2016-04-29 | 조에티스 서비시즈 엘엘씨 | Pcv2b divergent vaccine composition and methods of use |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
AU2014340092B2 (en) | 2013-10-22 | 2019-09-19 | Translate Bio, Inc. | mRNA therapy for Argininosuccinate Synthetase Deficiency |
WO2015061491A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
AU2014341879B2 (en) | 2013-11-04 | 2020-07-23 | Beeologics, Inc. | Compositions and methods for controlling arthropod parasite and pest infestations |
US9487536B2 (en) | 2013-11-08 | 2016-11-08 | Board Of Trustees Of The University Of Arkansas | Melampomagnolide B derivatives |
US9469650B2 (en) | 2013-11-08 | 2016-10-18 | Board Of Trustees Of The University Of Arkansas | Melampomagnolide B derivatives |
WO2015126502A2 (en) | 2013-12-03 | 2015-08-27 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
UA119253C2 (en) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Compositions and methods for virus control in varroa mite and bees |
DK3079712T3 (en) | 2013-12-11 | 2022-04-25 | Massachusetts Gen Hospital | USE OF MÜLLER INHIBITANT SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION AND OVARIAN RESERVE PRESERVATION |
AU2015206585A1 (en) | 2014-01-15 | 2016-07-21 | Monsanto Technology Llc | Methods and compositions for weed control using EPSPS polynucleotides |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
WO2015120075A2 (en) | 2014-02-04 | 2015-08-13 | Genentech, Inc. | Mutant smoothened and methods of using the same |
US11053291B2 (en) | 2014-02-19 | 2021-07-06 | University Of Florida Research Foundation, Incorporated | Delivery of Nrf2 as therapy for protection against reactive oxygen species |
US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
KR101605421B1 (en) | 2014-03-05 | 2016-03-23 | 국립암센터 | A monoclonal antibody which specifically recognizes B cell lymphoma and use thereof |
WO2015153339A2 (en) | 2014-04-01 | 2015-10-08 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
SG11201608725YA (en) | 2014-04-25 | 2016-11-29 | Shire Human Genetic Therapies | Methods for purification of messenger rna |
EP3708170A1 (en) | 2014-05-05 | 2020-09-16 | BioVentures, LLC | Compositions and methods for inhibiting antiapoptotic bcl-2 proteins as anti-aging agents |
WO2015171918A2 (en) | 2014-05-07 | 2015-11-12 | Louisiana State University And Agricultural And Mechanical College | Compositions and uses for treatment thereof |
US10238675B2 (en) | 2014-05-15 | 2019-03-26 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
CN106535876B (en) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications |
AU2015280252A1 (en) | 2014-06-23 | 2017-01-12 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via RNA interference |
US11807857B2 (en) | 2014-06-25 | 2023-11-07 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
CA2985344A1 (en) | 2014-06-26 | 2015-12-30 | The Trustees Of Columbia University In The City Of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
AU2015292710A1 (en) | 2014-07-22 | 2017-02-16 | Bioventures, Llc. | Compositions and methods for selectively depleting senescent cells |
US10449261B2 (en) | 2014-07-24 | 2019-10-22 | Washington University | Compositions targeting radiation-induced molecules and methods of use thereof |
RU2021123470A (en) | 2014-07-29 | 2021-09-06 | Монсанто Текнолоджи Ллс | COMPOSITIONS AND METHODS FOR COMBATING PESTS |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
AU2015315047A1 (en) | 2014-09-10 | 2017-04-27 | Washington University | Compositions and methods for treatment of pre-cancerous skin lesions |
JP6567657B2 (en) | 2014-09-17 | 2019-08-28 | イントレキソン コーポレーション | Boron-containing diacylhydrazine compounds |
WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
JP2017536092A (en) | 2014-10-02 | 2017-12-07 | プロティバ バイオセラピューティクス インコーポレイテッド | Compositions and methods for silencing gene expression of hepatitis B virus |
CA2963931A1 (en) | 2014-10-06 | 2016-04-14 | Exicure, Inc. | Anti-tnf compounds |
US10918629B2 (en) | 2014-10-20 | 2021-02-16 | The Curators Of The University Of Missouri | Method for treating lymphedema |
WO2016081728A1 (en) | 2014-11-19 | 2016-05-26 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for frailty associated with aging |
WO2016085986A1 (en) | 2014-11-24 | 2016-06-02 | Northwestern University | High density lipoprptein nanoparticles for inflammation |
US9981990B2 (en) | 2014-12-03 | 2018-05-29 | Bioventures, Llc | Melampomagnolide B dimers |
KR102583917B1 (en) * | 2014-12-08 | 2023-10-04 | 니치유 가부시키가이샤 | Method for producing cationic lipid |
PL3233192T3 (en) | 2014-12-15 | 2021-11-02 | Washington University | Compositions and methods for targeted cytokine delivery |
WO2016118762A1 (en) | 2015-01-22 | 2016-07-28 | Monsanto Technology Llc | Compositions and methods for controlling leptinotarsa |
WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
BR112017017460A2 (en) | 2015-02-19 | 2018-04-10 | Pfizer Inc. | neisseria meningitidis compositions and methods thereof |
EP3265063A4 (en) * | 2015-03-03 | 2018-11-07 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
WO2016141167A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
MA41795A (en) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
WO2016168601A1 (en) | 2015-04-17 | 2016-10-20 | Khalid Shah | Agents, systems and methods for treating cancer |
CA2984154A1 (en) | 2015-05-01 | 2016-11-10 | Onl Therapeutics, Inc. | Peptide compositions and methods of use |
US10716827B2 (en) | 2015-05-20 | 2020-07-21 | Syracuse University | Compositions and methods for enhancing peptide stability against protease digestion |
US20180154007A1 (en) | 2015-05-20 | 2018-06-07 | Syracuse University | Glycemic Control Using Intrinsic Factor Bound to A Vitamin B12 Conjugate of a Glucagon-Like Peptide-1 Receptor Agonist |
EP3851531A1 (en) | 2015-06-01 | 2021-07-21 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
UY36703A (en) | 2015-06-02 | 2016-12-30 | Monsanto Technology Llc | COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF A POLINUCLEOTIDE ON A PLANT |
WO2016196782A1 (en) | 2015-06-03 | 2016-12-08 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
US20180245074A1 (en) | 2015-06-04 | 2018-08-30 | Protiva Biotherapeutics, Inc. | Treating hepatitis b virus infection using crispr |
TW201710503A (en) | 2015-06-12 | 2017-03-16 | 長庚醫療財團法人林口長庚紀念醫院 | Novel polynucleotides, vactor, pharmaceutical compositions and use thereof |
CN108136008A (en) | 2015-07-15 | 2018-06-08 | 华盛顿大学 | For the antibody and its application method of the tumour related compound N- glycan with end GlcNAc β residues |
WO2017019891A2 (en) | 2015-07-29 | 2017-02-02 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis b virus gene expression |
MX2018002090A (en) | 2015-08-24 | 2018-09-12 | Halo Bio Rnai Therapeutics Inc | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof. |
AU2016317726B2 (en) | 2015-08-28 | 2022-05-26 | Serpin Pharma, Llc | Methods for treatment of diseases |
AU2016328279A1 (en) | 2015-09-24 | 2018-05-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for reducing metastases |
US10954300B2 (en) | 2015-09-28 | 2021-03-23 | The Trustees Of Columbia University In The City Of New York | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
JP2018530560A (en) | 2015-10-09 | 2018-10-18 | サレプタ セラピューティクス, インコーポレイテッド | Compositions and methods for the treatment of Duchenne muscular dystrophy and related disorders |
WO2017062953A1 (en) | 2015-10-10 | 2017-04-13 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
EP3362049A1 (en) | 2015-10-16 | 2018-08-22 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
EP3370734B1 (en) | 2015-11-05 | 2023-01-04 | Children's Hospital Los Angeles | Antisense oligo for use in treating acute myeloid leukemia |
US20180319815A1 (en) | 2015-11-05 | 2018-11-08 | Board Of Trustees Of The University Of Arkansas | Hetero-substituted cyclic lactone analogues and uses thereof |
WO2017083820A1 (en) | 2015-11-13 | 2017-05-18 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
US10596248B2 (en) | 2015-12-09 | 2020-03-24 | Jingang Medicine (Australia) Pty Ltd | Immunomodulating composition for treatment |
WO2017120589A1 (en) | 2016-01-08 | 2017-07-13 | Washington University | Compositions comprising chemerin and methods of use thereof |
AU2017212653A1 (en) | 2016-01-29 | 2018-07-19 | Bioventures, Llc | Triazole derivatives of melampomagnolide B and methods of use thereof |
CA3019952A1 (en) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened and methods of using the same |
US11053293B2 (en) | 2016-02-05 | 2021-07-06 | Washington University | Compositions and methods for targeted cytokine delivery |
ES2754785T3 (en) | 2016-02-22 | 2020-04-20 | Caribou Biosciences Inc | DNA repair results modulation procedures |
GB201604235D0 (en) | 2016-03-11 | 2016-04-27 | Ucl Business Plc | Lipids and complexes for the delivery of biologically-active material to cells |
US10213448B2 (en) | 2016-03-25 | 2019-02-26 | Novazoi Theranostics | Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof |
KR102522059B1 (en) | 2016-04-18 | 2023-04-14 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | Antisense oligomers and methods of their use to treat diseases associated with the acid alpha-glucosidase gene |
KR102447884B1 (en) | 2016-04-21 | 2022-09-27 | 바이오벤처스, 엘엘씨 | Compounds inducing degradation of anti-apoptotic BCL-2 family proteins and uses thereof |
KR102471787B1 (en) | 2016-05-02 | 2022-11-29 | 프로테나 바이오사이언시즈 리미티드 | Tau recognition antibody |
ES2933491T3 (en) | 2016-05-02 | 2023-02-09 | Prothena Biosciences Ltd | tau immunotherapy |
CN109415434B (en) | 2016-05-02 | 2022-12-30 | 普罗塞纳生物科学有限公司 | Antibodies recognizing TAU |
WO2017193087A1 (en) | 2016-05-06 | 2017-11-09 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs prsenting antisense oligonucleotides(aso) for specific knockdown of interleukin 17 receptor mrna |
MX2018016389A (en) | 2016-06-30 | 2019-08-16 | Arbutus Biopharma Corp | Compositions and methods for delivering messenger rna. |
EP3943613A1 (en) | 2016-07-05 | 2022-01-26 | California Institute of Technology | Fractional initiator hybridization chain reaction |
CA3034617A1 (en) | 2016-08-30 | 2018-03-08 | California Institute Of Technology | Immunohistochemistry via hybridization chain reaction |
EP3519578B1 (en) * | 2016-10-03 | 2021-12-22 | Precision Nanosystems Inc | Compositions for transfecting resistant cell types |
EP3939604A3 (en) | 2016-10-21 | 2022-06-22 | Merck Sharp & Dohme Corp. | Influenza hemagglutinin protein vaccines |
WO2018081388A1 (en) | 2016-10-26 | 2018-05-03 | Washington University | Compositions comprising desaminotyrosine and uses thereof to enhance type i interferon stimulation |
NZ752941A (en) | 2016-11-09 | 2023-04-28 | Intrexon Corp | Frataxin expression constructs |
US10011848B2 (en) | 2016-11-09 | 2018-07-03 | City University Of Hong Kong | System and method for delivery of substance into mammalian cells |
AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
WO2018148595A1 (en) | 2017-02-10 | 2018-08-16 | Washington University | Antibodies to tip1 and methods of use thereof |
WO2018157154A2 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Novel codon-optimized cftr mrna |
CA3084252A1 (en) | 2017-03-28 | 2018-10-04 | Caribou Biosciences, Inc. | Crispr-associated (cas) protein |
US11351227B2 (en) | 2017-04-27 | 2022-06-07 | Washington University | Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof |
WO2018201088A1 (en) | 2017-04-27 | 2018-11-01 | Washington University | Activation of natural cytotoxicity receptor 2 (ncr2) |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
CA3061516A1 (en) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
US10994025B2 (en) | 2017-05-12 | 2021-05-04 | Massachusetts Institute Of Technology | Argonaute protein-double stranded RNA complexes and uses related thereto |
EP3624824A1 (en) | 2017-05-16 | 2020-03-25 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
CA3067164A1 (en) | 2017-06-12 | 2018-12-20 | Washington University | Zika virus strains for treatment of glioblastoma |
KR20200028997A (en) | 2017-07-13 | 2020-03-17 | 노오쓰웨스턴 유니버시티 | General and direct method of preparing oligonucleotide-functionalized metal-organic framework nanoparticles |
US20200165203A1 (en) | 2017-07-31 | 2020-05-28 | Washington University | Use of pirfenidone and derivatives for modulation of b lymphocyte activity and organ protection from acute tissue damage |
US20200375929A1 (en) | 2017-08-14 | 2020-12-03 | Washington University | Methods and compositions for the treatment of diseases associated with cancer, inflammation, or immune response |
US11097018B2 (en) | 2017-09-06 | 2021-08-24 | Washington University | Organomedicinals for imaging and treatment of neurodegenerative disorders |
WO2019079637A2 (en) | 2017-10-18 | 2019-04-25 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
CN107827762B (en) * | 2017-11-14 | 2020-10-02 | 苏州东南药业股份有限公司 | (2, 3-dioleoyl-propyl) trimethyl ammonium chloride and preparation method and application thereof |
TW201936201A (en) | 2017-12-14 | 2019-09-16 | 美商堅固生物科技公司 | Non-viral production and delivery of genes |
JP7385284B2 (en) | 2018-01-22 | 2023-11-22 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニー | BCL-2 proteolytic agents for cancer treatment |
WO2019147749A2 (en) | 2018-01-29 | 2019-08-01 | Merck Sharp & Dohme Corp. | Stabilized rsv f proteins and uses thereof |
CN108129338A (en) * | 2018-02-01 | 2018-06-08 | 爱斯特(成都)生物制药股份有限公司 | A kind of preparation method of cationic liposome DOTAP |
EP3539975A1 (en) | 2018-03-15 | 2019-09-18 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Micropeptides and uses thereof |
WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
US20210155959A1 (en) | 2018-04-06 | 2021-05-27 | Children's Medical Center Corporation | Compositions and methods for somatic cell reprogramming and modulating imprinting |
JP2021534101A (en) | 2018-08-09 | 2021-12-09 | ヴェルソー セラピューティクス, インコーポレイテッド | Oligonucleotide compositions for targeting CCR2 and CSF1R and their use |
EP3835320A4 (en) | 2018-08-10 | 2022-06-01 | Eutilex Co., Ltd. | Chimeric antigen receptor binding to hla-dr, and car-t cell |
AU2019325702A1 (en) | 2018-08-24 | 2021-02-25 | Translate Bio, Inc. | Methods for purification of messenger RNA |
WO2020180819A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
AU2020236937B2 (en) | 2019-03-08 | 2023-06-15 | Obsidian Therapeutics, Inc. | CD40L compositions and methods for tunable regulation |
US11964001B2 (en) | 2019-04-09 | 2024-04-23 | Washington University | Compositions for treating or preventing respiratory tract infections and method of use thereof |
WO2020219531A1 (en) | 2019-04-22 | 2020-10-29 | The Penn State Research Foundation | Methods and compositions relating to inhibition of aldehyde dehydrogenases for treatment of cancer |
WO2021142376A1 (en) | 2020-01-08 | 2021-07-15 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
PE20230493A1 (en) | 2020-02-14 | 2023-03-23 | Merck Sharp And Dohme Llc | HPV VACCINE |
US11752199B1 (en) | 2020-02-25 | 2023-09-12 | Mallinckrodt Ard Ip Unlimited Company | Methods of modulating pericytes |
EP3885440A1 (en) | 2020-03-26 | 2021-09-29 | Splicebio, S.L. | Split inteins and their uses |
CN111393595A (en) * | 2020-05-06 | 2020-07-10 | 东莞市竤穗实业投资有限公司 | Bio-based polycarbodiimide crosslinking agent with temperature-sensitive characteristic and preparation method thereof |
EP4153210A2 (en) | 2020-05-19 | 2023-03-29 | Othair Prothena Limited | Multi-epitope vaccine for the treatment of alzheimer's disease |
EP3973978A1 (en) | 2020-09-25 | 2022-03-30 | Mallinckrodt Ard IP Unlimited Company | Methods of modulating corticosteroid response |
EP4225330A1 (en) | 2020-10-06 | 2023-08-16 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022133149A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
JP2023554395A (en) | 2020-12-17 | 2023-12-27 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment with tumor-infiltrating lymphocyte therapy in combination with CTLA-4 and PD-1 inhibitors |
WO2022164796A1 (en) | 2021-01-26 | 2022-08-04 | California Institute Of Technology | Allosteric conditional guide rnas for cell-selective regulation of crispr/cas |
TW202245835A (en) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | Nanoemulsion adjuvant composition for pneumococcal conjugate vaccines |
KR20240037185A (en) | 2021-04-19 | 2024-03-21 | 이오반스 바이오테라퓨틱스, 인크. | Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy |
AU2022261124A1 (en) | 2021-04-22 | 2023-10-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
WO2023288287A2 (en) | 2021-07-15 | 2023-01-19 | Turn Biotechnologies, Inc. | Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment |
WO2023288285A1 (en) | 2021-07-15 | 2023-01-19 | Turn Biotechnologies, Inc. | Polycistronic expression vectors |
WO2023288288A1 (en) | 2021-07-15 | 2023-01-19 | Turn Biotechnologies, Inc. | Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use |
GB202110644D0 (en) | 2021-07-23 | 2021-09-08 | Sisaf Ltd | Improved nucleic acid vector particles |
GB202110646D0 (en) | 2021-07-23 | 2021-09-08 | Sisaf Ltd | Nucleic acid vector compositions |
WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
AR126813A1 (en) | 2021-08-19 | 2023-11-15 | Merck Sharp & Dohme Llc | NEW THERMOSTABLE LIPID NANOPARTICLE AND METHODS OF USE OF THE SAME |
WO2023069498A1 (en) | 2021-10-22 | 2023-04-27 | Senda Biosciences, Inc. | Mrna vaccine composition |
AR127482A1 (en) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | SYSTEMS AND METHODS TO COORDINATE THE MANUFACTURE OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023096858A1 (en) | 2021-11-23 | 2023-06-01 | Senda Biosciences, Inc. | A bacteria-derived lipid composition and use thereof |
WO2023122080A1 (en) | 2021-12-20 | 2023-06-29 | Senda Biosciences, Inc. | Compositions comprising mrna and lipid reconstructed plant messenger packs |
WO2023220603A1 (en) | 2022-05-09 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
WO2023235818A2 (en) | 2022-06-02 | 2023-12-07 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
US20230392188A1 (en) | 2022-06-02 | 2023-12-07 | Perkinelmer Health Sciences, Inc. | Electrophoresis-mediated characterization of dna content of adeno-associated virus capsids |
EP4314267A1 (en) | 2022-06-07 | 2024-02-07 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
WO2023240074A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3931397A (en) * | 1971-11-05 | 1976-01-06 | Beecham Group Limited | Biologically active material |
IT1196363B (en) * | 1984-12-10 | 1988-11-16 | Bracco Ind Chimica Spa | DERIVATIVES OF 5-ALCOXY-2,4,6-TRIIODE- OR -TRIBROME-ISOPHTHALIC ACID, METHOD FOR THEIR PREPARATION AND RELATED RADIOLOGICAL CONTRAST MEANS |
US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
NZ214716A (en) * | 1985-01-07 | 1989-04-26 | Syntex Inc | 1,2-dialkoxy-omega-trialkylammonium cationic surfactants |
JPS63102682A (en) * | 1986-10-20 | 1988-05-07 | Medeisa Shinyaku Kk | Transduction of dna into eukaryocyte |
US4840738A (en) * | 1988-02-25 | 1989-06-20 | The Procter & Gamble Company | Stable biodegradable fabric softening compositions containing 2-hydroxypropyl monoester quaternized ammonium salts |
CA2001401A1 (en) * | 1988-10-25 | 1990-04-25 | Claude Piantadosi | Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions |
JP2805092B2 (en) * | 1989-09-14 | 1998-09-30 | ソニー株式会社 | Disk drive device |
JP2604268B2 (en) * | 1990-04-09 | 1997-04-30 | 富士写真フイルム株式会社 | Liposomes and thin films using peptide derivative amphiphilic compounds, intermediates thereof, and peptide derivative amphiphilic compounds |
DE4013632A1 (en) * | 1990-04-27 | 1991-10-31 | Max Planck Gesellschaft | LIPOSOMES WITH POSITIVE EXCESS CHARGE |
WO1991017424A1 (en) * | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
-
1991
- 1991-04-16 US US07/686,746 patent/US5264618A/en not_active Expired - Lifetime
- 1991-04-18 JP JP3508835A patent/JP2538474B2/en not_active Expired - Lifetime
- 1991-04-18 DE DE69131347T patent/DE69131347T2/en not_active Expired - Lifetime
- 1991-04-18 EP EP91908905A patent/EP0523189B1/en not_active Expired - Lifetime
- 1991-04-18 AU AU78547/91A patent/AU7854791A/en not_active Abandoned
- 1991-04-18 WO PCT/US1991/002691 patent/WO1991016024A1/en active IP Right Grant
- 1991-04-18 DK DK91908905T patent/DK0523189T3/en active
- 1991-04-18 ES ES91908905T patent/ES2134775T3/en not_active Expired - Lifetime
- 1991-04-18 CA CA002079814A patent/CA2079814C/en not_active Expired - Lifetime
- 1991-04-18 AT AT91908905T patent/ATE181319T1/en not_active IP Right Cessation
-
1993
- 1993-09-16 US US08/123,757 patent/US5459127A/en not_active Expired - Lifetime
-
1999
- 1999-08-13 GR GR990402051T patent/GR3030974T3/en unknown
Non-Patent Citations (2)
Title |
---|
K.L. MEYER et al., "In Vitro Evaluation of Phosphocholine and Quaternary Ammonium Containing Lipids as Novel Anti-HIV Agents", J. Med. Chem. 1991, 34, 1377-1383. * |
R. ELBERT et al., "Hydrophilic Spacer Groups in Polymerizable Lipids: Formation of Biomembrane Models from Bulk Polymerized Lipids", J. Amer. Chem. Soc. 1985, 107, 4134-4141. * |
Cited By (854)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5667764A (en) * | 1988-05-02 | 1997-09-16 | Zynaxis, Inc. | Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles |
EP0737750A2 (en) * | 1989-03-21 | 1996-10-16 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
US6710035B2 (en) | 1989-03-21 | 2004-03-23 | Vical Incorporated | Generation of an immune response to a pathogen |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
US7250404B2 (en) | 1989-03-21 | 2007-07-31 | Vical Incorporated | Lipid-mediated polynucleotide administration to deliver a biologically active peptide and to induce a cellular immune response |
EP0737750A3 (en) * | 1989-03-21 | 1996-12-11 | Vical Inc | Expression of exogenous polynucleotide sequences in a vertebrate |
US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US6024977A (en) * | 1990-11-01 | 2000-02-15 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US6858582B2 (en) | 1990-11-01 | 2005-02-22 | Oregon Health And Sciences University | Composition containing porous microparticle impregnated with biologically-active compound for treatment of infection |
US5965519A (en) * | 1990-11-01 | 1999-10-12 | Oregon Health Sciences University | Covalent polar lipid conjugates with biologically-active compounds for use in salves |
US6063759A (en) * | 1990-11-01 | 2000-05-16 | Oregon Health Sciences University | Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting |
US6436437B1 (en) | 1990-11-01 | 2002-08-20 | Oregon Health And Science University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US6339060B1 (en) | 1990-11-01 | 2002-01-15 | Oregon Health & Science University | Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting |
US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
US5693769A (en) * | 1991-12-13 | 1997-12-02 | Transcell Technologies, Inc. | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
US5795870A (en) * | 1991-12-13 | 1998-08-18 | Trustees Of Princeton University | Compositions and methods for cell transformation |
EP0625049A4 (en) * | 1992-01-23 | 1995-07-12 | Vical Inc | Ex vivo gene transfer. |
EP0625049A1 (en) * | 1992-01-23 | 1994-11-23 | Vical, Inc. | Ex vivo gene transfer |
EP1236473A3 (en) * | 1992-04-03 | 2003-01-15 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system |
EP0636028A1 (en) * | 1992-04-03 | 1995-02-01 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system |
EP0636028A4 (en) * | 1992-04-03 | 1998-12-09 | Univ California | Self-assembling polynucleotide delivery system. |
EP1236473A2 (en) * | 1992-04-03 | 2002-09-04 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system |
US5770580A (en) * | 1992-04-13 | 1998-06-23 | Baylor College Of Medicine | Somatic gene therapy to cells associated with fluid spaces |
WO1994001138A1 (en) * | 1992-07-09 | 1994-01-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Covalent polar lipid-peptide conjugates for biological targeting |
EP1034795A2 (en) * | 1992-07-09 | 2000-09-13 | THE STATE OF OREGON acting by and through THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON HEALTH SCIENCES UNIVERSITY | Conjugates of lipids and biologically active compounds |
EP1034795A3 (en) * | 1992-07-09 | 2001-02-07 | THE STATE OF OREGON acting by and through THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON HEALTH SCIENCES UNIVERSITY | Conjugates of lipids and biologically active compounds |
EP0607408A4 (en) * | 1992-07-13 | 1997-12-10 | Eukarion Inc | Transvascular and intracellular delivery of lipidized proteins. |
EP0607408A1 (en) * | 1992-07-13 | 1994-07-27 | Eukarion, Inc. | Transvascular and intracellular delivery of lipidized proteins |
KR100372119B1 (en) * | 1992-07-13 | 2003-06-28 | 유카리언, 인코포레이티드 | How to Deliver Lipidized Protein into Acuvascular and Intracellular Cells |
EP0656883A1 (en) * | 1992-08-28 | 1995-06-14 | Life Technologies, Inc. | Cationic lipids |
EP0656883A4 (en) * | 1992-08-28 | 1995-08-09 | Life Technologies Inc | Cationic lipids. |
WO1994009827A1 (en) * | 1992-11-05 | 1994-05-11 | Genzyme Corporation | Process for making lipid conjugates |
US5552155A (en) * | 1992-12-04 | 1996-09-03 | The Liposome Company, Inc. | Fusogenic lipsomes and methods for making and using same |
EP1624068A1 (en) * | 1993-06-01 | 2006-02-08 | Life Technologies Inc. | Genetic immunization with cationic lipids |
US7166298B2 (en) | 1993-06-01 | 2007-01-23 | Invitrogen Corporation | Genetic immunization with cationic lipids |
EP0702516A1 (en) * | 1993-06-01 | 1996-03-27 | Life Technologies Inc. | Genetic immunization with cationic lipids |
US6890554B2 (en) | 1993-06-01 | 2005-05-10 | Invitrogen Corporation | Genetic immunization with cationic lipids |
EP0702516A4 (en) * | 1993-06-01 | 1998-04-22 | Life Technologies Inc | Genetic immunization with cationic lipids |
US5578475A (en) * | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
WO1995002698A1 (en) * | 1993-07-12 | 1995-01-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
US6020202A (en) * | 1993-07-12 | 2000-02-01 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
EP0638236A1 (en) * | 1993-08-03 | 1995-02-15 | Kao Corporation | Agricultural chemical composition |
EP0842603A1 (en) * | 1993-08-03 | 1998-05-20 | Kao Corporation | Agricultural chemical composition |
US5563111A (en) * | 1993-08-03 | 1996-10-08 | Kao Corporation | Agricultural chemical composition comprising amine surfactants with at least one ester or amide linkage |
CN1073795C (en) * | 1993-08-03 | 2001-10-31 | 花王株式会社 | Agricultural chemical composition |
US6399663B1 (en) | 1993-12-20 | 2002-06-04 | Invitrogen Corporation | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
US6110916A (en) * | 1993-12-20 | 2000-08-29 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
US5674908A (en) * | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
US6716882B2 (en) | 1993-12-20 | 2004-04-06 | Invitrogen Corporation | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
WO1995017373A1 (en) * | 1993-12-20 | 1995-06-29 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
US5834439A (en) * | 1993-12-20 | 1998-11-10 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
US7501542B2 (en) | 1993-12-20 | 2009-03-10 | Invitrogen Corporation | Highly-packed polycationic ammonium, sulfonium and phosphonium lipids |
US6057299A (en) * | 1994-01-13 | 2000-05-02 | Calydon, Inc. | Tissue-specific enhancer active in prostate |
US6136792A (en) * | 1994-01-13 | 2000-10-24 | Calydon, Inc. | Prostate specific enhancer polynucleotides and methods of use thereof |
US6075012A (en) * | 1994-02-11 | 2000-06-13 | Life Technologies, Inc. | Reagents for intracellular delivery of macromolecules |
US6989434B1 (en) | 1994-02-11 | 2006-01-24 | Invitrogen Corporation | Reagents for intracellular delivery of macromolecules |
US7687070B2 (en) | 1994-02-11 | 2010-03-30 | Life Technologies Corporation | Reagents for intracellular delivery of macromolecules |
US6995008B1 (en) | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
US5891714A (en) * | 1994-03-29 | 1999-04-06 | Northwestern University | Cationic phospholipids for transfection |
US5651981A (en) * | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
WO1995026356A1 (en) * | 1994-03-29 | 1995-10-05 | Northwestern University | Novel cationic phospholipids for transfection |
US5688958A (en) * | 1994-03-29 | 1997-11-18 | Northwestern University | Cationic phospholipids for transfection |
US5780053A (en) * | 1994-03-29 | 1998-07-14 | Northwestern University | Cationic phospholipids for transfection |
US5686620A (en) * | 1994-03-29 | 1997-11-11 | Northwestern University | Cationic phospholipids for transfection |
US5855910A (en) * | 1994-03-29 | 1999-01-05 | Northwestern University | Cationic phospholipids for transfection |
US5695780A (en) * | 1994-03-29 | 1997-12-09 | Northwestern University | Cationic phospholipids for transfection |
US7423010B2 (en) | 1994-05-19 | 2008-09-09 | Oregon Health & Science University | Nonporous microparticle-prodrug conjugates for treatment of infection |
EP0807116A1 (en) * | 1994-06-22 | 1997-11-19 | Megabios Corporation | Cationic amphiphiles |
EP0807116A4 (en) * | 1994-06-22 | 1998-01-07 | Megabios Corp | Cationic amphiphiles |
US5777153A (en) * | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
US5705693A (en) * | 1994-07-08 | 1998-01-06 | Gilead Sciences, Inc. | Cationic lipids |
FR2722506A1 (en) * | 1994-07-13 | 1996-01-19 | Rhone Poulenc Rorer Sa | COMPOSITION CONTAINING NUCLEIC ACIDS, PREPARATION AND USES |
WO1996002655A1 (en) * | 1994-07-13 | 1996-02-01 | Rhone-Poulenc Rorer S.A. | Nucleic acid containing composition, preparation and uses of same |
US6013240A (en) * | 1994-07-13 | 2000-01-11 | Rhone-Poulenc Rorer Sa | Nucleic acid containing composition, preparation and uses of same |
WO1996003517A1 (en) * | 1994-07-26 | 1996-02-08 | Boehringer Ingelheim International Gmbh | Process for preparing viruses and viral vectors |
US7202227B2 (en) | 1994-09-28 | 2007-04-10 | Wyeth | Multifunctional molecular complexes for gene transfer to cells |
US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US6379965B1 (en) | 1994-09-28 | 2002-04-30 | American Home Products Corporation | Multifunctional complexes for gene transfer into cells comprising a nucleic acid bound to a polyamine and having an endosome disruption agent |
US6127170A (en) * | 1994-09-28 | 2000-10-03 | American Home Products Corporation | Multifunctional complexes for gene transfer into cells comprising a nucleic acid bound to a polyamine and having a endosome disruption agent |
US5753613A (en) * | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US5785992A (en) * | 1994-09-30 | 1998-07-28 | Inex Pharmaceuticals Corp. | Compositions for the introduction of polyanionic materials into cells |
US6383814B1 (en) | 1994-12-09 | 2002-05-07 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5948767A (en) * | 1994-12-09 | 1999-09-07 | Genzyme Corporation | Cationic amphiphile/DNA complexes |
US5939401A (en) * | 1994-12-09 | 1999-08-17 | Genzyme Corporation | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules |
US6331524B1 (en) | 1994-12-09 | 2001-12-18 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy |
WO1996034109A1 (en) * | 1995-04-25 | 1996-10-31 | Vical Incorporated | Single-vial formulations of dna/lipid complexes |
WO1996040627A3 (en) * | 1995-06-07 | 1997-02-13 | Gen Probe Inc | Thiocationic lipids, pharmaceutical compositions and methods of use thereof |
US5736392A (en) * | 1995-06-07 | 1998-04-07 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
US5851548A (en) * | 1995-06-07 | 1998-12-22 | Gen-Probe Incorporated | Liposomes containing cationic lipids and vitamin D |
EP0747351A3 (en) * | 1995-06-07 | 1997-02-26 | Gen Probe Inc | Thiocationic lipids, pharmaceutical compositions and methods of use thereof |
US5711964A (en) * | 1995-06-07 | 1998-01-27 | United States Of America | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D |
EP1489184A1 (en) * | 1995-06-07 | 2004-12-22 | Inex Pharmaceutical Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US6815432B2 (en) | 1995-06-07 | 2004-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US6051429A (en) * | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
US5739271A (en) * | 1995-06-07 | 1998-04-14 | Gen-Probe Incorporated | Thiocationic lipids |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US6586410B1 (en) | 1995-06-07 | 2003-07-01 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US6534484B1 (en) | 1995-06-07 | 2003-03-18 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US5976567A (en) * | 1995-06-07 | 1999-11-02 | Inex Pharmaceuticals Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
EP0747351A2 (en) * | 1995-06-07 | 1996-12-11 | Gen-Probe Incorporated | Thiocationic lipids, pharmaceutical compositions and methods of use thereof |
WO1996040627A2 (en) * | 1995-06-07 | 1996-12-19 | Gen-Probe Incorporated | Thiocationic lipids, pharmaceutical compositions and methods of use thereof |
US5759519A (en) * | 1995-06-07 | 1998-06-02 | Gen-Probe Incorporated | Method for the intracellular delivery of biomolecules using thiocationic lipids |
US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US5756352A (en) * | 1995-06-07 | 1998-05-26 | Gen-Probe Incorporated | Thiocationic lipid-nucleic acid conjugates |
WO1997013743A1 (en) * | 1995-09-27 | 1997-04-17 | Univ California | Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin: polynucleotide transfection complexes |
WO1997011935A1 (en) * | 1995-09-27 | 1997-04-03 | The Regents Of The University Of California | Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes |
US8541628B2 (en) | 1995-11-30 | 2013-09-24 | Vical Incorporated | Complex cationic lipids having quaternary nitrogens therein |
EP1015470A1 (en) * | 1996-01-05 | 2000-07-05 | Commonwealth Scientific And Industrial Research Organisation | Composition and method for delivery of nucleic acids |
WO1997025339A1 (en) * | 1996-01-05 | 1997-07-17 | Commonwealth Scientific And Industrial Research Organisation | Composition and method for delivery of nucleic acids |
EP1015470A4 (en) * | 1996-01-05 | 2008-05-07 | Commw Scient Ind Res Org | Composition and method for delivery of nucleic acids |
CZ299809B6 (en) * | 1996-05-08 | 2008-12-03 | Nika Health Products Limited | Lipid vesicle having positively charged lipid bilayer membrane for transfer of genetic material and process for preparing thereof |
WO1997041834A1 (en) * | 1996-05-08 | 1997-11-13 | Nika Health Products Limited | Cationic virosomes as transfer system for genetic material |
US6210708B1 (en) | 1996-05-08 | 2001-04-03 | Nika Health Products Limited | Cationic virosomes as transfer system for genetic material |
US6093816A (en) * | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
US6610664B2 (en) | 1996-06-27 | 2003-08-26 | Isis Pharmaceuticals, Inc. | Cationic lipids |
US6437121B1 (en) | 1996-06-27 | 2002-08-20 | Isis Pharmaceuticals, Inc. | Cationic lipids |
US7105331B2 (en) | 1996-07-03 | 2006-09-12 | Genetics Institute, Llc | ICE/CED-3 like protease designated FMH-1 |
WO1998002190A2 (en) * | 1996-07-12 | 1998-01-22 | Genzyme Corporation | Cationic amphiphile/dna complexes |
WO1998002190A3 (en) * | 1996-07-12 | 1998-10-22 | Genzyme Corp | Cationic amphiphile/dna complexes |
WO1998003204A1 (en) * | 1996-07-23 | 1998-01-29 | Oregon Health Sciences University | Covalent polar lipid conjugates with biologically-active compounds for use in salves |
EP1783139A2 (en) | 1996-10-01 | 2007-05-09 | Geron Corporation | Human telomerase catalytic subunit |
EP1333094A2 (en) | 1996-10-01 | 2003-08-06 | Geron Corporation | Human telomerase catalytic subunit |
EP2213740A1 (en) | 1996-10-01 | 2010-08-04 | The Regents of the University of Colorado | Human telomerase catalytic subunit |
WO1998017818A1 (en) * | 1996-10-23 | 1998-04-30 | Universite Paul Sabatier Toulouse Iii | Artificial polymeric membrane structure, method for preparing same, method for preparing this polymer, particle and film containing this structure |
FR2754828A1 (en) * | 1996-10-23 | 1998-04-24 | Univ Toulouse | ARTIFICIAL MEMBRANAR STRUCTURE, PROCESS AND POLYMER FOR ITS PREPARATION, PROCEDURE FOR PREPARING THIS POLYMER, PARTICLE AND FILM INCLUDING THIS STRUCTURE |
US5965441A (en) * | 1996-11-13 | 1999-10-12 | The General Hospital Coporation | HSV/AAV hybrid amplicon vectors |
WO1998037916A1 (en) * | 1997-02-28 | 1998-09-03 | Transgene S.A. | Novel lipid compounds and compositions containing same used for the transfer of at least an active substance, in particular a polynucleotide, in a target cell and therapeutic use |
US6335199B1 (en) | 1997-02-28 | 2002-01-01 | Transgene S.A. | Lipid compounds and compositions containing same used for the transfer of at least an active substance, in particular a polynucleotide, in a target cell and therapeutic use |
FR2760193A1 (en) * | 1997-02-28 | 1998-09-04 | Transgene Sa | LIPIDS AND COMPLEXES OF CATIONIC LIPIDS AND ACTIVE SUBSTANCES, IN PARTICULAR FOR THE TRANSFECTION OF CELLS |
US7135192B2 (en) | 1997-03-12 | 2006-11-14 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
US7238369B2 (en) | 1997-03-12 | 2007-07-03 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
US7494666B2 (en) | 1997-03-12 | 2009-02-24 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
US6376248B1 (en) | 1997-03-14 | 2002-04-23 | Life Technologies, Inc. | Peptide-enhanced transfections |
US6916918B2 (en) | 1997-08-04 | 2005-07-12 | Cell Genesys, Inc. | Human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof |
US6281371B1 (en) | 1997-08-13 | 2001-08-28 | Biontex Laboratories Gmbh | Lipopolyamines, and the preparation and use thereof |
WO1999008997A1 (en) * | 1997-08-13 | 1999-02-25 | Biontex Laboratories Gmbh | Novel lipopolyamines, and the preparation and use thereof |
US7414026B2 (en) | 1998-05-06 | 2008-08-19 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Inhibitors of NF-kappaB activation |
US7901709B2 (en) | 1998-06-18 | 2011-03-08 | Duke University | Temperature-sensitive liposomal formulation |
US9492385B2 (en) | 1998-06-18 | 2016-11-15 | Duke University | Temperature-sensitive liposomal formulation |
US9358300B2 (en) | 1998-11-12 | 2016-06-07 | Life Technologies Corporation | Transfection reagents |
US8435960B2 (en) | 1998-12-30 | 2013-05-07 | Lakewood-Amedex, Inc. | Devices for improved wound management |
US7868162B2 (en) | 1998-12-30 | 2011-01-11 | Lakewood-Amedex, Inc. | Antimicrobial and antiviral compounds and methods for their use |
EP2397549A2 (en) | 1999-02-04 | 2011-12-21 | BP Corporation North America Inc. | Non-stochastic generation of genetic vaccines and enzymes |
US6750198B1 (en) | 1999-02-25 | 2004-06-15 | Fumedica Gmbh | Preparation for the treatment of pigmentation disorders |
EP2081028A1 (en) | 1999-07-15 | 2009-07-22 | bioMérieux S.A. | Use of a polypeptide to detect, prevent or treat a pathological state associated with a degenerative, neurological, autoimmune illness |
EP2207032A1 (en) | 2000-02-08 | 2010-07-14 | Sangamo BioSciences, Inc. | Cells expressing zinc finger protein for drug discovery |
WO2002051800A3 (en) * | 2000-12-27 | 2002-08-15 | G O T Therapeutics Gmbh | Sulphur-containing amphiphilic agents for the transfer of biologically active molecules into cells |
WO2002051800A2 (en) * | 2000-12-27 | 2002-07-04 | G.O.T. Therapeutics Gmbh | Sulphur-containing amphiphilic agents for the transfer of biologically active molecules into cells |
EP2311466A2 (en) | 2001-05-03 | 2011-04-20 | Lakewood-Amedex, Inc | Antimicrobial compounds and methods for their use |
US7094756B2 (en) | 2001-06-22 | 2006-08-22 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Abin-mediated hepatitis protection |
EP2351765A2 (en) | 2001-07-10 | 2011-08-03 | Lakewood-Amedex, Inc | Oligonucleotide-containing pharmacological compositions and their use |
US9567584B2 (en) | 2001-07-10 | 2017-02-14 | Lakewood Amedex, Inc. | Oligonucleotide—containing pharmacological compositions and their use |
US8188259B2 (en) | 2001-07-10 | 2012-05-29 | Lakewood-Amedex, Inc. | Oligonucleotide-containing pharmacological compositions and their use |
US8183361B2 (en) | 2001-07-10 | 2012-05-22 | Lakewood-Amedex, Inc. | Oligonucleotide-containing pharmacological compositions and their use |
US8916529B2 (en) | 2001-07-10 | 2014-12-23 | Lakewood-Amedex, Inc. | Oligonucleotide-containing pharmacological compositions and their use |
US9624509B2 (en) | 2001-09-24 | 2017-04-18 | Sangamo Biosciences, Inc. | Modulation of stem cells using zinc finger proteins |
US8735153B2 (en) | 2001-09-24 | 2014-05-27 | Sangamo Biosciences, Inc. | Modulation of stem cells using zinc finger proteins |
EP2266396A2 (en) | 2001-09-24 | 2010-12-29 | Sangamo BioSciences, Inc. | Modulation of stem cells using zinc finger proteins |
US10888589B2 (en) | 2001-09-24 | 2021-01-12 | Sangamo Therapeutics, Inc. | Modulation of stem cells using zinc finger proteins |
WO2003052095A2 (en) * | 2001-12-14 | 2003-06-26 | Transgene S.A. | Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell |
WO2003052095A3 (en) * | 2001-12-14 | 2003-10-30 | Transgene Sa | Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell |
US7122656B2 (en) | 2002-01-10 | 2006-10-17 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Splice variant of MyD88 and uses thereof |
US9777275B2 (en) | 2002-02-01 | 2017-10-03 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
EP2213737A1 (en) | 2002-02-01 | 2010-08-04 | Life Technologies Corporation | Double-stranded oligonucleotides |
US10196640B1 (en) | 2002-02-01 | 2019-02-05 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US10106793B2 (en) | 2002-02-01 | 2018-10-23 | Life Technologies Corporation | Double-stranded oligonucleotides |
EP2351836A1 (en) | 2002-02-01 | 2011-08-03 | Life Technologies Corporation | Double-stranded oligonucleotides |
US10626398B2 (en) | 2002-02-01 | 2020-04-21 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US10036025B2 (en) | 2002-02-01 | 2018-07-31 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US9592250B2 (en) | 2002-02-01 | 2017-03-14 | Life Technologies Corporation | Double-stranded oligonucleotides |
EP2213292A1 (en) | 2002-02-01 | 2010-08-04 | Life Technologies Corporation | Double-stranded oligonucleotides |
EP3415625A1 (en) | 2002-02-01 | 2018-12-19 | Life Technologies Corporation | Double-stranded oligonucleotides |
US9796978B1 (en) | 2002-02-01 | 2017-10-24 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
EP2455467A1 (en) | 2002-02-01 | 2012-05-23 | Life Technologies Corporation | Double-stranded oligonucleotides |
EP2924116A1 (en) | 2002-02-01 | 2015-09-30 | Life Technologies Corporation | Double-stranded oligonucleotides |
EP2128248A1 (en) | 2002-02-01 | 2009-12-02 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US11298320B2 (en) | 2002-06-28 | 2022-04-12 | Arbutus Biopharma Corporation | Liposomal apparatus and manufacturing methods |
US9504651B2 (en) | 2002-06-28 | 2016-11-29 | Protiva Biotherapeutics, Inc. | Lipid compositions for nucleic acid delivery |
US9492386B2 (en) | 2002-06-28 | 2016-11-15 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
US11318098B2 (en) | 2002-06-28 | 2022-05-03 | Arbutus Biopharma Corporation | Liposomal apparatus and manufacturing methods |
US7135324B2 (en) | 2002-09-04 | 2006-11-14 | The University Of Connecticut | Viral recombinases, related articles, and methods of use thereof |
US8754201B2 (en) | 2003-03-07 | 2014-06-17 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
US10669544B2 (en) | 2003-03-07 | 2020-06-02 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
EP3450559A1 (en) | 2003-03-07 | 2019-03-06 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
US8110674B2 (en) | 2003-03-07 | 2012-02-07 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
US10273477B2 (en) | 2003-03-07 | 2019-04-30 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
US8809516B2 (en) | 2003-03-07 | 2014-08-19 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
US11530408B2 (en) | 2003-03-07 | 2022-12-20 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
EP2216407A2 (en) | 2003-03-07 | 2010-08-11 | Alnylam Pharmaceuticals, Inc. | Therapeutic Compositions |
EP2239329A1 (en) | 2003-03-07 | 2010-10-13 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
US8420799B2 (en) | 2003-03-07 | 2013-04-16 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
US9708615B2 (en) | 2003-03-07 | 2017-07-18 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
US8445665B2 (en) | 2003-03-07 | 2013-05-21 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
US9222091B2 (en) | 2003-03-07 | 2015-12-29 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
EP2660322A2 (en) | 2003-04-17 | 2013-11-06 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
EP2664672A1 (en) | 2003-04-17 | 2013-11-20 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
EP2666858A1 (en) | 2003-04-17 | 2013-11-27 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
EP2669377A2 (en) | 2003-04-17 | 2013-12-04 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
US7982027B2 (en) | 2003-07-16 | 2011-07-19 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
EP3222715A1 (en) | 2003-08-08 | 2017-09-27 | Sangamo BioSciences, Inc. | Methods and compositions for targeted cleavage and recombination |
WO2005014791A2 (en) | 2003-08-08 | 2005-02-17 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
EP2927318A1 (en) | 2003-08-08 | 2015-10-07 | Sangamo BioSciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US9260726B2 (en) | 2003-08-08 | 2016-02-16 | Sangamo Biosciences, Inc. | Targeted integration and expression on exogenous nucleic acid sequences |
US8936942B2 (en) | 2003-09-15 | 2015-01-20 | Protiva Biotherapeutics, Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
US7803397B2 (en) | 2003-09-15 | 2010-09-28 | Protiva Biotherapeutics, Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
US7407776B2 (en) | 2003-09-19 | 2008-08-05 | Sangamo Biosciences, Inc. | Engineered zinc finger proteins for regulation of gene expression |
EP2947146A1 (en) | 2004-02-05 | 2015-11-25 | Sangamo BioSciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7534775B2 (en) | 2004-04-08 | 2009-05-19 | Sangamo Biosciences, Inc. | Methods and compositions for modulating cardiac contractility |
US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
US9926560B2 (en) | 2004-06-07 | 2018-03-27 | Protiva Biotherapeutics, Inc. | Lipid encapsulating interfering RNA |
US9181545B2 (en) | 2004-06-07 | 2015-11-10 | Protiva Biotherapeutics, Inc. | Lipid encapsulating interfering RNA |
US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
US7807815B2 (en) | 2004-07-02 | 2010-10-05 | Protiva Biotherapeutics, Inc. | Compositions comprising immunostimulatory siRNA molecules and DLinDMA or DLenDMA |
US8034598B2 (en) | 2004-08-06 | 2011-10-11 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
US8771986B2 (en) | 2004-08-06 | 2014-07-08 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
EP2292274A1 (en) | 2004-09-16 | 2011-03-09 | Sangamo BioSciences, Inc. | Compositions and methods for protein production |
US9309568B2 (en) | 2004-10-05 | 2016-04-12 | California Institute Of Technology | Aptamer regulated nucleic acids and uses thereof |
US9315862B2 (en) | 2004-10-05 | 2016-04-19 | California Institute Of Technology | Aptamer regulated nucleic acids and uses thereof |
CN102796016A (en) * | 2004-11-26 | 2012-11-28 | 默克专利股份有限公司 | Stable crystal modifications of dotap chloride |
CN102796016B (en) * | 2004-11-26 | 2015-09-02 | 默克专利股份有限公司 | Stable DOTAP muriate crystalline form |
EP2314614A1 (en) | 2005-02-28 | 2011-04-27 | Sangamo BioSciences, Inc. | Anti-angiogenic methods and compositions |
US7893022B2 (en) | 2005-02-28 | 2011-02-22 | Sangamo Biosciences, Inc. | Anti-angiogenic methods and compositions |
US7732196B2 (en) | 2005-02-28 | 2010-06-08 | Sangamo Biosciences, Inc. | Anti-angiogenic methods and compositions |
US7358085B2 (en) | 2005-02-28 | 2008-04-15 | Sangamo Biosciences, Inc. | Anti-angiogenic methods and compositions |
US7795209B2 (en) | 2005-02-28 | 2010-09-14 | Sangamo Biosciences, Inc. | Anti-angiogenic methods and compositions |
US8012946B1 (en) | 2005-02-28 | 2011-09-06 | Sangamo Biosciences, Inc. | Anti-angiogenic methods and compositions |
WO2006130974A1 (en) | 2005-06-08 | 2006-12-14 | Cangene Corporation | Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria |
US8313925B2 (en) | 2005-07-26 | 2012-11-20 | Sangamo Biosciences, Inc. | Zinc finger proteins and method for inactivating a dhfr gene in a chinese hamster ovary cell |
EP2980220A1 (en) | 2005-09-20 | 2016-02-03 | BASF Plant Science GmbH | Improved methods controlling gene expression |
EP3061834A1 (en) | 2005-10-21 | 2016-08-31 | The Regents of the University of California | Shp-2 gene mutations in melanoma |
US9074208B2 (en) | 2005-11-02 | 2015-07-07 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US8188263B2 (en) | 2005-11-02 | 2012-05-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US8101741B2 (en) | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US8513403B2 (en) | 2005-11-02 | 2013-08-20 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
EP2345417A1 (en) | 2005-12-22 | 2011-07-20 | Vib Vzw | Means and methods for mediating protein interference |
US8669418B2 (en) | 2005-12-22 | 2014-03-11 | Vib Vzw | Means and methods for mediating protein interference |
US9095556B2 (en) | 2005-12-22 | 2015-08-04 | Vib Vzw | Method for inducing protein aggregation using a polypeptide with an aggregation region |
US10336791B2 (en) | 2005-12-22 | 2019-07-02 | Vib Vzw | Means and methods for mediating protein interference |
US7914796B2 (en) | 2006-05-25 | 2011-03-29 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
EP2213731A1 (en) | 2006-05-25 | 2010-08-04 | Sangamo BioSciences, Inc. | Variant foki cleavage half-domains |
US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US8158595B2 (en) | 2006-11-09 | 2012-04-17 | California Institute Of Technology | Modular aptamer-regulated ribozymes |
EP1938843A1 (en) * | 2006-12-19 | 2008-07-02 | Novosom AG | Lipids and lipid assemblies comrising transfection enhancer elements |
EP2527435A2 (en) | 2007-07-12 | 2012-11-28 | Sangamo BioSciences, Inc. | Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression |
US9040495B2 (en) | 2007-08-28 | 2015-05-26 | California Institute Of Technology | General composition framework for ligand-controlled RNA regulatory systems |
US8367815B2 (en) | 2007-08-28 | 2013-02-05 | California Institute Of Technology | Modular polynucleotides for ligand-controlled regulatory systems |
US8865667B2 (en) | 2007-09-12 | 2014-10-21 | California Institute Of Technology | Higher-order cellular information processing devices |
EP3705125A1 (en) | 2007-12-04 | 2020-09-09 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
EP3141265A1 (en) | 2007-12-04 | 2017-03-15 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
EP4321177A2 (en) | 2007-12-04 | 2024-02-14 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
EP4223299A2 (en) | 2007-12-04 | 2023-08-09 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US9029524B2 (en) | 2007-12-10 | 2015-05-12 | California Institute Of Technology | Signal activated RNA interference |
EP2610340A1 (en) | 2007-12-11 | 2013-07-03 | The Scripps Research Institute | Compositions and methods related to mRNA translational enhancer elements |
EP2527439A2 (en) | 2007-12-11 | 2012-11-28 | The Scripps Research Institute | Compositions and methods related to mRNA translational enhancer elements |
EP2584038A1 (en) | 2007-12-11 | 2013-04-24 | The Scripps Research Institute | Compositions and methods related to mRNA translational enhancer elements |
EP2610341A1 (en) | 2007-12-11 | 2013-07-03 | The Scripps Research Institute | Compositions and methods related to mRNA translational enhancer elements |
US8785611B2 (en) | 2007-12-11 | 2014-07-22 | The Scripps Research Institute | Compositions and methods related to mRNA translational enhancer elements |
US10131904B2 (en) | 2008-02-11 | 2018-11-20 | Rxi Pharmaceuticals Corporation | Modified RNAi polynucleotides and uses thereof |
EP3643782A1 (en) | 2008-02-11 | 2020-04-29 | Phio Pharmaceuticals Corp. | Modified rnai polynucleotides and uses thereof |
US10633654B2 (en) | 2008-02-11 | 2020-04-28 | Phio Pharmaceuticals Corp. | Modified RNAi polynucleotides and uses thereof |
EP3604533A1 (en) | 2008-04-11 | 2020-02-05 | Arbutus Biopharma Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
US11141378B2 (en) | 2008-04-15 | 2021-10-12 | Arbutus Biopharma Corporation | Lipid formulations for nucleic acid delivery |
US9364435B2 (en) | 2008-04-15 | 2016-06-14 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
US8492359B2 (en) | 2008-04-15 | 2013-07-23 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
US8058069B2 (en) | 2008-04-15 | 2011-11-15 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
US8822668B2 (en) | 2008-04-15 | 2014-09-02 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
EP2910568A2 (en) | 2008-06-10 | 2015-08-26 | Sangamo BioSciences, Inc. | Methods and compositions for generation of BAX- and BAK-deficient cell lines |
WO2009151591A2 (en) | 2008-06-10 | 2009-12-17 | Sangamo Biosciences, Inc. | Methods and compositions for generation of bax- and bak-deficient cell lines |
US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
WO2010021692A1 (en) | 2008-08-22 | 2010-02-25 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
EP2789691A1 (en) | 2008-08-22 | 2014-10-15 | Sangamo BioSciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
EP3336188A1 (en) | 2008-09-22 | 2018-06-20 | RXi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
US10774330B2 (en) | 2008-09-22 | 2020-09-15 | Phio Pharmaceuticals Corp. | Reduced size self-delivering RNAI compounds |
US10138485B2 (en) | 2008-09-22 | 2018-11-27 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
US9303259B2 (en) | 2008-09-22 | 2016-04-05 | Rxi Pharmaceuticals Corporation | RNA interference in skin indications |
US10041073B2 (en) | 2008-09-22 | 2018-08-07 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
EP2949752A2 (en) | 2008-09-22 | 2015-12-02 | RXi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
US11396654B2 (en) | 2008-09-22 | 2022-07-26 | Phio Pharmaceuticals Corp. | Neutral nanotransporters |
US8664189B2 (en) | 2008-09-22 | 2014-03-04 | Rxi Pharmaceuticals Corporation | RNA interference in skin indications |
US10876119B2 (en) | 2008-09-22 | 2020-12-29 | Phio Pharmaceuticals Corp. | Reduced size self-delivering RNAI compounds |
US8796443B2 (en) | 2008-09-22 | 2014-08-05 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
US9175289B2 (en) | 2008-09-22 | 2015-11-03 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
US9139554B2 (en) | 2008-10-09 | 2015-09-22 | Tekmira Pharmaceuticals Corporation | Amino lipids and methods for the delivery of nucleic acids |
US10653780B2 (en) | 2008-10-09 | 2020-05-19 | The University Of British Columbia | Amino lipids and methods for the delivery of nucleic acids |
US11254940B2 (en) | 2008-11-19 | 2022-02-22 | Phio Pharmaceuticals Corp. | Inhibition of MAP4K4 through RNAi |
US9074211B2 (en) | 2008-11-19 | 2015-07-07 | Rxi Pharmaceuticals Corporation | Inhibition of MAP4K4 through RNAI |
WO2010065123A1 (en) | 2008-12-04 | 2010-06-10 | Sangamo Biosciences, Inc. | Genome editing in rats using zinc-finger nucleases |
EP3156494A1 (en) | 2008-12-04 | 2017-04-19 | Sangamo BioSciences, Inc. | Genome editing in rats using zinc-finger nucleases |
US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
US10167471B2 (en) | 2009-01-05 | 2019-01-01 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAI |
US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
US11667915B2 (en) | 2009-02-04 | 2023-06-06 | Phio Pharmaceuticals Corp. | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
EP3354275A1 (en) | 2009-02-04 | 2018-08-01 | Sangamo Therapeutics, Inc. | Methods and compositions for treating neuropathies |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
US10479992B2 (en) | 2009-02-04 | 2019-11-19 | Phio Pharmaceuticals Corp. | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
US9145555B2 (en) | 2009-04-02 | 2015-09-29 | California Institute Of Technology | Integrated—ligand-responsive microRNAs |
WO2010117464A1 (en) | 2009-04-09 | 2010-10-14 | Sangamo Biosciences, Inc. | Targeted integration into stem cells |
WO2010148010A1 (en) | 2009-06-15 | 2010-12-23 | 4S3 Bioscience Inc. | Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides |
US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
US8283333B2 (en) | 2009-07-01 | 2012-10-09 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
US11786598B2 (en) | 2009-07-01 | 2023-10-17 | Arbutus Biopharma Corporation | Lipid formulations for delivery of therapeutic agents |
US11446383B2 (en) | 2009-07-01 | 2022-09-20 | Arbutus Biopharma Corporation | Lipid formulations for delivery of therapeutic agents |
US9878042B2 (en) | 2009-07-01 | 2018-01-30 | Protiva Biotherapeutics, Inc. | Lipid formulations for delivery of therapeutic agents to solid tumors |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
WO2011003834A1 (en) | 2009-07-09 | 2011-01-13 | Marina Biotech, Inc. | Amphoteric liposomes comprising imino lipids |
EP2823810A1 (en) | 2009-07-09 | 2015-01-14 | Marina Biotech, Inc. | Amphoteric liposomes comprising imino lipids |
EP2727600A1 (en) | 2009-07-28 | 2014-05-07 | Sangamo BioSciences, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
US9074224B2 (en) | 2009-08-03 | 2015-07-07 | Recombinetics, Inc. | Methods and compositions for targeted gene modification |
WO2011090804A1 (en) | 2010-01-22 | 2011-07-28 | Dow Agrosciences Llc | Targeted genomic alteration |
EP4328304A2 (en) | 2010-02-08 | 2024-02-28 | Sangamo Therapeutics, Inc. | Engineered cleavage half-domains |
EP3594333A1 (en) | 2010-02-08 | 2020-01-15 | Sangamo Therapeutics, Inc. | Engineered cleavage half-domains |
EP2615106A1 (en) | 2010-02-08 | 2013-07-17 | Sangamo BioSciences, Inc. | Engineered cleavage half-domains |
EP2660318A1 (en) | 2010-02-09 | 2013-11-06 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
WO2011109427A2 (en) | 2010-03-01 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Improving the biological activity of sirna through modulation of its thermodynamic profile |
US9963702B2 (en) | 2010-03-24 | 2018-05-08 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
US9340786B2 (en) | 2010-03-24 | 2016-05-17 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
US10913948B2 (en) | 2010-03-24 | 2021-02-09 | Phio Pharmaceuticals Corp. | RNA interference in dermal and fibrotic indications |
EP3560503A1 (en) | 2010-03-24 | 2019-10-30 | Phio Pharmaceuticals Corp. | Rna interference in dermal and fibrotic indications |
WO2011117352A1 (en) | 2010-03-24 | 2011-09-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Primate model from the family cercopithecidae infected by a hbv strain of human genotype |
WO2011119871A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Phrmaceuticals Corporation | Rna interference in ocular indications |
EP3578183A1 (en) | 2010-03-24 | 2019-12-11 | Phio Pharmaceuticals Corp. | Rna interference in ocular indications |
WO2011119887A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Rna interference in dermal and fibrotic indications |
WO2011130729A2 (en) | 2010-04-16 | 2011-10-20 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using fgf |
US9408914B2 (en) | 2010-04-28 | 2016-08-09 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
US9920028B2 (en) | 2010-04-28 | 2018-03-20 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
WO2011136369A1 (en) | 2010-04-28 | 2011-11-03 | 協和発酵キリン株式会社 | Cationic lipid |
US9845306B2 (en) | 2010-04-28 | 2017-12-19 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
WO2011136368A1 (en) | 2010-04-28 | 2011-11-03 | 協和発酵キリン株式会社 | Cationic lipid |
EP3156062A1 (en) | 2010-05-17 | 2017-04-19 | Sangamo BioSciences, Inc. | Novel dna-binding proteins and uses thereof |
US9518272B2 (en) | 2010-06-30 | 2016-12-13 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
US9404127B2 (en) | 2010-06-30 | 2016-08-02 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
US11718852B2 (en) | 2010-06-30 | 2023-08-08 | Arbutus Biopharma Corporation | Non-liposomal systems for nucleic acid delivery |
US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
US9057057B2 (en) | 2010-07-27 | 2015-06-16 | The Johns Hopkins University | Obligate heterodimer variants of foki cleavage domain |
WO2012047598A1 (en) | 2010-09-27 | 2012-04-12 | Sangamo Biosciences, Inc. | Methods and compositions for inhibiting viral entry into cells |
EP3511420A1 (en) | 2010-09-27 | 2019-07-17 | Sangamo Therapeutics, Inc. | Methods and compositions for inhibiting viral entry into cells |
EP3311822A1 (en) | 2010-11-17 | 2018-04-25 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating pd1 |
US9950068B2 (en) | 2011-03-31 | 2018-04-24 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9533047B2 (en) | 2011-03-31 | 2017-01-03 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
EP3444348A1 (en) | 2011-06-21 | 2019-02-20 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
EP3656860A1 (en) | 2011-06-21 | 2020-05-27 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
WO2012177784A2 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals | Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof |
EP4092120A1 (en) | 2011-06-21 | 2022-11-23 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (anglptl3) irna compositions and methods of use thereof |
EP3461896A2 (en) | 2011-07-15 | 2019-04-03 | The General Hospital Corporation | Methods of transcription activator like effector assembly |
US10273271B2 (en) | 2011-07-15 | 2019-04-30 | The General Hospital Corporation | Methods of transcription activator like effector assembly |
WO2013012674A1 (en) | 2011-07-15 | 2013-01-24 | The General Hospital Corporation | Methods of transcription activator like effector assembly |
US11472849B2 (en) | 2011-07-15 | 2022-10-18 | The General Hospital Corporation | Methods of transcription activator like effector assembly |
EP3498833A1 (en) | 2011-09-21 | 2019-06-19 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of transgene expression |
EP3301086A1 (en) | 2011-11-02 | 2018-04-04 | Kyowa Hakko Kirin Co., Ltd. | Production of a composition containing a complex between a membrane composed of a lipid monolayer and a nucleic acid, and, a lipid membrane for encapsulating the complex therein |
WO2013065825A1 (en) | 2011-11-02 | 2013-05-10 | 協和発酵キリン株式会社 | Cationic lipid |
EP3913056A1 (en) | 2011-11-18 | 2021-11-24 | Alnylam Pharmaceuticals, Inc. | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
EP3366775A1 (en) | 2011-11-18 | 2018-08-29 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
WO2013074974A2 (en) | 2011-11-18 | 2013-05-23 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
WO2013075035A1 (en) | 2011-11-18 | 2013-05-23 | Alnylam Pharmaceuticals | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
EP3730618A1 (en) | 2011-11-18 | 2020-10-28 | Alnylam Pharmaceuticals, Inc. | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
EP3301177A1 (en) | 2011-11-18 | 2018-04-04 | Alnylam Pharmaceuticals, Inc. | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
EP4141116A1 (en) | 2011-11-18 | 2023-03-01 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
US11633480B2 (en) | 2011-12-07 | 2023-04-25 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
US11382979B2 (en) | 2011-12-07 | 2022-07-12 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
US11633479B2 (en) | 2011-12-07 | 2023-04-25 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
US11246933B1 (en) | 2011-12-07 | 2022-02-15 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
US11590229B2 (en) | 2011-12-07 | 2023-02-28 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
US11679158B2 (en) | 2011-12-07 | 2023-06-20 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
US11400158B2 (en) | 2011-12-07 | 2022-08-02 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
US11612657B2 (en) | 2011-12-07 | 2023-03-28 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
US9839616B2 (en) | 2011-12-12 | 2017-12-12 | Kyowa Hakko Kirin Co., Ltd. | Lipid nano particles comprising cationic lipid for drug delivery system |
WO2013089152A1 (en) | 2011-12-12 | 2013-06-20 | 協和発酵キリン株式会社 | Lipid nanoparticles containing combinations of cationic lipids |
WO2013089151A1 (en) | 2011-12-12 | 2013-06-20 | 協和発酵キリン株式会社 | Lipid nanoparticles for drug delivery system containing cationic lipids |
US20130156849A1 (en) * | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
US9295689B2 (en) | 2011-12-16 | 2016-03-29 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US20130245107A1 (en) * | 2011-12-16 | 2013-09-19 | modeRNA Therapeutics | Dlin-mc3-dma lipid nanoparticle delivery of modified polynucleotides |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
WO2013130824A1 (en) | 2012-02-29 | 2013-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9675668B2 (en) | 2012-04-02 | 2017-06-13 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding hepatitis A virus cellular receptor 2 |
US9301993B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding apoptosis inducing factor 1 |
US9255129B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1 |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9828416B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of secreted proteins |
US9572896B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | In vivo production of proteins |
US9827332B2 (en) | 2012-04-02 | 2017-11-28 | Modernatx, Inc. | Modified polynucleotides for the production of proteins |
US9814760B2 (en) | 2012-04-02 | 2017-11-14 | Modernatx, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
EP4209592A1 (en) | 2012-04-26 | 2023-07-12 | Genzyme Corporation | Serpinc1 irna compositions and methods of use thereof |
WO2013163430A2 (en) | 2012-04-26 | 2013-10-31 | Alnylam Pharmaceuticals | Serpinc1 irna compositions and methods of use thereof |
EP3744835A1 (en) | 2012-05-29 | 2020-12-02 | The General Hospital Corporation | Dna modifying fusion proteins and methods of use thereof |
US10894950B2 (en) | 2012-05-29 | 2021-01-19 | The General Hospital Corporation | TAL-Tet1 fusion proteins and methods of use thereof |
EP3747999A1 (en) | 2012-05-29 | 2020-12-09 | The General Hospital Corporation | Dna modifying fusion proteins and methods of use thereof |
US9890364B2 (en) | 2012-05-29 | 2018-02-13 | The General Hospital Corporation | TAL-Tet1 fusion proteins and methods of use thereof |
WO2014007398A1 (en) | 2012-07-06 | 2014-01-09 | 協和発酵キリン株式会社 | Cationic lipid |
EP3444342A1 (en) | 2012-07-11 | 2019-02-20 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
WO2014011237A1 (en) | 2012-07-11 | 2014-01-16 | Sangamo Biosciences, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
EP3816281A1 (en) | 2012-07-11 | 2021-05-05 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
EP3196301A1 (en) | 2012-07-11 | 2017-07-26 | Sangamo BioSciences, Inc. | Methods and compositions for the treatment of monogenic diseases |
WO2014011901A2 (en) | 2012-07-11 | 2014-01-16 | Sangamo Biosciences, Inc. | Methods and compositions for delivery of biologics |
WO2014013995A1 (en) | 2012-07-16 | 2014-01-23 | 協和発酵キリン株式会社 | Rnai pharmaceutical composition capable of suppressing expression of kras gene |
WO2014022739A2 (en) | 2012-08-03 | 2014-02-06 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
WO2014036219A2 (en) | 2012-08-29 | 2014-03-06 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
WO2014059173A2 (en) | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
EP3763810A2 (en) | 2012-10-10 | 2021-01-13 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
WO2014059255A1 (en) | 2012-10-12 | 2014-04-17 | The General Hospital Corporation | Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins |
EP3483185A1 (en) | 2012-10-12 | 2019-05-15 | The General Hospital Corporation | Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins |
US11891631B2 (en) | 2012-10-12 | 2024-02-06 | The General Hospital Corporation | Transcription activator-like effector (tale) - lysine-specific demethylase 1 (LSD1) fusion proteins |
EP3789405A1 (en) | 2012-10-12 | 2021-03-10 | The General Hospital Corporation | Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins |
WO2014089313A1 (en) | 2012-12-05 | 2014-06-12 | Alnylam Pharmaceuticals | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
EP3336187A1 (en) | 2012-12-05 | 2018-06-20 | Alnylam Pharmaceuticals, Inc. | Pcsk9 irna compositions and methods of use thereof |
EP4083209A1 (en) | 2012-12-05 | 2022-11-02 | Alnylam Pharmaceuticals, Inc. | Pcsk9 irna compositions and methods of use thereof |
WO2014089541A2 (en) | 2012-12-07 | 2014-06-12 | Haplomics, Inc. | Factor viii mutation repair and tolerance induction |
WO2014093622A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
WO2014093595A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
EP3064585A1 (en) | 2012-12-12 | 2016-09-07 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
EP3705490A1 (en) | 2012-12-12 | 2020-09-09 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
EP4286404A2 (en) | 2012-12-12 | 2023-12-06 | The Broad Institute Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
EP2998400A1 (en) | 2012-12-12 | 2016-03-23 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products |
EP4286402A2 (en) | 2012-12-12 | 2023-12-06 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
EP3252160A1 (en) | 2012-12-12 | 2017-12-06 | The Broad Institute Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
EP4279588A2 (en) | 2012-12-12 | 2023-11-22 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
EP3825401A1 (en) | 2012-12-12 | 2021-05-26 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
WO2014093635A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
EP2921557A1 (en) | 2012-12-12 | 2015-09-23 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
EP2896697A1 (en) | 2012-12-12 | 2015-07-22 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
EP3327127A1 (en) | 2012-12-12 | 2018-05-30 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
WO2014093712A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
EP2940140A1 (en) | 2012-12-12 | 2015-11-04 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
EP2848690A1 (en) | 2012-12-12 | 2015-03-18 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
EP4286403A2 (en) | 2012-12-12 | 2023-12-06 | The Broad Institute Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
EP2784162A1 (en) | 2012-12-12 | 2014-10-01 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
WO2014093661A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products |
EP3702463A1 (en) | 2012-12-12 | 2020-09-02 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
EP4234696A2 (en) | 2012-12-12 | 2023-08-30 | The Broad Institute Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
EP3045537A1 (en) | 2012-12-12 | 2016-07-20 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
EP4299741A2 (en) | 2012-12-12 | 2024-01-03 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
EP3144390A1 (en) | 2012-12-12 | 2017-03-22 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
EP2840140A1 (en) | 2012-12-12 | 2015-02-25 | The Broad Institute, Inc. | Crispr-Cas component systems, methods and compositions for sequence manipulation |
US10544405B2 (en) | 2013-01-16 | 2020-01-28 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
US11312945B2 (en) | 2013-01-16 | 2022-04-26 | Emory University | CAS9-nucleic acid complexes and uses related thereto |
US10731167B2 (en) | 2013-02-07 | 2020-08-04 | The General Hospital Corporation | Tale transcriptional activators |
US10676749B2 (en) | 2013-02-07 | 2020-06-09 | The General Hospital Corporation | Tale transcriptional activators |
US10017581B2 (en) | 2013-02-20 | 2018-07-10 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
WO2014130723A1 (en) | 2013-02-20 | 2014-08-28 | Valerion Therapeutics, Llc | Methods and compositions for treatment of pompe disease |
EP3312281A2 (en) | 2013-03-14 | 2018-04-25 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
EP3730615A2 (en) | 2013-05-15 | 2020-10-28 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
WO2014190137A1 (en) | 2013-05-22 | 2014-11-27 | Alnylam Pharmaceuticals, Inc. | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
EP3778899A1 (en) | 2013-05-22 | 2021-02-17 | Northwestern University | Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis |
WO2014190157A1 (en) | 2013-05-22 | 2014-11-27 | Alnylam Pharmaceuticals, Inc. | Tmprss6 compositions and methods of use thereof |
EP3828276A1 (en) | 2013-05-22 | 2021-06-02 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
WO2014190181A1 (en) | 2013-05-22 | 2014-11-27 | Northwestern University | Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis |
EP3587578A1 (en) | 2013-05-22 | 2020-01-01 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
WO2014204728A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
EP3725885A1 (en) | 2013-06-17 | 2020-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
WO2014204729A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
EP3825406A1 (en) | 2013-06-17 | 2021-05-26 | The Broad Institute Inc. | Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy |
EP3674411A1 (en) | 2013-06-17 | 2020-07-01 | The Broad Institute, Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
EP3597755A1 (en) | 2013-06-17 | 2020-01-22 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
EP4245853A2 (en) | 2013-06-17 | 2023-09-20 | The Broad Institute, Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
WO2015031619A1 (en) | 2013-08-28 | 2015-03-05 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
EP3591045A1 (en) | 2013-08-28 | 2020-01-08 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
EP3988654A1 (en) | 2013-08-28 | 2022-04-27 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
WO2015042564A1 (en) | 2013-09-23 | 2015-03-26 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing transthyretin (ttr) associated diseases |
WO2015057980A1 (en) | 2013-10-17 | 2015-04-23 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
EP3441468A2 (en) | 2013-10-17 | 2019-02-13 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
WO2015070212A1 (en) | 2013-11-11 | 2015-05-14 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
EP3492593A1 (en) | 2013-11-13 | 2019-06-05 | Children's Medical Center Corporation | Nuclease-mediated regulation of gene expression |
WO2015085113A1 (en) | 2013-12-04 | 2015-06-11 | Rxi Pharmaceuticals Corporation | Methods for treatment of wound healing utilizing chemically modified oligonucleotides |
EP3757116A1 (en) | 2013-12-09 | 2020-12-30 | Sangamo Therapeutics, Inc. | Methods and compositions for genome engineering |
EP3653229A1 (en) | 2013-12-12 | 2020-05-20 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing |
EP3470089A1 (en) | 2013-12-12 | 2019-04-17 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
EP3798306A1 (en) | 2013-12-12 | 2021-03-31 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
EP3540051A1 (en) | 2013-12-12 | 2019-09-18 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
WO2015089465A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
EP4183876A1 (en) | 2013-12-12 | 2023-05-24 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
WO2015106128A2 (en) | 2014-01-09 | 2015-07-16 | Alnylam Pharmaceuticals, Inc. | MODIFIED RNAi AGENTS |
WO2015117081A2 (en) | 2014-02-03 | 2015-08-06 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a beta thalessemia |
WO2015123264A1 (en) | 2014-02-11 | 2015-08-20 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
EP3960860A2 (en) | 2014-02-11 | 2022-03-02 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
EP3929279A1 (en) | 2014-03-18 | 2021-12-29 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of zinc finger protein expression |
WO2015143046A2 (en) | 2014-03-18 | 2015-09-24 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of zinc finger protein expression |
WO2015168108A2 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic targeting mdm2 or mycn |
WO2015168605A1 (en) | 2014-05-01 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules |
WO2015171932A1 (en) | 2014-05-08 | 2015-11-12 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
WO2015179724A1 (en) | 2014-05-22 | 2015-11-26 | Alnylam Pharmaceuticals, Inc. | Angiotensinogen (agt) irna compositions and methods of use thereof |
EP3739048A1 (en) | 2014-05-22 | 2020-11-18 | Alnylam Pharmaceuticals, Inc. | Angiotensinogen (agt) irna compositions and methods of use thereof |
US10066241B2 (en) | 2014-05-30 | 2018-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods of delivering treatments for latent viral infections |
US9487802B2 (en) | 2014-05-30 | 2016-11-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods to treat latent viral infections |
WO2015184268A1 (en) | 2014-05-30 | 2015-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods of delivering treatments for latent viral infections |
EP3674408A1 (en) | 2014-06-16 | 2020-07-01 | The Johns Hopkins University | Compositions and methods for the expression of crispr guide rnas |
US11872285B2 (en) | 2014-07-15 | 2024-01-16 | Life Technologies Corporation | Compositions and methods for efficient delivery of molecules to cells |
US10738278B2 (en) | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
US10195280B2 (en) | 2014-07-15 | 2019-02-05 | Life Technologies Corporation | Compositions and methods for efficient delivery of molecules to cells |
US10792362B2 (en) | 2014-07-15 | 2020-10-06 | Life Technologies Corporation | Compositions and methods for efficient delivery of molecules to cells |
US10287565B2 (en) | 2014-07-28 | 2019-05-14 | Sk Innovation Co., Ltd. | Isoprene synthase and method of preparing isoprene using thereof |
US11254922B2 (en) | 2014-07-28 | 2022-02-22 | Sk Innovation Co., Ltd. | Isoprene synthase and method of preparing isoprene using thereof |
US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
EP3686279A1 (en) | 2014-08-17 | 2020-07-29 | The Broad Institute, Inc. | Genome editing using cas9 nickases |
EP3812462A1 (en) | 2014-08-20 | 2021-04-28 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
WO2016028649A1 (en) | 2014-08-20 | 2016-02-25 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
EP3808846A1 (en) | 2014-08-20 | 2021-04-21 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
US11926828B2 (en) | 2014-09-05 | 2024-03-12 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1 |
WO2016037071A2 (en) | 2014-09-05 | 2016-03-10 | Rxi Pharmaceuticals Corporation | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
EP3878948A1 (en) | 2014-09-16 | 2021-09-15 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
WO2016044416A1 (en) | 2014-09-16 | 2016-03-24 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
US11459557B2 (en) | 2014-09-24 | 2022-10-04 | The Broad Institute, Inc. | Use and production of CHD8+/− transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
US11197467B2 (en) | 2014-09-24 | 2021-12-14 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-cas systems and compositions for modeling mutations in leukocytes |
WO2016049251A1 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes |
US11124796B2 (en) | 2014-09-24 | 2021-09-21 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
EP4039809A1 (en) | 2014-10-10 | 2022-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
WO2016057693A1 (en) | 2014-10-10 | 2016-04-14 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
WO2016057893A1 (en) | 2014-10-10 | 2016-04-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
WO2016061487A1 (en) | 2014-10-17 | 2016-04-21 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
EP3904519A1 (en) | 2014-10-30 | 2021-11-03 | Genzyme Corporation | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
EP3647424A1 (en) | 2014-11-10 | 2020-05-06 | Alnylam Pharmaceuticals, Inc. | Hepatitis b virus (hbv) irna compositions and methods of use thereof |
WO2016077321A1 (en) | 2014-11-10 | 2016-05-19 | Alnylam Pharmaceuticals, Inc. | Hepatitis b virus (hbv) irna compositions and methods of use thereof |
WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
WO2016094872A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
EP3889260A1 (en) | 2014-12-12 | 2021-10-06 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
WO2016094867A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Protected guide rnas (pgrnas) |
WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
EP3702456A1 (en) | 2014-12-24 | 2020-09-02 | The Broad Institute, Inc. | Crispr having or associated with destabilization domains |
WO2016106244A1 (en) | 2014-12-24 | 2016-06-30 | The Broad Institute Inc. | Crispr having or associated with destabilization domains |
WO2016108926A1 (en) | 2014-12-30 | 2016-07-07 | The Broad Institute Inc. | Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis |
WO2016123230A1 (en) | 2015-01-28 | 2016-08-04 | Pioneer Hi-Bred International, Inc. | Crispr hybrid dna/rna polynucleotides and methods of use |
EP4257690A2 (en) | 2015-01-28 | 2023-10-11 | Caribou Biosciences, Inc. | Crispr hybrid dna/rna polynucleotides and methods of use |
WO2016130806A2 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
WO2016161446A1 (en) | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
EP4335918A2 (en) | 2015-04-03 | 2024-03-13 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
WO2017176806A1 (en) | 2015-04-03 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b cells |
WO2016164746A1 (en) | 2015-04-08 | 2016-10-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
WO2016179342A2 (en) | 2015-05-06 | 2016-11-10 | Alnylam Pharmaceuticals, Inc. | Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof |
WO2016186772A2 (en) | 2015-05-16 | 2016-11-24 | Genzyme Corporation | Gene editing of deep intronic mutations |
WO2016196388A1 (en) | 2015-05-29 | 2016-12-08 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
WO2016201301A1 (en) | 2015-06-12 | 2016-12-15 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
US11643669B2 (en) | 2015-06-17 | 2023-05-09 | Massachusetts Institute Of Technology | CRISPR mediated recording of cellular events |
WO2016205728A1 (en) | 2015-06-17 | 2016-12-22 | Massachusetts Institute Of Technology | Crispr mediated recording of cellular events |
US11180751B2 (en) | 2015-06-18 | 2021-11-23 | The Broad Institute, Inc. | CRISPR enzymes and systems |
EP3666895A1 (en) | 2015-06-18 | 2020-06-17 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
WO2016205711A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2016205764A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
EP3009511A2 (en) | 2015-06-18 | 2016-04-20 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
WO2016205749A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
EP4159856A1 (en) | 2015-06-18 | 2023-04-05 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
EP3502253A1 (en) | 2015-06-18 | 2019-06-26 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
US11001845B2 (en) | 2015-07-06 | 2021-05-11 | Phio Pharmaceuticals Corp. | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) |
EP3862005A1 (en) | 2015-07-06 | 2021-08-11 | Phio Pharmaceuticals Corp. | Nucleic acid molecules targeting superoxide dismutase 1 (sod1) |
US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
WO2017011286A1 (en) | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof |
WO2017011519A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
US10786533B2 (en) | 2015-07-15 | 2020-09-29 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
WO2017040078A1 (en) | 2015-09-02 | 2017-03-09 | Alnylam Pharmaceuticals, Inc. | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2017048620A1 (en) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
US11692182B2 (en) | 2015-10-09 | 2023-07-04 | Monsanto Technology Llc | RNA-guided DNA nucleases and uses thereof |
US11021707B2 (en) | 2015-10-19 | 2021-06-01 | Phio Pharmaceuticals Corp. | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA |
WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
WO2017070605A1 (en) | 2015-10-22 | 2017-04-27 | The Broad Institute Inc. | Type vi-b crispr enzymes and systems |
US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
WO2017100542A1 (en) | 2015-12-10 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof |
WO2017106537A2 (en) | 2015-12-18 | 2017-06-22 | Sangamo Biosciences, Inc. | Targeted disruption of the mhc cell receptor |
WO2017106528A2 (en) | 2015-12-18 | 2017-06-22 | Sangamo Biosciences, Inc. | Targeted disruption of the t cell receptor |
WO2017106657A1 (en) | 2015-12-18 | 2017-06-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2017111172A1 (en) | 2015-12-25 | 2017-06-29 | 協和発酵キリン株式会社 | Compounds as cationic lipids |
WO2017123757A1 (en) | 2016-01-15 | 2017-07-20 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of neurologic disease |
US10724020B2 (en) | 2016-02-02 | 2020-07-28 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
EP3769775A2 (en) | 2016-02-02 | 2021-01-27 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
US11920169B2 (en) | 2016-02-02 | 2024-03-05 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
WO2017165788A1 (en) | 2016-03-24 | 2017-09-28 | Marquette University | Quantitative flagellar fluorescent markers and standards |
WO2017189308A1 (en) | 2016-04-19 | 2017-11-02 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2017184786A1 (en) | 2016-04-19 | 2017-10-26 | The Broad Institute Inc. | Cpf1 complexes with reduced indel activity |
WO2017184768A1 (en) | 2016-04-19 | 2017-10-26 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2017214518A1 (en) | 2016-06-10 | 2017-12-14 | Alnylam Pharmaceuticals, Inc. | COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
WO2018229521A1 (en) | 2016-06-16 | 2018-12-20 | Oslo Universitetssykehus Hf | Improved gene editing |
WO2017219027A1 (en) | 2016-06-17 | 2017-12-21 | The Broad Institute Inc. | Type vi crispr orthologs and systems |
US11788083B2 (en) | 2016-06-17 | 2023-10-17 | The Broad Institute, Inc. | Type VI CRISPR orthologs and systems |
WO2018005873A1 (en) | 2016-06-29 | 2018-01-04 | The Broad Institute Inc. | Crispr-cas systems having destabilization domain |
US11766488B2 (en) | 2016-07-05 | 2023-09-26 | The Johns Hopkins University | Compositions and methods comprising improvements of CRISPR guide RNAS using the H1 promoter |
EP4219462A1 (en) | 2016-07-13 | 2023-08-02 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
WO2018013840A1 (en) | 2016-07-13 | 2018-01-18 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
US11959094B2 (en) | 2016-07-15 | 2024-04-16 | Salk Institute For Biological Studies | Methods and compositions for genome editing in non-dividing cells |
WO2018013932A1 (en) | 2016-07-15 | 2018-01-18 | Salk Institute For Biological Studies | Methods and compositions for genome editing in non-dividing cells |
US11674158B2 (en) | 2016-07-15 | 2023-06-13 | Salk Institute For Biological Studies | Methods and compositions for genome editing in non-dividing cells |
EP4321623A2 (en) | 2016-07-15 | 2024-02-14 | Salk Institute for Biological Studies | Methods and compositions for genome editing in non-dividing cells |
US10730942B2 (en) | 2016-07-25 | 2020-08-04 | Ucl Business Ltd | Protein-based T-cell receptor knockdown |
US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
WO2018029586A1 (en) | 2016-08-07 | 2018-02-15 | Novartis Ag | Mrna-mediated immunization methods |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
WO2018035387A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
WO2018035388A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
WO2018039448A1 (en) | 2016-08-24 | 2018-03-01 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
EP3964573A1 (en) | 2016-08-24 | 2022-03-09 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
WO2018039440A1 (en) | 2016-08-24 | 2018-03-01 | Sangamo Therapeutics, Inc. | Regulation of gene expression using engineered nucleases |
EP3995574A1 (en) | 2016-08-24 | 2022-05-11 | Sangamo Therapeutics, Inc. | Regulation of gene expression using engineered nucleases |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
WO2018067826A1 (en) | 2016-10-05 | 2018-04-12 | Cellular Dynamics International, Inc. | Generating mature lineages from induced pluripotent stem cells with mecp2 disruption |
EP4190335A1 (en) | 2016-10-13 | 2023-06-07 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
WO2018071873A2 (en) | 2016-10-13 | 2018-04-19 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
US11896615B2 (en) | 2016-10-13 | 2024-02-13 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11219695B2 (en) | 2016-10-20 | 2022-01-11 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of Fabry disease |
WO2018081775A1 (en) | 2016-10-31 | 2018-05-03 | Sangamo Therapeutics, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
WO2018098117A1 (en) | 2016-11-23 | 2018-05-31 | Alnylam Pharmaceuticals, Inc. | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
US11793833B2 (en) | 2016-12-02 | 2023-10-24 | Juno Therapeutics, Inc. | Engineered B cells and related compositions and methods |
WO2018102612A1 (en) | 2016-12-02 | 2018-06-07 | Juno Therapeutics, Inc. | Engineered b cells and related compositions and methods |
WO2018106782A1 (en) | 2016-12-08 | 2018-06-14 | Case Western Reserve University | Methods and compositions for enhancing functional myelin production |
EP4276187A2 (en) | 2016-12-08 | 2023-11-15 | Case Western Reserve University | Methods and compositions for enhancing functional myelin production |
WO2018112320A1 (en) | 2016-12-16 | 2018-06-21 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions |
EP4286523A2 (en) | 2016-12-20 | 2023-12-06 | Bristol-Myers Squibb Company | Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome |
WO2018119060A1 (en) | 2016-12-20 | 2018-06-28 | Bristol-Myers Squibb Company | Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome |
US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
WO2018170333A1 (en) | 2017-03-15 | 2018-09-20 | The Broad Institute, Inc. | Novel cas13b orthologues crispr enzymes and systems |
US11739308B2 (en) | 2017-03-15 | 2023-08-29 | The Broad Institute, Inc. | Cas13b orthologues CRISPR enzymes and systems |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
WO2018191388A1 (en) | 2017-04-12 | 2018-10-18 | The Broad Institute, Inc. | Novel type vi crispr orthologs and systems |
WO2018195165A1 (en) | 2017-04-18 | 2018-10-25 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
WO2018208910A1 (en) | 2017-05-09 | 2018-11-15 | The Broad Institute Inc. | Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases |
US11872262B2 (en) | 2017-05-09 | 2024-01-16 | Vib Vzw | Means and methods for treating bacterial infections |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
EP3828264A1 (en) | 2017-06-20 | 2021-06-02 | Institut Curie | Immune cells defective for suv39h1 |
WO2018234370A1 (en) | 2017-06-20 | 2018-12-27 | Institut Curie | Immune cells defective for suv39h1 |
EP3916086A1 (en) | 2017-06-23 | 2021-12-01 | Inscripta, Inc. | Nucleic acid-guided nucleases |
WO2019005884A1 (en) | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
WO2019060746A1 (en) | 2017-09-21 | 2019-03-28 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
WO2019089922A1 (en) | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
WO2019100023A1 (en) | 2017-11-17 | 2019-05-23 | Iovance Biotherapeutics, Inc. | Til expansion from fine needle aspirates and small biopsies |
WO2019100039A1 (en) | 2017-11-20 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
WO2019103857A1 (en) | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
WO2019126651A1 (en) | 2017-12-21 | 2019-06-27 | Alnylam Pharmaceuticals, Inc. | Chirally-enriched double-stranded rna agents |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
WO2019136456A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
WO2019143677A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency |
WO2019143678A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
WO2019143675A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
WO2019160383A1 (en) | 2018-02-19 | 2019-08-22 | 고려대학교 산학협력단 | Vaccine comprising epitope of heat shock protein, and use thereof |
WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
WO2019236566A1 (en) | 2018-06-05 | 2019-12-12 | Lifeedit, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2020033601A1 (en) | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Novel cas12b enzymes and systems |
WO2020041380A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
EP4234570A2 (en) | 2018-09-18 | 2023-08-30 | Sangamo Therapeutics, Inc. | Programmed cell death 1 (pd1) specific nucleases |
WO2020060986A1 (en) | 2018-09-18 | 2020-03-26 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
WO2020069029A1 (en) | 2018-09-26 | 2020-04-02 | Emendobio Inc. | Novel crispr nucleases |
WO2020065062A1 (en) | 2018-09-28 | 2020-04-02 | Wageningen Universiteit | Off-target activity inhibitors for guided endonucleases |
WO2020069373A1 (en) | 2018-09-28 | 2020-04-02 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
WO2020079033A1 (en) | 2018-10-15 | 2020-04-23 | Fondazione Telethon | Genome editing methods and constructs |
WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
WO2020096988A2 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
WO2020096989A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
WO2020096986A2 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
WO2020096927A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
WO2020102659A1 (en) | 2018-11-15 | 2020-05-22 | The Broad Institute, Inc. | G-to-t base editors and uses thereof |
WO2020117840A2 (en) | 2018-12-05 | 2020-06-11 | Empirico Inc. | Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions |
WO2020131862A1 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Crispr-associated transposase systems and methods of use thereof |
WO2020131547A1 (en) | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
WO2020132521A1 (en) | 2018-12-20 | 2020-06-25 | Praxis Precision Medicines, Inc. | Compositions and methods for the treatment of kcnt1 related disorders |
WO2020139783A2 (en) | 2018-12-27 | 2020-07-02 | Lifeedit, Inc. | Polypeptides useful for gene editing and methods of use |
EP4339286A2 (en) | 2018-12-27 | 2024-03-20 | LifeEDIT Therapeutics, Inc. | Polypeptides useful for gene editing and methods of use |
US11116778B2 (en) | 2019-01-15 | 2021-09-14 | Empirico Inc. | Prodrugs of ALOX-15 inhibitors and methods of using the same |
US11666588B2 (en) | 2019-01-15 | 2023-06-06 | Empirico Inc. | Prodrugs of ALOX-15 inhibitors and methods of using the same |
WO2020163379A1 (en) | 2019-02-05 | 2020-08-13 | Emendobio Inc. | Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene |
WO2020163307A1 (en) | 2019-02-06 | 2020-08-13 | Emendobio Inc. | New engineered high fidelity cas9 |
US11866469B2 (en) | 2019-02-06 | 2024-01-09 | Klogenix Llc | DNA binding proteins and uses thereof |
WO2020172343A2 (en) | 2019-02-19 | 2020-08-27 | Massachusetts Institute Of Technology | Methods for treating injuries |
WO2020180733A1 (en) | 2019-03-01 | 2020-09-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2020181193A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through adenosine methylation |
WO2020181178A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through thymine alkylation |
WO2020181202A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | A:t to t:a base editing through adenine deamination and oxidation |
WO2020181180A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | A:t to c:g base editors and uses thereof |
WO2020181195A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through adenine excision |
WO2020183197A1 (en) | 2019-03-14 | 2020-09-17 | Ucl Business Ltd | Minimal promoter |
WO2020191102A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
DE112020001339T5 (en) | 2019-03-19 | 2022-01-13 | President and Fellows of Harvard College | METHOD AND COMPOSITION FOR EDITING NUCLEOTIDE SEQUENCES |
WO2020191171A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
DE112020001306T5 (en) | 2019-03-19 | 2022-01-27 | Massachusetts Institute Of Technology | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES |
DE112020001342T5 (en) | 2019-03-19 | 2022-01-13 | President and Fellows of Harvard College | Methods and compositions for editing nucleotide sequences |
US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
WO2020191153A2 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
WO2020205838A1 (en) | 2019-04-02 | 2020-10-08 | Sangamo Therapeutics, Inc. | Methods for the treatment of beta-thalassemia |
EP4335925A2 (en) | 2019-04-09 | 2024-03-13 | The Regents of the University of California | Long-lasting analgesia via targeted in vivo epigenetic repression |
WO2020210751A1 (en) | 2019-04-12 | 2020-10-15 | The Broad Institute, Inc. | System for genome editing |
WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
WO2020223539A1 (en) | 2019-04-30 | 2020-11-05 | The Broad Institute, Inc. | Methods and compositions for barcoding nucleic acid libraries and cell populations |
WO2020232029A1 (en) | 2019-05-13 | 2020-11-19 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
WO2020232271A1 (en) | 2019-05-14 | 2020-11-19 | The Broad Institute, Inc. | Compositions and methods for targeting multinucleated cells |
WO2020236600A1 (en) | 2019-05-17 | 2020-11-26 | Alnylam Pharmaceuticals, Inc. | Oral delivery of oligonucleotides |
WO2020236982A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Aav delivery of nucleobase editors |
WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
WO2020243485A1 (en) | 2019-05-29 | 2020-12-03 | Massachusetts Institute Of Technology | Hiv-1 specific immunogen compositions and methods of use |
US11447790B2 (en) | 2019-05-29 | 2022-09-20 | Altria Client Services Llc | Compositions and methods for producing tobacco plants and products having reduced or eliminated suckers |
WO2020243276A1 (en) | 2019-05-29 | 2020-12-03 | Altria Client Services Llc | Compositions and methods for producing tobacco plants and products having reduced or eliminated suckers |
EP4166671A1 (en) | 2019-05-29 | 2023-04-19 | Altria Client Services LLC | Compositions and methods for producing tobacco plants and products having reduced or eliminated suckers |
WO2021001534A1 (en) | 2019-07-03 | 2021-01-07 | Wageningen Universiteit | Crispr type v-u1 system from mycobacterium mucogenicum and uses thereof |
WO2021013950A1 (en) | 2019-07-23 | 2021-01-28 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
WO2021025750A1 (en) | 2019-08-08 | 2021-02-11 | The Broad Institute, Inc. | Base editors with diversified targeting scope |
WO2021030344A1 (en) | 2019-08-12 | 2021-02-18 | Lifeedit, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2021030522A1 (en) | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021030666A1 (en) | 2019-08-15 | 2021-02-18 | The Broad Institute, Inc. | Base editing by transglycosylation |
WO2021034717A1 (en) | 2019-08-16 | 2021-02-25 | Massachusetts Institute Of Technology | Targeted trans-splicing using crispr/cas13 |
WO2021045292A1 (en) | 2019-09-03 | 2021-03-11 | 주식회사 제노포커스 | Crm197 protein expression method |
US11827893B2 (en) | 2019-10-10 | 2023-11-28 | Altria Client Services Llc | Pale yellow locus and its applications in tobacco |
WO2021072328A1 (en) | 2019-10-10 | 2021-04-15 | The Broad Institute, Inc. | Methods and compositions for prime editing rna |
WO2021072248A2 (en) | 2019-10-10 | 2021-04-15 | Altria Client Services Llc | Pale yellow locus and its applications in tobacco |
WO2021087361A1 (en) | 2019-11-01 | 2021-05-06 | Sangamo Therapeutics, Inc. | Zinc finger nuclease variants for treating or preventing lysosomal storage diseases |
WO2021087366A1 (en) | 2019-11-01 | 2021-05-06 | Sangamo Therapeutics, Inc. | Compositions and methods for genome engineering |
WO2021087036A1 (en) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021092464A2 (en) | 2019-11-08 | 2021-05-14 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy |
WO2021102373A1 (en) | 2019-11-22 | 2021-05-27 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
WO2021108717A2 (en) | 2019-11-26 | 2021-06-03 | The Broad Institute, Inc | Systems and methods for evaluating cas9-independent off-target editing of nucleic acids |
WO2021118990A1 (en) | 2019-12-11 | 2021-06-17 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
WO2021119226A1 (en) | 2019-12-13 | 2021-06-17 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
WO2021126435A1 (en) | 2019-12-20 | 2021-06-24 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
WO2021138247A1 (en) | 2019-12-30 | 2021-07-08 | LifeEDIT Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2021138537A1 (en) | 2019-12-31 | 2021-07-08 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides with improved systemic delivery |
GB202000934D0 (en) | 2020-01-22 | 2020-03-04 | Ucl Business Ltd | Engineered immune cells |
WO2021148788A1 (en) | 2020-01-22 | 2021-07-29 | Ucl Business Ltd | Engineered immune cells |
WO2021155065A1 (en) | 2020-01-28 | 2021-08-05 | The Broad Institute, Inc. | Base editors, compositions, and methods for modifying the mitochondrial genome |
WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
WO2021158999A1 (en) | 2020-02-05 | 2021-08-12 | The Broad Institute, Inc. | Gene editing methods for treating spinal muscular atrophy |
WO2021158921A2 (en) | 2020-02-05 | 2021-08-12 | The Broad Institute, Inc. | Adenine base editors and uses thereof |
WO2021163191A1 (en) | 2020-02-10 | 2021-08-19 | Board Of Regents, The University Of Texas System | Methods for rapid cloning and expression of hla class i cells |
WO2021178607A1 (en) | 2020-03-05 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
WO2021195307A1 (en) | 2020-03-26 | 2021-09-30 | Alnylam Pharmaceuticals, Inc. | Coronavirus irna compositions and methods of use thereof |
WO2021206917A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021206922A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
EP4242306A2 (en) | 2020-04-24 | 2023-09-13 | Lifeedit Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2021217002A1 (en) | 2020-04-24 | 2021-10-28 | Lifeedit Therapeutics, Inc . | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2021222065A1 (en) | 2020-04-27 | 2021-11-04 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein e (apoe) irna agent compositions and methods of use thereof |
WO2021222318A1 (en) | 2020-04-28 | 2021-11-04 | The Broad Institute, Inc. | Targeted base editing of the ush2a gene |
WO2021226061A1 (en) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
WO2021224395A1 (en) | 2020-05-06 | 2021-11-11 | Cellectis S.A. | Methods for targeted insertion of exogenous sequences in cellular genomes |
WO2021224416A1 (en) | 2020-05-06 | 2021-11-11 | Cellectis S.A. | Methods to genetically modify cells for delivery of therapeutic proteins |
DE112021002672T5 (en) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
WO2021231437A1 (en) | 2020-05-11 | 2021-11-18 | LifeEDIT Therapeutics, Inc. | Rna-guided nucleic acid binding proteins and active fragments and variants thereof and methods of use |
WO2021231691A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi) |
WO2021231675A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
WO2021231679A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
WO2021231673A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
WO2021231685A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
WO2021231692A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
WO2021231698A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
WO2021231680A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
US11408000B2 (en) | 2020-06-03 | 2022-08-09 | Triplet Therapeutics, Inc. | Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity |
WO2021252557A1 (en) | 2020-06-09 | 2021-12-16 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
WO2022011262A1 (en) | 2020-07-10 | 2022-01-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating epilepsy |
WO2022015969A1 (en) | 2020-07-15 | 2022-01-20 | LifeEDIT Therapeutics, Inc. | Uracil stabilizing proteins and active fragments and variants thereof and methods of use |
WO2022023576A1 (en) | 2020-07-30 | 2022-02-03 | Institut Curie | Immune cells defective for socs1 |
WO2022034374A2 (en) | 2020-08-11 | 2022-02-17 | University Of Oslo | Improved gene editing |
WO2022046760A2 (en) | 2020-08-25 | 2022-03-03 | Kite Pharma, Inc. | T cells with improved functionality |
WO2022051591A2 (en) | 2020-09-04 | 2022-03-10 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
WO2022056254A2 (en) | 2020-09-11 | 2022-03-17 | LifeEDIT Therapeutics, Inc. | Dna modifying enzymes and active fragments and variants thereof and methods of use |
WO2022060927A1 (en) | 2020-09-17 | 2022-03-24 | Northwestern University | Engineered mammalian genetic circuits and methods of using the same |
WO2022066847A1 (en) | 2020-09-24 | 2022-03-31 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
WO2022076291A1 (en) | 2020-10-05 | 2022-04-14 | Alnylam Pharmaceuticals, Inc. | G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof |
WO2022081015A1 (en) | 2020-10-16 | 2022-04-21 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Anti-tumor immunity induces the presentation of aberrant peptides |
WO2022087041A1 (en) | 2020-10-21 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
WO2022087329A1 (en) | 2020-10-23 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
US11591544B2 (en) | 2020-11-25 | 2023-02-28 | Akagera Medicines, Inc. | Ionizable cationic lipids |
WO2022119873A1 (en) | 2020-12-01 | 2022-06-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
WO2022150790A2 (en) | 2021-01-11 | 2022-07-14 | The Broad Institute, Inc. | Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision |
WO2022164319A1 (en) | 2021-01-29 | 2022-08-04 | Wageningen Universiteit | Crispr-associated base-editing of the complementary strand |
WO2022169836A1 (en) | 2021-02-03 | 2022-08-11 | Altria Client Services Llc | Terpene production in plants |
WO2022169839A1 (en) | 2021-02-03 | 2022-08-11 | Altria Client Services Llc | Increasing trichome density and improving transport of metabolites in plant trichomes |
WO2022169837A1 (en) | 2021-02-03 | 2022-08-11 | Altria Client Services Llc | Tissue-specific promoters in plants |
WO2022174000A2 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
WO2022182864A1 (en) | 2021-02-25 | 2022-09-01 | Alnylam Pharmaceuticals, Inc. | Prion protein (prnp) irna compositions and methods and methods of use thereof |
WO2022192789A1 (en) | 2021-03-12 | 2022-09-15 | Synthego Corporation | Genetically modified cells expressing antigen-containing fusion proteins and uses thereof |
WO2022192519A1 (en) | 2021-03-12 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
WO2022204093A1 (en) | 2021-03-22 | 2022-09-29 | LifeEDIT Therapeutics, Inc. | Dna modifyng enzymes and active fragments and variants thereof and methods of use |
WO2022212231A2 (en) | 2021-03-29 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
WO2022232343A1 (en) | 2021-04-29 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
WO2022245583A1 (en) | 2021-05-18 | 2022-11-24 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
WO2022246023A1 (en) | 2021-05-20 | 2022-11-24 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2022243565A1 (en) | 2021-05-21 | 2022-11-24 | Cellectis S.A. | Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors |
WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
WO2022256290A2 (en) | 2021-06-04 | 2022-12-08 | Alnylam Pharmaceuticals, Inc. | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2022261509A1 (en) | 2021-06-11 | 2022-12-15 | The Broad Institute, Inc. | Improved cytosine to guanine base editors |
WO2022261394A1 (en) | 2021-06-11 | 2022-12-15 | LifeEDIT Therapeutics, Inc. | Rna polymerase iii promoters and methods of use |
WO2023278410A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2023278407A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2023003995A1 (en) | 2021-07-23 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Beta-catenin (ctnnb1) irna compositions and methods of use thereof |
WO2023015265A2 (en) | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides |
WO2023015264A1 (en) | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides |
WO2023015309A2 (en) | 2021-08-06 | 2023-02-09 | The Broad Institute, Inc. | Improved prime editors and methods of use |
WO2023055239A1 (en) | 2021-10-01 | 2023-04-06 | Koninklijke Nederlandse Akademie Van Wetenschappen | Mammalian cardiac regeneration |
WO2023069603A1 (en) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
WO2023076898A1 (en) | 2021-10-25 | 2023-05-04 | The Broad Institute, Inc. | Methods and compositions for editing a genome with prime editing and a recombinase |
WO2023076450A2 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2023077148A1 (en) | 2021-11-01 | 2023-05-04 | Tome Biosciences, Inc. | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
US11649444B1 (en) | 2021-11-02 | 2023-05-16 | Huidagene Therapeutics Co., Ltd. | CRISPR-CAS12i systems |
WO2023080788A1 (en) | 2021-11-05 | 2023-05-11 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Tryptophan depletion induces production and presentation of tryptophan to phenylalanine substitutions |
WO2023096494A1 (en) | 2021-11-26 | 2023-06-01 | Synvolux Ip B.V. | Conserved coronavirus t cell epitopes |
WO2023122762A1 (en) | 2021-12-22 | 2023-06-29 | Camp4 Therapeutics Corporation | Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas |
WO2023122764A1 (en) | 2021-12-22 | 2023-06-29 | Tome Biosciences, Inc. | Co-delivery of a gene editor construct and a donor template |
WO2023126458A1 (en) | 2021-12-28 | 2023-07-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
WO2023139557A1 (en) | 2022-01-24 | 2023-07-27 | LifeEDIT Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2023150637A1 (en) | 2022-02-02 | 2023-08-10 | Inscripta, Inc. | Nucleic acid-guided nickase fusion proteins |
WO2023196802A1 (en) | 2022-04-04 | 2023-10-12 | The Broad Institute, Inc. | Cas9 variants having non-canonical pam specificities and uses thereof |
WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
WO2023196851A1 (en) | 2022-04-06 | 2023-10-12 | President And Fellows Of Harvard College | Reversing aging of the central nervous system |
WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
WO2023212715A1 (en) | 2022-04-28 | 2023-11-02 | The Broad Institute, Inc. | Aav vectors encoding base editors and uses thereof |
WO2023215831A1 (en) | 2022-05-04 | 2023-11-09 | Tome Biosciences, Inc. | Guide rna compositions for programmable gene insertion |
WO2023220459A1 (en) | 2022-05-13 | 2023-11-16 | Northwestern University | Active loading of cargo entity into lipid bilayer particles using dimerization domains |
WO2023220457A1 (en) | 2022-05-13 | 2023-11-16 | Northwestern University | Receptor engagement-mediated enhancement of biologics delivery |
WO2023220392A1 (en) | 2022-05-13 | 2023-11-16 | Northwestern University | Synthetic modular extracellular sensors that employ natural receptor ligand-binding domains |
WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
WO2023222928A2 (en) | 2022-05-20 | 2023-11-23 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
WO2023230433A1 (en) | 2022-05-23 | 2023-11-30 | Altria Client Services Llc | Methods and compositions for regulating alkaloids in tobacco field |
WO2023230613A1 (en) | 2022-05-27 | 2023-11-30 | The Broad Institute, Inc. | Improved mitochondrial base editors and methods for editing mitochondrial dna |
WO2023240137A1 (en) | 2022-06-08 | 2023-12-14 | The Board Institute, Inc. | Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing |
WO2023240277A2 (en) | 2022-06-10 | 2023-12-14 | Camp4 Therapeutics Corporation | Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas |
WO2024003334A1 (en) | 2022-06-30 | 2024-01-04 | Cellectis S.A. | Enhancing safety of t-cell-mediated immunotherapy |
WO2024015383A1 (en) | 2022-07-12 | 2024-01-18 | Northwestern University | Engineered hypoxia biosensors and methods of using the same |
WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
WO2024031038A1 (en) | 2022-08-05 | 2024-02-08 | Altria Client Services Llc | Methods and compositions for regulating alkaloids in tobacco |
WO2024033901A1 (en) | 2022-08-12 | 2024-02-15 | LifeEDIT Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
WO2024040083A1 (en) | 2022-08-16 | 2024-02-22 | The Broad Institute, Inc. | Evolved cytosine deaminases and methods of editing dna using same |
WO2024042489A1 (en) | 2022-08-25 | 2024-02-29 | LifeEDIT Therapeutics, Inc. | Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing |
WO2024047587A1 (en) | 2022-08-31 | 2024-03-07 | Regel Therapeutics, Inc. | Cas-phi compositions and methods of use |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
ATE181319T1 (en) | 1999-07-15 |
JPH05508626A (en) | 1993-12-02 |
JP2538474B2 (en) | 1996-09-25 |
EP0523189A4 (en) | 1995-04-26 |
EP0523189B1 (en) | 1999-06-16 |
US5264618A (en) | 1993-11-23 |
DK0523189T3 (en) | 1999-12-13 |
DE69131347T2 (en) | 2000-03-30 |
DE69131347D1 (en) | 1999-07-22 |
ES2134775T3 (en) | 1999-10-16 |
CA2079814A1 (en) | 1991-10-20 |
US5459127A (en) | 1995-10-17 |
AU7854791A (en) | 1991-11-11 |
CA2079814C (en) | 2005-09-27 |
EP0523189A1 (en) | 1993-01-20 |
GR3030974T3 (en) | 1999-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0523189B1 (en) | Cationic lipids for intracellular delivery of biologically active molecules | |
US6656498B1 (en) | Cationic liposomes for gene transfer | |
US6110745A (en) | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method | |
US6815432B2 (en) | Methods for encapsulating plasmids in lipid bilayers | |
US5705385A (en) | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer | |
EP1019365B1 (en) | Novel compositions for the delivery of negatively charged molecules | |
AU738083B2 (en) | Cationic amphiphile/ DNA complexes | |
ES2531520T3 (en) | Lipoamino acids and their uses | |
CA2263705C (en) | Novel sandwich liposome complexes comprising a biologically active agent | |
US5753613A (en) | Compositions for the introduction of polyanionic materials into cells | |
JP4430135B2 (en) | Cationic lipid complex | |
WO1991017424A1 (en) | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes | |
AU731503B2 (en) | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules | |
WO1998051285A2 (en) | Cationic amphiphile formulations | |
WO1998002190A9 (en) | Cationic amphiphile/dna complexes | |
WO1996040265A1 (en) | Stabilization of polynucleotide complexes | |
JP2007512355A (en) | Gene delivery mediated by liposome-DNA complexes surface-modified with cleavable PEG | |
US5958894A (en) | Amphiphilic biguanide derivatives | |
US6245520B1 (en) | Methods for introducing nucleic acids into mammalian cells using imidazolium lipids | |
WO2001042200A1 (en) | Cationic amphiphiles for intracellular delivery of therapeutic molecules | |
AU720187B2 (en) | Gene therapy using polynucleotide complexes | |
Mok | Characterization of libid-based DNA delivery systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1-68,DESCRIPTION AND PAGES 69-76,CLAIMS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;PAGES 1/19-19/19,DRAWINGS,REPLACED BY NEW PAGES 1/18-18/18;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2079814 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991908905 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991908905 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991908905 Country of ref document: EP |